image_name
stringlengths 68
68
| type
stringclasses 2
values | gt_table
stringlengths 116
12.6k
|
|---|---|---|
d460898c0ad43e0072a01029a9c01acdda3e7621c79d1c3040cb67486516544e.png | complex | <table><tr><td>Year</td><td>Main Objetive</td><td>Assay Employed</td><td>Reference</td></tr><tr><td colspan="4">In vitro studies</td></tr><tr><td>2014</td><td>Effect of MGN on gamma radiation-induced DNA damage in human lymphocytes and lymphoblastoid cells.</td><td>Comet assay</td><td>[74]</td></tr><tr><td>2012</td><td>Evaluation of protective effects of MGN against several mutagens (bleomycin, CP, AFB<sub>1</sub>, B[a]P, 2-AAF, H<sub>2</sub>O<sub>2</sub>, sodium azide, cisplatin, MMC, and DMNA).</td><td>Ames test, SOS Chromotest assay & Comet assay</td><td>[75]</td></tr><tr><td>2009</td><td>Cytoprotective and antigenotoxic potential of mangiferine against cadmium chloride CdCl<sub>2</sub>-induced toxicity in HepG2 cells.</td><td>Comet assay & Micronucleus</td><td>[76]</td></tr><tr><td>2011</td><td>Evaluation of the protector effect of MGN against methylmercury (MeHg) induced neurotoxicity by employing IMR-32 (human neuroblastoma) cell line.</td><td>Comet assay & Micronucleus</td><td>[77]</td></tr><tr><td>2011</td><td>Antigenotoxic potential of MGN against mercuric chloride (HgCl<sub>2</sub>)-induced genotoxicity in HepG<sub>2</sub> cell line.</td><td>Comet assay & Micronucleus</td><td>[78]</td></tr><tr><td>2015</td><td>Evaluation of the Mangiferin to reduce etoposide-induced DNA damage in human umbilical cord mononuclear blood cells.</td><td>Comet assay & Micronucleus</td><td>[79]</td></tr><tr><td colspan="4">In vivo studies</td></tr><tr><td>2008</td><td>Protective role of mangiferin against B[a]P induced lung carcinogenesis in experimental animals.</td><td>Comet assay</td><td>[80]</td></tr><tr><td>2005</td><td>Ability of the mangiferin to reduce the frequency of radiation-induced micronucleated binucleate cells (MNBNCs) in cultured human peripheral blood lymphocytes.</td><td>Micronucleus</td><td>[81]</td></tr><tr><td>2010</td><td>The protective role of mangiferin (MGN) against cadmium chloride CdCl<sub>2</sub>-induced genotoxicity studied in Swiss albino mice.</td><td>Micronucleus</td><td>[82]</td></tr></table> |
291da7d3f2b48403f2821744a65bd26e957ec73993de79a5ad31946cc1f61c9a.png | simple | <table><tr><td>Age group</td><td>No. negative</td><td>No. positive</td><td>positive (%)</td></tr><tr><td>3 to 10</td><td>201</td><td>11</td><td>5.19</td></tr><tr><td>11 to 15</td><td>346</td><td>11</td><td>3.08</td></tr><tr><td>16 to 20</td><td>702</td><td>21</td><td>2.90</td></tr><tr><td>21 to 30</td><td>1116</td><td>46</td><td>3.96</td></tr><tr><td>31 to 40</td><td>642</td><td>45</td><td>6.55</td></tr><tr><td>41 to 50</td><td>368</td><td>20</td><td>5.15</td></tr><tr><td>51 to 60</td><td>211</td><td>24</td><td>10.21</td></tr><tr><td>61 to 70</td><td>123</td><td>15</td><td>10.87</td></tr><tr><td>70+</td><td>46</td><td>6</td><td>11.54</td></tr><tr><td>Grand total</td><td>4154</td><td>209</td><td>4.8</td></tr></table> |
2352996350386baa3191ac351e3a5640e5e439f090fd666eb9e32e68ec3b32ca.png | complex | <table><tr><td rowspan="3"></td><td colspan="2">RMSE</td></tr><tr><td>EKF</td><td>BD-AEKF</td></tr><tr><td>Heading (degree)</td><td>1.0069</td><td>0.3751</td></tr><tr><td>Pitch (degree)</td><td>0.6812</td><td>0.1453</td></tr><tr><td>Roll (degree)</td><td>0.6488</td><td>0.1466</td></tr><tr><td>East position (m)</td><td>0.8297</td><td>0.2050</td></tr><tr><td>North position (m)</td><td>0.8104</td><td>0.2194</td></tr></table> |
467dd24f7533ab096812b77aa3456c5a096f74d01f2de1a4a61e75c6adcdbb0e.png | complex | <table><tr><td><i>Ownership</i></td><td><i>n(%)</i></td></tr><tr><td>Household owning nets</td><td>638(95.2)</td></tr><tr><td>Households without nets</td><td>32(4.8)</td></tr><tr><td>Total</td><td>670(100)</td></tr><tr><td><i>No. of bed nets</i></td><td><i>No. of HH(%)</i></td></tr><tr><td>0</td><td>32(4.8)</td></tr><tr><td>1</td><td>120(17.9)</td></tr><tr><td>2</td><td>244(36.4)</td></tr><tr><td>3</td><td>147(21.9)</td></tr><tr><td>4</td><td>88(13.1)</td></tr><tr><td>5+</td><td>39(5.8)</td></tr><tr><td>Total</td><td>670(100)</td></tr><tr><td colspan="2"><i>Mean number of nets per HH 2.4</i></td></tr><tr><td><i>Source of bed nets</i></td><td><i>No. of HH(%)</i></td></tr><tr><td>Campaign nets</td><td>298(46.7)</td></tr><tr><td>Non campaign nets</td><td>205(32.1)</td></tr><tr><td>Campaign &non campaign nets</td><td>112(17.6)</td></tr><tr><td>*Other sources</td><td>23(3.6)</td></tr><tr><td>Total</td><td>638(100)</td></tr><tr><td>Cost of non-campaign nets (KES)</td><td></td></tr><tr><td>50</td><td>180(56.8)</td></tr><tr><td>100</td><td>64(20.2)</td></tr><tr><td>> 100</td><td>73(23.0)</td></tr><tr><td>Total HH</td><td>317(100)</td></tr></table> |
33ee493dc3ccba7be30fc2b1e51e8604743c6217135b3779fb3a6113326285d4.png | simple | <table><tr><td>Rank</td><td>Symptoms</td><td>Rate of patients with the symptom</td><td>Rate of patients with high PeCDF (> 50 pg/g lipids)</td></tr><tr><td>1</td><td>Black comedones (trunk) <+ or severer></td><td>0.0671</td><td>0.6563</td></tr><tr><td>2</td><td>uric acid (high)</td><td>0.1761</td><td>0.6310*</td></tr><tr><td>3</td><td>Black comedones (face) <+ or severer></td><td>0.0860</td><td>0.6098</td></tr><tr><td>4</td><td>Third quartile age</td><td>0.2348</td><td>0.6071*</td></tr><tr><td>5</td><td>urea nitrogen (high)</td><td>0.1111</td><td>0.6038</td></tr><tr><td>6</td><td>red blood cell count (low)</td><td>0.1342</td><td>0.5938</td></tr><tr><td>7</td><td>History of pigmentation <present></td><td>0.3669</td><td>0.5886*</td></tr><tr><td>8</td><td>Classification of testee <qualified></td><td>0.7526</td><td>0.5794*</td></tr><tr><td>9</td><td>Subjective symptoms, etc. <present></td><td>0.1488</td><td>0.5775</td></tr><tr><td>10</td><td>Second quartile age</td><td>0.2788</td><td>0.5714</td></tr></table> |
a70fab74927ecf0f1bd88880082c177431aeb0fc88fa8533a0a82fb42e275118.png | complex | <table><tr><td rowspan="2">Item</td><td colspan="3">IntraobserverObserver 1</td><td colspan="3">IntraobserverObserver 2</td><td colspan="3">InterobserverOver assessments 1</td></tr><tr><td>ICC</td><td>Agreement (in %) </td><td>95% CI</td><td>ICC</td><td>Agreement (in %)</td><td>95% CI</td><td>ICC</td><td>Agreement (in %)</td><td>95% CI</td></tr><tr><td>(Q1) Frowning</td><td>0.64</td><td>82.3</td><td>0.56–0.71</td><td>0.48</td><td>74.7</td><td>0.38–0.57</td><td>0.50</td><td>75.5</td><td>0.40–0.59</td></tr><tr><td>(Q2) Narrowing or closing eyes</td><td>0.68</td><td>84.0</td><td>0.61–0.74</td><td>0.31</td><td>69.6</td><td>0.19–0.42</td><td>0.25</td><td>62.4</td><td>0.13–0.37</td></tr><tr><td>(Q3) Raising upper lip</td><td>0.61</td><td>85.2</td><td>0.52–0.68</td><td>0.35</td><td>67.5</td><td>0.24–0.49</td><td>0.30</td><td>64.1</td><td>0.15–0.43</td></tr><tr><td>(Q5) Tightened lips</td><td>0.80</td><td>90.3</td><td>0.75–0.84</td><td>0.29</td><td>74.7</td><td>0.17–0.40</td><td>0.35</td><td>70.5</td><td>0.23–0.46</td></tr><tr><td>(Q9) Restlessness</td><td>0.92</td><td>99.6</td><td>0.90–0.94</td><td>0.49</td><td>96.6</td><td>0.38–0.58</td><td>0.40</td><td>95.4</td><td>0.29–0.50</td></tr><tr><td>(Q14) Restricting jaw movement</td><td>0.77</td><td>93.7</td><td>0.71–0.81</td><td>0.40</td><td>86.1</td><td>0.29–0.50</td><td>0.41</td><td>86.1</td><td>0.30–0.51</td></tr></table> |
88995dabab71c8674c23f421a7bc4908da67c01937871776138593065c061afd.png | simple | <table><tr><td>Protocol</td><td>Denaturation</td><td>Touchdown annealing cycles</td><td>Additional annealing cycles</td><td>Extension</td><td>Final extension</td></tr><tr><td>GP5+/GP6+</td><td>1 min, 94°C</td><td>-</td><td>2 min, 40°C (40–50 cycles)</td><td>1.5 min, 72°C</td><td>4 min, 72°C</td></tr><tr><td>TDP1</td><td>1 min, 94°C</td><td>2 min, 45°C to 40°C in 0.5°C decrements (11 cycles)</td><td>2 min, 40°C (29–39 cycles)</td><td>1.5 min, 72°C</td><td>4 min, 72°C</td></tr><tr><td>TDP2</td><td>1 min, 94°C</td><td>2 min, 50°C to 40°C in 1.0°C decrements (11 cycles)</td><td>2 min, 40°C (29–39 cycles)</td><td>1.5 min, 72°C</td><td>4 min, 72°C</td></tr><tr><td>TDP3</td><td>1 min, 94°C</td><td>2 min, 50°C to 40°C in 0.5°C decrements (21 cycles)</td><td>2 min, 40°C (19–29 cycles)</td><td>1.5 min, 72°C</td><td>4 min, 72°C</td></tr><tr><td>TDP4</td><td>1 min, 94°C</td><td>2 min, 55°C to 40°C in 1.0°C decrements (16 cycles)</td><td>2 min, 40°C (24–34 cycles)</td><td>1.5 min, 72°C</td><td>4 min, 72°C</td></tr></table> |
70ecd44d511913d4389f8a03285e910ceae6a767b6c7e9108c6d54010fb79687.png | simple | <table><tr><td>Characteristic</td><td>HR</td><td>95% CI</td></tr><tr><td>Male sex</td><td>1.39</td><td>1.06–1.81</td></tr><tr><td>Age, per 10-year increment</td><td>1.09</td><td>1.07–1.10</td></tr><tr><td>Smoking</td><td>1.34</td><td>1.03–1.76</td></tr><tr><td>Drinking</td><td>1.03</td><td>0.81–1.31</td></tr><tr><td>Obesity</td><td>0.96</td><td>0.75–1.23</td></tr><tr><td>Hypertension</td><td>2.65</td><td>2.11–3.31</td></tr><tr><td>Dyslipidemia</td><td>1.08</td><td>0.87–1.35</td></tr><tr><td>Diabetes mellitus</td><td>2.07</td><td>1.40–3.06</td></tr><tr><td>AF</td><td>4.11</td><td>2.28–7.41</td></tr></table> |
42d44c89ee37e67c8db8f994e277d91e7fcbab6455fee9b84817d39e3404180f.png | simple | <table><tr><td>Time (h)</td><td><i>p</i>NO<sub>2</sub>PheDU<sup>a</sup> (mM)</td><td>Conversion (%)</td></tr><tr><td>0</td><td>1.94 ± 0.03</td><td>–</td></tr><tr><td>1</td><td>1.63 ± 0.05</td><td>16</td></tr><tr><td>2</td><td>1.29 ± 0.04</td><td>34</td></tr><tr><td>3</td><td>1.24 ± 0.02</td><td>36</td></tr><tr><td>4</td><td>1.18 ± 0.04</td><td>39</td></tr><tr><td>5</td><td>1.16 ± 0.11</td><td>40</td></tr><tr><td>24</td><td>0.54 ± 0.05</td><td>72</td></tr></table> |
ad2f149ce48fb360b61edae19876361a2547fb2ea7e83f07d5425f775c513f48.png | simple | <table><tr><td></td><td>t0 control</td><td>t0 inoculated</td><td>t1 control</td><td>t1 inoculated</td><td>t2 control</td><td>t2 inoculated</td></tr><tr><td>Resistance to antibiotics and toxic compounds</td><td>80.7</td><td>81.4</td><td>78.9</td><td>78.8</td><td>79.7</td><td>79.8</td></tr><tr><td>–</td><td>9.7</td><td>9.1</td><td>10.3</td><td>10.2</td><td>10.4</td><td>10.2</td></tr><tr><td>Multi locus sequence typing</td><td>7.2</td><td>7.2</td><td>8.2</td><td>8.4</td><td>7.5</td><td>7.4</td></tr><tr><td>Adhesion</td><td>1.4</td><td>1.4</td><td>1.5</td><td>1.5</td><td>1.5</td><td>1.5</td></tr><tr><td>Bacteriocins, ribosomally synthesized antibacterial peptides</td><td>0.4</td><td>0.5</td><td>0.6</td><td>0.5</td><td>0.4</td><td>0.6</td></tr><tr><td>Invasion and intracellular resistance</td><td>0.4</td><td>0.3</td><td>0.3</td><td>0.3</td><td>0.3</td><td>0.3</td></tr><tr><td>Toxins and superantigens</td><td>0.1</td><td>0.1</td><td>0.2</td><td>0.2</td><td>0.2</td><td>0.1</td></tr></table> |
8a0bc3cf52b515b097bc6b58d5c4889c1fde7e29b18e4a7d22c6e67039a798b3.png | complex | <table><tr><td><i>Baseline Characteristics (at time of diagnosis)</i></td><td><i>Mean ± SD or N (%)</i></td></tr><tr><td>Age (Years)</td><td>37.41 ± 10.14</td></tr><tr><td colspan="2"><i>Gender</i></td></tr><tr><td> Male</td><td>14 (66.7%)</td></tr><tr><td> Female</td><td>07 (33.3%)</td></tr><tr><td colspan="2"><i>Stage of Disease</i></td></tr><tr><td> I</td><td>3 (14.3%)</td></tr><tr><td> II</td><td>2 (9.5%)</td></tr><tr><td> III</td><td>4 (19.0%)</td></tr><tr><td> IV</td><td>12 (57.1%)</td></tr><tr><td colspan="2"><i>LDH</i></td></tr><tr><td> High</td><td>18 (85.7%)</td></tr><tr><td> Normal</td><td>03 (14.3%)</td></tr><tr><td colspan="2"><i>Extra Nodal site involvement</i></td></tr><tr><td> None</td><td>5 (23.8%)</td></tr><tr><td> Yes</td><td>16 (76.2%)</td></tr><tr><td colspan="2"><i>Bulky Disease</i></td></tr><tr><td> Yes</td><td>5 (23.8%)</td></tr><tr><td> No</td><td>16 (76.2%)</td></tr><tr><td colspan="2"><i>Bone Marrow Involvement</i></td></tr><tr><td> Yes</td><td>8 (38.1%)</td></tr><tr><td> No</td><td>13 (61.9%)</td></tr><tr><td colspan="2"><i>IPI</i></td></tr><tr><td> 1</td><td>04 (19.0%)</td></tr><tr><td> 2</td><td>09 (42.9%)</td></tr><tr><td> 3</td><td>08 (38.1%)</td></tr></table> |
e2d7bdc44eaaf6c996d2c44d32272f06579a7d4c6e2c6f8f1d026b45a259f000.png | complex | <table><tr><td colspan="2"><i>Variables</i></td><td><i>N</i></td><td><i>%</i></td></tr><tr><td rowspan="2"><i>Gender</i></td><td>Male</td><td>29</td><td>58</td></tr><tr><td>Female</td><td>21</td><td>42</td></tr><tr><td rowspan="2"><i>Educational level</i></td><td>Basic science (pre-clinical) years</td><td>12</td><td>24</td></tr><tr><td>Clinical years</td><td>38</td><td>76</td></tr><tr><td rowspan="2"><i>Previous EBM exposure</i></td><td>Read about or attended a lecture</td><td>28</td><td>56</td></tr><tr><td>Had a formal EBM training</td><td>0</td><td> 0</td></tr><tr><td rowspan="2"><i>Previous research exposure</i></td><td>Participated in ≥ 1 research activity</td><td>31</td><td>62</td></tr><tr><td>No previous research exposure</td><td>19</td><td>38</td></tr><tr><td rowspan="2"><i>Frequency of online search for evidence</i></td><td>≥ once per week</td><td>16</td><td>32</td></tr><tr><td>< once per week, or not at all</td><td>34</td><td>68</td></tr><tr><td rowspan="5"><i>First source sought for evidence (before the course)</i></td><td>Google</td><td>23</td><td>46</td></tr><tr><td>UpToDate<sup>TM</sup></td><td>13</td><td>26</td></tr><tr><td>PubMed</td><td>7</td><td>14</td></tr><tr><td>The Cochrane library</td><td>1</td><td> 2</td></tr><tr><td>Other</td><td>3</td><td> 6</td></tr></table> |
3b355d1d44a3c08bd8bd628c3ebc034aa6b06a363cc2745e1e86c57e78313cf0.png | complex | <table><tr><td>Characteristics</td><td>Patients (P, <i>n</i>=131)</td><td colspan="3">Spousal caregivers (SC, <i>n</i>=131)</td></tr><tr><td></td><td><i>n</i> (%)</td><td colspan="3"><i>n</i> (%)</td></tr><tr><td>Age (mean± SD), years</td><td>56.6±12.1 (ranging from 25 to 79)</td><td colspan="3">56.0±11.3 (ranging from 29 to 80)</td></tr><tr><td colspan="5">Gender</td></tr><tr><td> Male</td><td>82 (62.6)</td><td>49 (37.4)</td><td></td><td></td></tr><tr><td> Female</td><td>49 (37.4)</td><td>82 (62.6)</td><td></td><td></td></tr><tr><td colspan="5">Level of education</td></tr><tr><td> Primary school or less</td><td>64 (48.9)</td><td>67 (51.1)</td><td></td><td></td></tr><tr><td> High school</td><td>49 (37.4)</td><td>49 (37.4)</td><td></td><td></td></tr><tr><td> University or above</td><td>18 (13.7)</td><td>15 (11.5)</td><td></td><td></td></tr><tr><td colspan="5">Working status</td></tr><tr><td> Working</td><td>75 (57.3)</td><td>69 (52.7)</td><td></td><td></td></tr><tr><td> Not working</td><td>56 (42.7)</td><td>62 (47.3)</td><td></td><td></td></tr><tr><td rowspan="4">The average time since diagnosis/the duration in their role as a SC</td><td rowspan="4">13.7±23.0 months (ranging from 1 to 192 months)</td><td><6 months:</td><td>67 (51.2)</td><td></td></tr><tr><td>6 months ~2 years:</td><td>43 (32.8)</td><td></td></tr><tr><td>>2 years ~5 years:</td><td>13 (9.9)</td><td></td></tr><tr><td>>5 years:</td><td>8 (6.1)</td><td></td></tr><tr><td colspan="5">Couples were informed about the disease<sup>b</sup></td></tr><tr><td> Partly informed</td><td>33 (25.2)</td><td colspan="3">24 (18.3)</td></tr><tr><td> Well informed</td><td>98 (74.8)</td><td colspan="3">107 (81.7)</td></tr><tr><td rowspan="5">Time spent by SC in caring for patients/day [in hours, n (%)]</td><td rowspan="5"></td><td><2 hours:</td><td>10 (7.6)</td><td></td></tr><tr><td>2~4 hours:</td><td>14 (10.7)</td><td></td></tr><tr><td>>4~6 hours:</td><td>25 (19.1)</td><td></td></tr><tr><td>>6~8 hours:</td><td>21 (16.0)</td><td></td></tr><tr><td>>8 hours:</td><td>61 (46.6)</td><td></td></tr><tr><td>Types of cancer<sup>a</sup></td><td colspan="4">Digestive system cancer: 72 (55.0); Lung cancer: 35 (26.7);</td></tr><tr><td></td><td colspan="4">Urogenital system cancer: 19 (14.5); Others: 5 (3.8)</td></tr><tr><td>Dyad Characteristics<sup>c</sup></td><td></td><td></td><td></td><td></td></tr><tr><td>Duration of marriage (mean± SD), years</td><td colspan="4">30.8±11.6 (ranging from 1–52)</td></tr><tr><td>Relationship with their partner before the diagnosis of the cancer</td><td>Very goodBad</td><td>115 (87.8)0</td><td>Normal</td><td>16 (12.2)</td></tr><tr><td>Change in the relationship with their partner after the diagnosis of the cancer</td><td>ImprovedGetting worse</td><td>38 (29.0)0</td><td>No change</td><td>93 (71.0)</td></tr><tr><td>Financial burden on the family due to the treatment of cancer</td><td>Serious</td><td>77 (58.8)</td><td>Normal</td><td>49 (37.4)</td></tr><tr><td></td><td>Mild or None</td><td>5 (3.8)</td><td></td><td></td></tr></table> |
b7f95da801e5c941833d48659c2194441fb0bd77b2396a91b926a61db994c384.png | simple | <table><tr><td>Characteristic</td><td>TeleWii Group (<i>n</i> = 38)</td><td>SIBT group (<i>n</i> = 38)</td><td>Baseline comparison <i>p</i> value</td></tr><tr><td>Age (years) (mean ± SD)</td><td>67.45 (7.18)</td><td>69.84 (9.41)</td><td>0.14</td></tr><tr><td>Gender (number of males/females)</td><td>23/15</td><td>28/10</td><td>0.22</td></tr><tr><td>Disease duration (years) (mean ± SD)</td><td>6.16 (3.81)</td><td>7.47 (3.90)</td><td>0.14</td></tr><tr><td>Dominant PD phenotype (NT/T/YO)</td><td>21/12/5</td><td>14/15/9</td><td>0.24</td></tr><tr><td>More affected side (B/R/L)</td><td>7/21/10</td><td>8/20/10</td><td>0.95</td></tr><tr><td>Modified H&Y stage median (Q1–Q3)</td><td>2.50 (2.5–2.5)</td><td>2.50 (2.5–3.0)</td><td>0.76</td></tr><tr><td>UPDRS score (mean ± SD)</td><td>44.13 (24.05)</td><td>50.76 (24.12)</td><td>0.15</td></tr><tr><td>Falls (number) (mean ± SD)</td><td>0.58 (1.44)</td><td>1.84 (5.29)</td><td>0.24</td></tr><tr><td>MMSE score</td><td>26.77 (1.48)</td><td>28.64 (6.96)</td><td>0.16</td></tr><tr><td>GDS score</td><td>8.26 (5.17)</td><td>9.79 (5.34)</td><td>0.21</td></tr></table> |
0504431b2c64ae52308862eda77b0aceb8071dc113fa6e2b78de65467826a366.png | complex | <table><tr><td> </td><td colspan="3">Johannesburg<sup>**</sup></td><td colspan="3">Cape town</td><td colspan="3">Rustenburg</td></tr><tr><td> </td><td>Surveys<sup>#</sup></td><td>FGDs<sup>^</sup></td><td>Diaries</td><td>Surveys<sup>#</sup></td><td>FGDs<sup>*</sup></td><td>Diaries</td><td>Surveys<sup>#</sup></td><td>FGDs<sup>^</sup></td><td>Diaries</td></tr><tr><td>Pre-World Cup</td><td>-</td><td>2</td><td>-</td><td>-</td><td>2</td><td>-</td><td>-</td><td>1</td><td>-</td></tr><tr><td>World Cup</td><td>350 (95%)</td><td>2</td><td>8</td><td>128 (77%)</td><td>2</td><td>7</td><td>123 (91%)</td><td>1</td><td>8</td></tr><tr><td>Post-World Cup</td><td>273 (98%)</td><td>1</td><td>16</td><td>83 (83%)</td><td>2</td><td>6</td><td>102 (88%)</td><td>1</td><td>8</td></tr></table> |
f5e551ab0c7280bbe509cfd541038b40eb73225902c4fa6bce98ff0e72ea2c43.png | complex | <table><tr><td rowspan="2">Variables</td><td>Total</td><td>First-year</td><td>Fifth-year</td><td rowspan="2">p<sup>c</sup></td></tr><tr><td>n (%)</td><td>n (%)</td><td>n (%)</td></tr><tr><td colspan="5">Sociodemographic</td></tr><tr><td> Age<sup>a</sup></td><td>20.4 (3.0)</td><td>19.0 (2.0)</td><td>23.2 (2.3)</td><td><0.001<sup>d</sup></td></tr><tr><td> Male gender</td><td>5224 (47.3)</td><td>3365 (46.6)</td><td>1859 (48.6)</td><td>0.040</td></tr><tr><td> Married/cohabiting</td><td>364 (3.3)</td><td>153 (2.1)</td><td>211 (5.5)</td><td><0.001</td></tr><tr><td> Have children</td><td>505 (4.6)</td><td>232 (3.3)</td><td>273 (7.2)</td><td><0.001</td></tr><tr><td> Born in a rural area</td><td>598 (5.7)</td><td>412 (6.1)</td><td>186 (5.1)</td><td>0.045</td></tr><tr><td> Religious</td><td>9746 (88.0)</td><td>6447 (89.1)</td><td>3299 (86.1)</td><td><0.001</td></tr><tr><td> Migrated for medical school</td><td>3524 (32.8)</td><td>2317 (32.9)</td><td>1207 (32.5)</td><td>0.695</td></tr><tr><td> Intermediate/advanced english language proficiency</td><td>5275 (47.6)</td><td>3282 (45.3)</td><td>1993 (52.0)</td><td><0.001</td></tr><tr><td> National language-speaker<sup>b</sup></td><td>887 (8.0)</td><td>595 (8.2)</td><td>292 (7.6)</td><td>0.265</td></tr><tr><td> Relative of a physician</td><td>5489 (49.8)</td><td>3635 (50.4)</td><td>1854 (48.6)</td><td>0.073</td></tr><tr><td> Relationship with someone living abroad</td><td>9182 (84.9)</td><td>6051 (85.7)</td><td>3131 (83.5)</td><td>0.002</td></tr><tr><td colspan="5">University</td></tr><tr><td> Country</td><td></td><td></td><td></td><td><0.001</td></tr><tr><td>Bolivia</td><td>1618 (14.6)</td><td>1219 (16.8)</td><td>399 (10.4)</td><td></td></tr><tr><td>Chile</td><td>606 (5.5)</td><td>302 (4.2)</td><td>304 (7.9)</td><td></td></tr><tr><td>Colombia</td><td>1423 (12.9)</td><td>874 (12.1)</td><td>549 (14.3)</td><td></td></tr><tr><td>Costa Rica</td><td>148 (1.3)</td><td>137 (1.9)</td><td>11 (0.3)</td><td></td></tr><tr><td>Ecuador</td><td>1174 (10.6)</td><td>866 (11.9)</td><td>308 (8.0)</td><td></td></tr><tr><td>El Salvador</td><td>94 (0.9)</td><td>51 (0.7)</td><td>43 (1.1)</td><td></td></tr><tr><td>Honduras</td><td>990 (8.9)</td><td>556 (7.7)</td><td>434 (11.3)</td><td></td></tr><tr><td>Mexico</td><td>201 (1.8)</td><td>136 (1.9)</td><td>65 (1.7)</td><td></td></tr><tr><td>Paraguay</td><td>156 (1.4)</td><td>100 (1.4)</td><td>56 (1.5)</td><td></td></tr><tr><td>Peru</td><td>3768 (34.0)</td><td>2422 (33.5)</td><td>1346 (35.1)</td><td></td></tr><tr><td>Venezuela</td><td>894 (8.1)</td><td>575 (7.9)</td><td>319 (8.3)</td><td></td></tr><tr><td>Capital city location</td><td>3441 (31.1)</td><td>2150 (29.7)</td><td>1291 (33.7)</td><td><0.001</td></tr><tr><td>Publicly funded</td><td>7204 (65.1)</td><td>4652 (64.3)</td><td>2552 (66.6)</td><td>0.016</td></tr><tr><td colspan="5">Medical career</td></tr><tr><td> Have failed a class</td><td>3334 (30.9)</td><td>1790 (25.4)</td><td>1544 (41.2)</td><td><0.001</td></tr><tr><td> Satisfied with medical career</td><td>9705 (88.7)</td><td>6393 (89.3)</td><td>3312 (87.6)</td><td>0.005</td></tr><tr><td>Total</td><td>11,072 (100)</td><td>7238 (65.4)</td><td>3834 (34.6)</td><td></td></tr></table> |
c8d1f99c5e8f154ad973caef2aa0c45dda06b12f928a01cbf00f10315f966b0e.png | complex | <table><tr><td colspan="2"> </td></tr><tr><td>Severe disability</td><td>Any severe cerebral palsy (child non-ambulant and likely to remain so; GMFCS level 4 or 5), severe developmental delay (standardised score <−3 SD) or blindness.</td></tr><tr><td>Moderate disability</td><td>Moderate cerebral palsy (child non-ambulant at 2 years of age but who is likely to ambulate subsequently; GMFCS level 2 or 3), or deafness, or moderate developmental delay (standardised score from −3 SD to <−2 SD).</td></tr><tr><td>Mild disability</td><td>Mild cerebral palsy (child walking at 2 years of age with only minimal limitation of movement (GMFCS level 1), or suspect developmental delay (standardised score from −2 SD to <−1 SD).</td></tr><tr><td>No neurosensory disability</td><td>Children without any neurosensory impairment.</td></tr></table> |
17a7e08c20dcbcacf9e0c73b6081986cf1cd6400886bdc1cb464fad0bef4ddf5.png | simple | <table><tr><td>What influences the decision about prenatal examinations?</td><td></td></tr><tr><td><i>n</i> = 302</td><td><i>n (%)</i></td></tr><tr><td>Worry about the health of the baby</td><td>268 (89)</td></tr><tr><td>I want to know as much as possible</td><td>117 (39)</td></tr><tr><td>No reasons to refuse</td><td>81 (27)</td></tr><tr><td>Personal experience of chromosomal aberration or other severe disease among relative</td><td>69 (23)</td></tr><tr><td>The values of the society</td><td>44 (15)</td></tr><tr><td>Expectations from others</td><td>41 (14)</td></tr><tr><td>Everyone else does</td><td>14 (5)</td></tr><tr><td>Important to know the gender of the baby</td><td>4 (1)</td></tr><tr><td>Who influences the decision about prenatal examinations?</td><td></td></tr><tr><td><i>n</i> = 302</td><td></td></tr><tr><td>My partner</td><td>250 (83)</td></tr><tr><td>The doctor in antenatal care</td><td>168 (56)</td></tr><tr><td>Family and friends</td><td>132 (44)</td></tr><tr><td>The midwife in antenatal care</td><td>129 (43)</td></tr><tr><td>No one, I make the decision myself</td><td>80 (26)</td></tr></table> |
e4d99f82f9fd710cb70f13a980a399021669128f9e56d5641a920e831058063f.png | complex | <table><tr><td></td><td></td><td>Crude ORs<sup>ab</sup></td><td>95% CI<sup>c</sup></td><td><i>p</i>-value</td><td colspan="2">Adjusted ORs<sup>d</sup></td><td colspan="2">95% CI</td><td><i>p</i>-value</td></tr><tr><td>Age</td><td>≥30 years</td><td>(reference)</td><td></td><td></td><td colspan="2">(reference)</td><td colspan="2"></td><td></td></tr><tr><td></td><td><30 years</td><td>3.43</td><td>1.96-5.99</td><td>< 0.001</td><td colspan="2">2.74</td><td colspan="2">1.36-5.50</td><td>0.005</td></tr><tr><td>Sex</td><td>Male</td><td>(reference)</td><td></td><td></td><td colspan="2">(reference)</td><td colspan="2"></td><td></td></tr><tr><td></td><td>Female</td><td>0.46</td><td>0.10-2.05</td><td>0.297</td><td colspan="2">0.30</td><td colspan="2">0.05-1.69</td><td>0.171</td></tr><tr><td>Mental health service</td><td>No</td><td>(reference)</td><td></td><td></td><td colspan="2">(reference)</td><td colspan="2"></td><td></td></tr><tr><td></td><td>Implemented</td><td>0.45</td><td>0.24-0.84</td><td>0.009</td><td colspan="2">0.35</td><td colspan="2">0.16-0.76</td><td>0.008</td></tr><tr><td>Key person</td><td>No</td><td>(reference)</td><td></td><td></td><td colspan="2">(reference)</td><td colspan="2"></td><td></td></tr><tr><td></td><td>Yes</td><td>0.80</td><td>0.45-1.41</td><td>0.438</td><td colspan="2">0.58</td><td colspan="2">0.28-1.19</td><td>0.135</td></tr><tr><td>Route of infection</td><td>Homosexual</td><td>(reference)</td><td></td><td></td><td></td><td colspan="2"></td></tr><tr><td></td><td>Others</td><td>0.75</td><td>0.42-1.34</td><td>0.327</td><td></td><td colspan="2"></td></tr><tr><td>Regular employment</td><td>Yes</td><td>(reference)</td><td></td><td></td><td colspan="2">(reference)</td><td colspan="2"></td><td></td></tr><tr><td></td><td>No</td><td>2.46</td><td>1.38-4.39</td><td>0.002</td><td colspan="2">3.38</td><td colspan="2">1.58-7.23</td><td>0.002</td></tr><tr><td>Welfare benefits</td><td>No</td><td>(reference)</td><td></td><td></td><td></td><td colspan="2"></td></tr><tr><td></td><td>Yes</td><td>0.43</td><td>0.05-3.48</td><td>0.414</td><td></td><td colspan="2"></td></tr><tr><td>HIV test motive</td><td>Voluntary</td><td>(reference)</td><td></td><td></td><td colspan="2">(reference)</td><td colspan="2"></td><td></td></tr><tr><td></td><td>Others</td><td>0.40</td><td>0.25-0.63</td><td><0.001</td><td colspan="2">1.50</td><td colspan="2">0.38-2.70</td><td>0.180</td></tr><tr><td>Mental illness</td><td>No</td><td>(reference)</td><td></td><td></td><td></td><td colspan="2"></td></tr><tr><td></td><td>Yes</td><td>0.92</td><td>0.31-2.77</td><td>0.886</td><td></td><td colspan="2"></td></tr><tr><td>Illicit drug use</td><td>No</td><td>(reference)</td><td></td><td></td><td></td><td colspan="2"></td></tr><tr><td></td><td>Yes</td><td>1.25</td><td>0.67-2.33</td><td>0.492</td><td></td><td colspan="2"></td></tr><tr><td>Nationality</td><td>Japanese</td><td>(reference)</td><td></td><td></td><td></td><td colspan="2"></td></tr><tr><td></td><td>Others</td><td>1.00</td><td>0.32-3.09</td><td>1.000</td><td></td><td colspan="2"></td></tr><tr><td>AIDS diagnosis</td><td>No</td><td>(reference)</td><td></td><td></td><td></td><td colspan="2"></td></tr><tr><td></td><td>Yes</td><td>0.19</td><td>0.07-0.51</td><td>0.002</td><td></td><td colspan="2"></td></tr><tr><td>Antiretroviral therapy</td><td>Yes</td><td>(reference)</td><td></td><td></td><td colspan="2">(reference)</td><td colspan="2"></td><td></td></tr><tr><td></td><td>No</td><td>8.47</td><td>3.91-18.33</td><td><0.001</td><td colspan="2">7.51</td><td colspan="2">3.34-16.9</td><td>< 0.001</td></tr><tr><td>CD4+ lymphocyte count</td><td><200/mm<sup>3</sup></td><td>(reference)</td><td></td><td></td><td></td><td colspan="2"></td></tr><tr><td></td><td>200-499/mm<sup>3</sup></td><td>3.94</td><td>1.35-11.5</td><td>0.012</td><td></td><td colspan="2"></td></tr><tr><td></td><td>≥500/mm<sup>3</sup></td><td>6.11</td><td>2.01-18.6</td><td>0.001</td><td></td><td colspan="2"></td></tr></table> |
00c9fe158868908f0bc3bdf236600848124167ab0c2fe149f934890470d725cc.png | simple | <table><tr><td>Vascular smooth muscle cells</td><td>Respiratory epithelial cells</td></tr><tr><td>Viability for different pressures (0, 0.4, 0.8, 1.2, 1.6, 2 bar)</td><td>Viability (0.4 bar)</td></tr><tr><td>Viability for different velocities (10, 30, 55, 75, 95 mL/min)</td><td>Short-term differentiation (pan-cytokeratin expression)</td></tr><tr><td>Short-term differentiation (α-SMA expression)</td><td>Long-term differentiation (14 and 28 days: pan-cytokeratin expression and PAS reaction)</td></tr></table> |
ebc327f8d28fe5c5ec353028175930d86bf3e85622c6b73461980f516b5d9781.png | simple | <table><tr><td><i>p</i> (FWEcorr)</td><td>T</td><td>Z</td><td>Coordinates x, y, z {mm} max. peak</td><td>Brain area</td></tr><tr><td>0.003843</td><td>7.936576</td><td>4.986516</td><td>18, 36, −8</td><td>Right medial orbitofrontal cortex</td></tr></table> |
dd084dbbacb84a96f6e4d39f95fd8cee9c026a49a2873065e80b24bd2edc64bb.png | simple | <table><tr><td>Economic interventions</td><td>Definition</td><td>Search terms</td></tr><tr><td>Price Interventions - Taxes and Subsidies</td><td>Interventions that target prices for goods and services paid/received by households or firms</td><td>“tax”, “subsidy”, “subsidized”, “subsidies”, “penalty”, “penalties”, “voucher”, “vouchers”</td></tr><tr><td>Income Transfer Programs</td><td>Interventions that transfer resources directly to households</td><td>“income support”, “financial supplement”, “income supplement”, “fina ncial assistance”, “welfare benefits”, “social security”, “cash assistance”, “income transfer”, “asset transfer”, “pensions”, “welfare payments”, “cash transfer”, “cash support”, “bonus”, “economic support”</td></tr><tr><td>Incentive Programs</td><td>Interventions that provide rewards or penalties to motivate specific behaviours/outcomes</td><td>“results-based financing”, “pay for performance”, “performance pay”, “performance incentives”, “financial incentives”, “activity based funding”, “provider payment”</td></tr><tr><td>Livelihood Support Programs</td><td>Interventions that provide resources or skills to support income generation</td><td>“livelihood support”, “entrepreneurship training”, “business training”, “vocational skills training”, “vocational training”</td></tr><tr><td>Health-related Financial Services</td><td>Interventions that provide mechanisms for managing resource allocations and financial risks.</td><td>“microcredit”, “microlending”, “microloans”, “microfinance”, “loans”, “lending”, “microinsurance”</td></tr></table> |
92f796b72b00a6b102886a8f13b0bac9ddc5212974c9d1cd64fee1369b17fef5.png | simple | <table><tr><td>Variables</td><td>Negative AV</td><td>Positive AV</td><td><i>P</i> value</td></tr><tr><td>Failure rate (%)</td><td>36.8</td><td>81.2</td><td>0.016*<sup>,b</sup></td></tr><tr><td>Surgical rate (%)</td><td>21.1</td><td>75.0</td><td>0.002*<sup>,b</sup></td></tr><tr><td>AV at PHV (°/y)</td><td>−9.6 ± 7.6</td><td>8.2 ± 4.0</td><td>0.000*<sup>,a</sup></td></tr><tr><td>Initial curve magnitude (°)</td><td>26.3 ± 4.6</td><td>26.7 ± 5.7</td><td>0.832</td></tr><tr><td>Final curve magnitude (°)</td><td>29.4 ± 9.1</td><td>39.6 ± 14.2</td><td>0.015*<sup>,a</sup></td></tr><tr><td>PHV (cm/y)</td><td>8.8 ± 1.5</td><td>9.4 ± 1.8</td><td>0.327</td></tr><tr><td>Timing of PHV (yrs)</td><td>11.7 ± 1.1</td><td>11.5 ± 0.8</td><td>0.732</td></tr><tr><td>Age at diagnosis (yrs)</td><td>11.0 ± 1.3</td><td>10.0 ± 1.0</td><td>0.014*<sup>,a</sup></td></tr><tr><td>Initial SSMS</td><td>2.7 ± 0.6</td><td>2.2 ± 0.5</td><td>0.006*<sup>,a</sup></td></tr><tr><td>Initial DRU (R)</td><td>7.0 ± 0.8</td><td>6.4 ± 1.0</td><td>0.053</td></tr><tr><td>Initial DRU (U)</td><td>5.1 ± 0.8</td><td>4.3 ± 0.9</td><td>0.016*<sup>,a</sup></td></tr><tr><td>SSMS at PHV</td><td>3.4 ± 0.5</td><td>3.5 ± 0.6</td><td>0.495</td></tr><tr><td>DRU (R) at PHV</td><td>8.0 ± 0.7</td><td>8.0 ± 0.7</td><td>0.999</td></tr><tr><td>DRU (U) at PHV</td><td>5.9 ± 0.5</td><td>5.8 ± 0.4</td><td>0.244</td></tr><tr><td>Percentage of major thoracic curve (%)</td><td>47.3</td><td>68.8</td><td>0.306</td></tr><tr><td>Initial height (cm)</td><td>145.2 ± 7.2</td><td>138.3 ± 8.2</td><td>0.013*<sup>,a</sup></td></tr><tr><td>Final height (cm)</td><td>161.3 ± 5.4</td><td>159.2 ± 5.6</td><td>0.257</td></tr></table> |
5418cb7071169c0ff80b85923501892780e114e693c3a243ca96da27643937fa.png | simple | <table><tr><td> </td><td>Paucigranulocytic phenotype</td><td>Eosinophilic phenotype</td><td>Neutrophilic phenotype</td><td>Mixed granulocytic phenotype</td></tr><tr><td>Steroid naïve (n = 153)</td><td>65 (42.5%)</td><td>60 (39.2%)</td><td>25 (16.3%)</td><td>3 (2%)</td></tr><tr><td>Steroid-treated (n = 355)</td><td>138 (38%)</td><td>151 (43%)</td><td>55 (15%)</td><td>11 (3%)*</td></tr></table> |
25059de33224b2dcfd393bad8a64cd19778f0a6305f37ddce82ef24e72bcd871.png | complex | <table><tr><td rowspan="2" colspan="2">Level of Training</td><td colspan="6">Teaching Method</td></tr><tr><td>M</td><td>C</td><td>A</td><td>E</td><td>SLE</td><td>Total</td></tr><tr><td>Junior</td><td>Count</td><td>24</td><td>29</td><td>4</td><td>2</td><td>7</td><td>66</td></tr><tr><td></td><td>% within TM</td><td>77.4</td><td>31.5</td><td>11.8</td><td>14.3</td><td>20</td><td>32 %</td></tr><tr><td></td><td>Std Residual</td><td>4.5</td><td>−0.1</td><td>−2.1</td><td>−1.2</td><td>−1.3</td><td></td></tr><tr><td>Intermediate</td><td>Count</td><td>4</td><td>40</td><td>7</td><td>3</td><td>8</td><td>62</td></tr><tr><td></td><td>% within TM</td><td>12.9</td><td>43.5</td><td>20.6</td><td>21.4</td><td>22.9</td><td>30.1 %</td></tr><tr><td></td><td>Std Residual</td><td>−1.7</td><td>2.3</td><td>−1.0</td><td>−0.6</td><td>−0.8</td><td></td></tr><tr><td>Senior</td><td>Count</td><td>3</td><td>23</td><td>23</td><td>9</td><td>20</td><td>78</td></tr><tr><td></td><td>% within TM</td><td>9.7</td><td>25</td><td>67.6</td><td>64.3</td><td>57.1</td><td>37.9 %</td></tr><tr><td></td><td>Std Residual</td><td>−2.6</td><td>−2.0</td><td>2.8</td><td>1.6</td><td>1.9</td><td></td></tr><tr><td>Total</td><td></td><td>31</td><td>92</td><td>34</td><td>14</td><td>35</td><td>206</td></tr></table> |
f0bc60cdec5dd736300e80bd920dcaa89071f0e45f4971c0344252c7fc52f3f5.png | simple | <table><tr><td>Sample No.</td><td>HN37</td><td>HN44</td><td>HN48</td></tr><tr><td>RL2</td><td>6a</td><td>9c</td><td>8b</td></tr><tr><td>RL3</td><td>11c</td><td>10b</td><td>9a</td></tr><tr><td>SL2</td><td>9a</td><td>12c</td><td>10b</td></tr><tr><td>SL3</td><td>12a</td><td>13b</td><td>12a</td></tr></table> |
f843d74585eeb05f85fc2aa7805d8bd43033dfa3f5bf14339e78bc487729846a.png | simple | <table><tr><td></td><td>Frequency</td></tr><tr><td>’NNP’,’DISEASE’,’NNP’</td><td>36</td></tr><tr><td>’NNP’,’NNP’,’DISEASE’,’NNP’</td><td>16</td></tr><tr><td>’NNP’,’DISEASE’,’NNP’,’NNP’</td><td>11</td></tr><tr><td>’IN’,’DISEASE’,’CC’</td><td>10</td></tr></table> |
7098a547f74b59eb47f6e2a045997850d40c29ec68e14256f8aec386948c1447.png | complex | <table><tr><td></td><td colspan="2">Women</td><td colspan="2">Men</td><td colspan="2">Denominatorwomen</td><td colspan="2">Denominatormen</td></tr><tr><td></td><td>Per cent</td><td>CI</td><td>Per cent</td><td>CI</td><td>Unwt</td><td>Wt</td><td>Unwt</td><td>Wt</td></tr><tr><td colspan="9">Lifetime diagnoses</td></tr><tr><td> 16–24</td><td>0.1</td><td>(0.0% to 0.4%)</td><td>0.1</td><td>(0.0% to 0.8%)</td><td>1726</td><td>962</td><td>1363</td><td>990</td></tr><tr><td> 25–34</td><td>0.3</td><td>(0.1% to 0.6%)</td><td>0.1</td><td>(0.0% to 0.4%)</td><td>2362</td><td>1304</td><td>1431</td><td>1281</td></tr><tr><td> 35–44</td><td>0.3</td><td>(0.1% to 0.9%)</td><td>0.1</td><td>(0.0% to 0.8%)</td><td>1169</td><td>1397</td><td>775</td><td>1367</td></tr><tr><td> 45–54</td><td>0.8</td><td>(0.4% to 1.5%)</td><td>0.0</td><td></td><td>1058</td><td>1365</td><td>745</td><td>1336</td></tr><tr><td> 55–64</td><td>0.8</td><td>(0.4% to 1.7%)</td><td>0.0</td><td></td><td>969</td><td>1169</td><td>692</td><td>1085</td></tr><tr><td> 65–74</td><td>0.7</td><td>(0.3% to 1.7%)</td><td>0.0</td><td></td><td>787</td><td>843</td><td>581</td><td>758</td></tr><tr><td>Total aged 16–44</td><td>0.2</td><td>(0.1% to 0.4%)</td><td>0.1</td><td>(0.0% to 0.3%)</td><td>5257</td><td>3662</td><td>3569</td><td>3639</td></tr><tr><td>Total aged 45–74</td><td>0.8</td><td>(0.5% to 1.2%)</td><td>0.0</td><td></td><td>2814</td><td>3377</td><td>2018</td><td>3180</td></tr><tr><td>Total</td><td>0.5</td><td>(0.3% to 0.7%)</td><td>0.0</td><td>(0.0% to 0.2%)</td><td>8071</td><td>7040</td><td>5587</td><td>6818</td></tr><tr><td colspan="9">Past 5 years</td></tr><tr><td> 16–24</td><td>0.1</td><td>(0.0% to 0.4%)</td><td>0.1</td><td>(0.0% to 0.8%)</td><td>1726</td><td>962</td><td>1363</td><td>990</td></tr><tr><td> 25–34</td><td>0.1</td><td>(0.0% to 0.4%)</td><td>0.1</td><td>(0.0% to 0.4%)</td><td>2362</td><td>1304</td><td>1431</td><td>1281</td></tr><tr><td> 35–44</td><td>0.0</td><td>0.0%</td><td>0.0</td><td>0.0%</td><td>1169</td><td>1397</td><td>775</td><td>1367</td></tr><tr><td> 45–54</td><td>0.0</td><td>0.0%</td><td>0.0</td><td>0.0%</td><td>1058</td><td>1365</td><td>745</td><td>1336</td></tr><tr><td> 55–64</td><td>0.0</td><td>0.0%</td><td>0.0</td><td>0.0%</td><td>969</td><td>1169</td><td>692</td><td>1085</td></tr><tr><td> 65–74</td><td>0.0</td><td>0.0%</td><td>0.0</td><td>0.0%</td><td>787</td><td>843</td><td>581</td><td>758</td></tr><tr><td>Total aged 16–44</td><td>0.1</td><td>(0.0% to 0.2%)</td><td>0.0</td><td>(0.0% to 0.2%)</td><td>5257</td><td>3662</td><td>3569</td><td>3639</td></tr><tr><td>Total aged 45–74</td><td>0.0</td><td></td><td>0.0</td><td></td><td>2814</td><td>3377</td><td>2018</td><td>3180</td></tr><tr><td>Total</td><td>0.0</td><td>(0.0% to 0.1%)</td><td>0.0</td><td>(0.0% to 0.1%)</td><td>8071</td><td>7040</td><td>5587</td><td>6818</td></tr></table> |
3b4758e5ed09c238379a692c4d9a726d794219c1ddd5d3a50c9f94030461bc47.png | complex | <table><tr><td>Ergonomic instructions</td><td colspan="10">Health complaints often</td></tr><tr><td></td><td colspan="2">Eyes</td><td colspan="2">Neck, shoulders</td><td colspan="2">Head</td><td colspan="2">Hands, fingers, wrists</td><td colspan="2">Lower back</td></tr><tr><td></td><td>n*</td><td>OR (95%Cl)</td><td>N</td><td>OR (95%Cl)</td><td>N</td><td>OR (95%Cl)</td><td>n</td><td>OR (95%Cl)</td><td>N</td><td>OR (95%Cl)</td></tr><tr><td>To arrange desk, chair and screen in the right position</td><td>285</td><td>0.9 (0.7-1.1)</td><td>206</td><td>1.3 (1.0-1.7)</td><td>178</td><td>0.8 (0.7-1.1)</td><td>107</td><td>1.4 (0.9-2.1)</td><td>82</td><td>1.2 (0.8-1.9)</td></tr><tr><td>To take rest breaks</td><td>364</td><td>1.3 (1.0-1.6)</td><td>241</td><td>1.2 (0.9-1.6)</td><td>228</td><td>1.2 (0.9-1.6)</td><td>126</td><td>1.4 (0.9-2.0)</td><td>95</td><td>1.4 (0.9-2.3)</td></tr></table> |
4f8448c4e7da2d6618149612cb37b6c026a4112651e366e598893b59d3bb24ba.png | complex | <table><tr><td>Characteristic</td><td>Total</td></tr><tr><td>Patients, N</td><td>448</td></tr><tr><td colspan="2">HAE diagnosis, n (%)</td></tr><tr><td> Type 1</td><td>423 (94.4)</td></tr><tr><td> Type 2</td><td>25 (5.6)</td></tr><tr><td colspan="2">Sex, n (%)</td></tr><tr><td> Female</td><td>263 (58.7)</td></tr><tr><td> Male</td><td>185 (41.3)</td></tr><tr><td colspan="2">Age at enrollment, y</td></tr><tr><td> Mean (SD)</td><td>40.8 (14.7)</td></tr><tr><td> Median (min, max)</td><td>39.1 (16.5, 81.8)</td></tr><tr><td colspan="2">Country, n (%)</td></tr><tr><td> France</td><td>119 (26.6)</td></tr><tr><td> Spain</td><td>69 (15.4)</td></tr><tr><td> Germany</td><td>57 (12.7)</td></tr><tr><td> United Kingdom</td><td>53 (11.8)</td></tr><tr><td> Italy</td><td>46 (10.3)</td></tr><tr><td> Israel</td><td>45 (10.0)</td></tr><tr><td> Denmark</td><td>19 (4.2)</td></tr><tr><td> Brazil</td><td>16 (3.6)</td></tr><tr><td> Greece</td><td>14 (3.1)</td></tr><tr><td> Austria</td><td>8 (1.8)</td></tr><tr><td> Sweden</td><td>2 (0.4)</td></tr></table> |
490b081ee4338da0b27e5b81c79ffddca19d7a17b39b13748852fed10044b74d.png | simple | <table><tr><td>Client Characteristic</td><td>No. (%)</td></tr><tr><td>Sex</td><td></td></tr><tr><td>Female</td><td>1303 (91)</td></tr><tr><td>Male</td><td>122 (9)</td></tr><tr><td>Age, years</td><td></td></tr><tr><td><15</td><td>75 (5)</td></tr><tr><td>15–18</td><td>786 (55)</td></tr><tr><td>19–20</td><td>514 (36)</td></tr><tr><td>21–24</td><td>50 (4)</td></tr><tr><td>No. of living children</td><td></td></tr><tr><td>0</td><td>757 (53)</td></tr><tr><td>1</td><td>502 (35)</td></tr><tr><td>2</td><td>148 (10)</td></tr><tr><td>3</td><td>14 (1)</td></tr><tr><td>5 or more</td><td>4 (0.3)</td></tr><tr><td>Marital status</td><td></td></tr><tr><td>Married or cohabiting</td><td>553 (39)</td></tr><tr><td>Single or living alone</td><td>872 (61)</td></tr><tr><td>First-time family planning user</td><td></td></tr><tr><td>Yes</td><td>987 (69)</td></tr><tr><td>No</td><td>438 (31)</td></tr></table> |
3d3d9920a51f3e376749246621e9e956d4d6f7975304c83f94f25230e2ca0200.png | complex | <table><tr><td></td><td colspan="2">Age</td><td colspan="2">IOP</td><td colspan="2">Number of Glaucoma Medications</td><td colspan="2">AL</td><td colspan="2">ACD</td><td colspan="2">LT</td><td colspan="2">VCD</td></tr><tr><td></td><td>ρ</td><td><i>P</i> value</td><td>ρ</td><td><i>P</i> value</td><td>ρ</td><td><i>P</i> value</td><td>ρ</td><td><i>P</i> value</td><td>ρ</td><td><i>P</i> value</td><td>ρ</td><td><i>P</i> value</td><td>ρ</td><td><i>P</i> value</td></tr><tr><td>G-CSF</td><td>−0.232</td><td>0.173</td><td>0.506</td><td>0.002*</td><td>0.464</td><td>0.004*</td><td>−0.060</td><td>0.729</td><td>−0.074</td><td>0.670</td><td>0.121</td><td>0.482</td><td>−0.097</td><td>0.572</td></tr><tr><td>IL-6</td><td>−0.115</td><td>0.503</td><td>0.424</td><td>0.010</td><td>0.443</td><td>0.007*</td><td>−0.089</td><td>0.605</td><td>0.031</td><td>0.860</td><td>0.040</td><td>0.815</td><td>−0.132</td><td>0.444</td></tr><tr><td>IL-8</td><td>−0.143</td><td>0.406</td><td>0.375</td><td>0.024</td><td>0.439</td><td>0.007*</td><td>−0.198</td><td>0.246</td><td>0.056</td><td>0.743</td><td>0.004</td><td>0.980</td><td>−0.201</td><td>0.239</td></tr><tr><td>MCP-1</td><td>−0.097</td><td>0.573</td><td>0.291</td><td>0.085</td><td>0.285</td><td>0.092</td><td>−0.110</td><td>0.523</td><td>0.040</td><td>0.817</td><td>−0.002</td><td>0.989</td><td>−0.140</td><td>0.414</td></tr><tr><td>MCP-3</td><td>−0.127</td><td>0.460</td><td>0.420</td><td>0.011</td><td>0.347</td><td>0.038</td><td>−0.040</td><td>0.816</td><td>0.005</td><td>0.977</td><td>0.177</td><td>0.300</td><td>−0.108</td><td>0.531</td></tr><tr><td>MDC</td><td>−0.261</td><td>0.125</td><td>0.201</td><td>0.240</td><td>0.131</td><td>0.445</td><td>−0.411</td><td>0.013</td><td>0.193</td><td>0.259</td><td>−0.182</td><td>0.288</td><td>−0.364</td><td>0.029</td></tr><tr><td>MIP-1β</td><td>−0.166</td><td>0.335</td><td>0.387</td><td>0.020</td><td>0.395</td><td>0.017</td><td>−0.130</td><td>0.450</td><td>0.003</td><td>0.985</td><td>0.029</td><td>0.865</td><td>−0.126</td><td>0.463</td></tr><tr><td>VEGF</td><td>0.013</td><td>0.941</td><td>0.318</td><td>0.058</td><td>0.198</td><td>0.247</td><td>−0.051</td><td>0.769</td><td>−0.091</td><td>0.597</td><td>0.300</td><td>0.075</td><td>−0.185</td><td>0.280</td></tr></table> |
d8c9a73fc6bb5973608bcfe200699cb0be5d50f223c4775647a7e00049d9b65d.png | simple | <table><tr><td>Phenotype</td><td>Loci</td><td>C/C</td><td>C/R</td><td>R/R</td></tr><tr><td>BMI</td><td><i>ht1</i></td><td>518(22.34 ± 3.70)</td><td>904(22.34 ± 3.62)</td><td>454(22.35 ± 3.59)</td></tr><tr><td></td><td><i>ht2</i></td><td>584(22.39 ± 3.64)</td><td>896(22.35 ± 3.63)</td><td>396(22.28 ± 3.62)</td></tr><tr><td></td><td><i>ht3</i></td><td>1719(22.31 ± 3.58)</td><td>152(22.72 ± 4.04)</td><td>5(23.54 ± 6.94)</td></tr><tr><td></td><td><i>ht4</i></td><td>1788(22.36 ± 3.65)</td><td>86(22.16 ± 3.21)</td><td>2(19.80 ± 1.41)</td></tr><tr><td>AUC_G</td><td><i>ht1</i></td><td>449(438.33 ± 74.35)</td><td>757(429.75 ± 79.48)</td><td>375(420.39 ± 84.28)</td></tr><tr><td></td><td><i>ht2</i></td><td>480(420.98 ± 83.23)</td><td>753(430.50 ± 78.91)</td><td>348(441.20 ± 73.83)</td></tr><tr><td></td><td><i>ht3</i></td><td>1446(430.46 ± 80.09)</td><td>130(425.51 ± 72.41)</td><td>5(405.10 ± 75.33)</td></tr><tr><td></td><td><i>ht4</i></td><td>1516(429.95 ± 79.07)</td><td>64(431.35 ± 88.89)</td><td>1(361.50)</td></tr><tr><td>HOMA_B</td><td><i>ht1</i></td><td>509(225.47 ± 126.01)</td><td>898(240.16 ± 144.09)</td><td>448(254.96 ± 200.10)</td></tr><tr><td></td><td><i>ht2</i></td><td>577(251.20 ± 186.38)</td><td>889(240.64 ± 143.02)</td><td>389(220.51 ± 128.44)</td></tr><tr><td></td><td><i>ht3</i></td><td>1700(239.45 ± 157.09)</td><td>150(242.64 ± 138.61)</td><td>5(239.14 ± 23.78)</td></tr><tr><td></td><td><i>ht4</i></td><td>1768(239.99 ± 157.73)</td><td>85(232.89 ± 98.82)</td><td>2(280.10 ± 66.75)</td></tr><tr><td>HOMA_IR</td><td><i>ht1</i></td><td>512(2.66 ± 1.60)</td><td>898(2.58 ± 1.45)</td><td>450(2.54 ± 1.50)</td></tr><tr><td></td><td><i>ht2</i></td><td>579(2.54 ± 1.61)</td><td>889(2.59 ± 1.34)</td><td>392(2.68 ± 1.68)</td></tr><tr><td></td><td><i>ht3</i></td><td>1705(2.59 ± 1.46)</td><td>150(2.65 ± 1.95)</td><td>5(2.58 ± 1.28)</td></tr><tr><td></td><td><i>ht4</i></td><td>1773(2.60 ± 1.52)</td><td>85(2.42 ± 1.16)</td><td>2(2.00 ± 0.24)</td></tr><tr><td>FPI</td><td><i>ht1</i></td><td>512(12.34 ± 6.48)</td><td>898(12.09 ± 5.64)</td><td>450(12.00 ± 5.71)</td></tr><tr><td></td><td><i>ht2</i></td><td>579(11.98 ± 6.12)</td><td>889(12.15 ± 5.31)</td><td>392(12.35 ± 6.78)</td></tr><tr><td></td><td><i>ht3</i></td><td>1705(12.11 ± 5.74)</td><td>150(12.45 ± 7.54)</td><td>5(12.36 ± 4.49)</td></tr><tr><td></td><td><i>ht4</i></td><td>1773(12.17 ± 5.96)</td><td>85(11.51 ± 4.61)</td><td>2(10.50 ± 0.71)</td></tr><tr><td>FPG</td><td><i>ht1</i></td><td>449(86.46 ± 12.66)</td><td>757(85.32 ± 11.89)</td><td>375(84.49 ± 13.30)</td></tr><tr><td></td><td><i>ht2</i></td><td>480(84.49 ± 12.83)</td><td>753(85.40 ± 11.82)</td><td>348(86.86 ± 13.23)</td></tr><tr><td></td><td><i>ht3</i></td><td>1446(85.53 ± 12.66)</td><td>130(84.65 ± 10.31)</td><td>5(82.20 ± 9.36)</td></tr><tr><td></td><td><i>ht4</i></td><td>1516(85.44 ± 12.50)</td><td>64(85.64 ± 11.87)</td><td>1(80.00)</td></tr></table> |
cf2d226cfee32122649925da9c177ed66de04aa67f5d8e3441c1ecd7ba859b2e.png | simple | <table><tr><td>Terms</td><td>aklB, ada</td><td>aklB, ada, dinJ</td></tr><tr><td>DNA repair (SP-PIR)</td><td>5.1E-28</td><td></td></tr><tr><td>DNA damage (SP-PIR)</td><td>6.2E-28</td><td></td></tr><tr><td>Cellular response to stress (GO)</td><td></td><td>7.5E-23</td></tr><tr><td>DNA repair (GO)</td><td></td><td>1.6E-21</td></tr><tr><td>Response to DNA damage stimulus (GO)</td><td></td><td>1.6E-21</td></tr></table> |
4ca1c17aee2e46f874c4ceaf22f09e848128bef6c264e93d214f6f0e82453bb8.png | complex | <table><tr><td rowspan="2"></td><td>≤ 11.6</td><td>> 11.6</td><td></td></tr><tr><td><i>N</i> = 129</td><td><i>N</i> = 135</td><td><i>P</i>-value</td></tr><tr><td>Gender (F/M)</td><td>57/72</td><td>62/73</td><td>0.776</td></tr><tr><td>Age (yr)</td><td>28.4 ± 18.75</td><td>41.2 ± 15.58</td><td>< 0.001</td></tr><tr><td>Body mass index (kg/m<sup>2</sup>)</td><td>23.4 ± 2.42</td><td>22.8 ± 2.63</td><td>0.029</td></tr><tr><td>White blood count (10<sup>9</sup>/L)</td><td>6.7 ± 1.44</td><td>6.3 ± 1.47</td><td>0.016</td></tr><tr><td>Hemoglobin (g/L)</td><td>128.8 ± 12.80</td><td>134.3 ± 12.31</td><td>< 0.001</td></tr><tr><td>Mean corpuscular hemoglobin (pg)</td><td>27.2 ± 2.98</td><td>28.5 ± 3.07</td><td>< 0.001</td></tr><tr><td>Mean corpuscular hemoglobin concentration (g/L)</td><td>326.5 ± 10.64</td><td>326.8 ± 27.54</td><td>0.902</td></tr><tr><td>Alanine aminotransferase (U/L)</td><td>17.5 ± 8.86</td><td>19.6 ± 8.40</td><td>0.047</td></tr><tr><td>Aspartate aminotransferase (U/L)</td><td>22.3 ± 6.20</td><td>21.9 ± 5.54</td><td>0.669</td></tr><tr><td>Creatinine (umol/L)</td><td>58.1 ± 17.60</td><td>70.1 ± 12.94</td><td>< 0.001</td></tr><tr><td>Albumin (g/L)</td><td>44.7 ± 3.53</td><td>44.6 ± 3.26</td><td>0.850</td></tr><tr><td>Globulin (g/L)</td><td>22.1 ± 4.09</td><td>22.8 ± 3.84</td><td>0.180</td></tr><tr><td>High-sensitivity C-reactive protein (mg/L)</td><td>1.4 ± 1.03</td><td>1.0 ± 0.90</td><td>0.002</td></tr><tr><td>Serum iron (μmol/L)</td><td>11.9 ± 1.88</td><td>15.7 ± 5.64</td><td>< 0.001</td></tr><tr><td>Serum copper (μmol/L)</td><td>12.7 ± 4.51</td><td>10.0 ± 3.22</td><td>< 0.001</td></tr><tr><td>Serum zinc (μmol/L)</td><td>10.9 ± 1.88</td><td>12.0 ± 2.64</td><td>< 0.001</td></tr></table> |
77d8034995fddc3eb8c0fd7e5f11693712bcd7c0975725fa11294391ef5f431d.png | complex | <table><tr><td>Data<sup><i>∗</i></sup></td><td>BJK recipe (<i>n</i> = 42)</td><td>Diclofenac (<i>n</i> = 42)</td><td> <i>P</i>value<sup><i>∗∗</i></sup></td></tr><tr><td>Female, number (%)</td><td>38 (90.5)</td><td>39 (92.9)</td><td>0.693<sup>c</sup></td></tr><tr><td>Age; yrs, mean (SD)</td><td>61.67 (7.3)</td><td>63.5 (8.19)</td><td>0.282<sup>t</sup></td></tr><tr><td>Weight; kg., mean (SD)</td><td>66.14 (9.48)</td><td>64.31 (10.03)</td><td>0.394<sup>t</sup></td></tr><tr><td>Height; cm., mean (SD)</td><td>155.76 (7.12)</td><td>155.31 (8.17)</td><td>0.464<sup>m</sup></td></tr><tr><td>BMI; Kg/m<sup>2</sup>, mean (SD)</td><td>27.23 (3.07)</td><td>26.62 (3.28)</td><td>0.277<sup>m</sup></td></tr><tr><td>Visual analogue scale (VAS; mm., mean (SD))</td><td>31.02 (21.54)</td><td>36.05 (22.69)</td><td>0.159<sup>m</sup></td></tr><tr><td>100-meter walking time; sec., mean (SD)</td><td>124.19 (24.31)</td><td>131.6 (33.56)</td><td>0.638<sup>m</sup></td></tr><tr><td colspan="4">WOMAC index score, mean (SD)</td></tr><tr><td>Pain index</td><td>16.19 (7.16)</td><td>18.69 (7.06)</td><td>0.119<sup>m</sup></td></tr><tr><td>Stiff index</td><td>5.4 (3.47)</td><td>7.48 (5.08)</td><td>0.056<sup>m</sup></td></tr><tr><td>Physical function index</td><td>49.73 (19.93)</td><td>59.8 (26.19)</td><td>0.062<sup>m</sup></td></tr><tr><td>Total score</td><td>71.49 (27.64)</td><td>85.68 (35.5)</td><td>0.051<sup>m</sup></td></tr><tr><td>Laboratory data, mean (SD)</td><td colspan="3"> </td></tr><tr><td colspan="4"><i>Blood pressure</i></td></tr><tr><td>Systolic (mm·Hg)</td><td>126.6 (12.82)</td><td>126.26 (17.24)</td><td>0.92<sup>t</sup></td></tr><tr><td>Diastolic (mm·Hg)</td><td>81.9 (9.23)</td><td>78.31 (8.5)</td><td>0.067<sup>t</sup></td></tr><tr><td colspan="4"><i>Renal function tests</i></td></tr><tr><td>BUN (mg/dL)</td><td>13.24 (3.7)</td><td>13.3 (3.4)</td><td>0.941<sup>t</sup></td></tr><tr><td>Creatinine (mg/dL)</td><td>0.71 (0.19)</td><td>0.71 (0.17)</td><td>0.865<sup>m</sup></td></tr><tr><td colspan="4"><i>Liver function tests</i></td></tr><tr><td>AST (U/L)</td><td>23.6 (10.68)</td><td>23.12 (8.27)</td><td>0.993<sup>m</sup></td></tr><tr><td>ALT (U/L)</td><td>39.6 (12.2)</td><td>40.69 (15.1)</td><td>0.816<sup>m</sup></td></tr><tr><td>ALP (U/L)</td><td>90.45 (18.19)</td><td>90.38 (22.6)</td><td>0.99<sup>t</sup></td></tr></table> |
2c764007bc2e8b99601930d5eef2874b7e0f012acb6e01651bcad796a7a455fc.png | complex | <table><tr><td rowspan="2">Compounds</td><td colspan="3">III Instar</td><td colspan="3">Pupae</td></tr><tr><td>LC<sub>50</sub></td><td>LC<sub> 90</sub></td><td>Chi **</td><td>LC<sub> 50</sub></td><td>LC<sub> 90</sub></td><td>Chi **</td></tr><tr><td><i>t</i>-anethole</td><td>7.4 (6.5–8.3)</td><td>18.8 (17.4–20.2)</td><td>0.055</td><td>28.6 (26.4–30.8)</td><td>48.6 (45.79–51.51)</td><td>0.039</td></tr><tr><td>carvacrol</td><td>5.5 (5.2–5.7)</td><td>11.3 (9.9–2.7)</td><td>2.684</td><td>53.2 (49.9–56.6)</td><td>111.4 (102.0–120.8)</td><td>0.483</td></tr><tr><td>cinnamaldehyde</td><td>18.4 (17.6–19.2)</td><td>39.2 (35.2–43.1)</td><td>1.203</td><td>90.1 (84.6–95.6)</td><td>179.3 (170.4–188.1)</td><td>0.048</td></tr><tr><td>cuminaldehyde</td><td>23.0 (21.9–24.1)</td><td>52.2 (50.1–54.3)</td><td>4.313</td><td>95.4 (91.1–99.6)</td><td>198.2 (193.7–202.7)</td><td>0.896</td></tr><tr><td><i>p-</i>cymene</td><td>23.1 (21.2–24.9)</td><td>91.9 (89.7–94.0)</td><td>0.253</td><td>306.3(297.4–315.1</td><td>549.2 (533.0–565.3)</td><td>1.326</td></tr><tr><td>eucalyptol</td><td>24.8 (22.7–26.8)</td><td>48.0 (44.9–51.1)</td><td>0.116</td><td>92.9 (89.1–96.6)</td><td>193.9 (186.9–201.0)</td><td>0.574</td></tr><tr><td>eugenol</td><td>23.0 (21.7–24.3)</td><td>51.2 (46.6–55.8)</td><td>0.279</td><td>106.9(99.5–114.3)</td><td>198.4 (189.6–207.1)</td><td>0.665</td></tr><tr><td>(-)-limonene</td><td>14.2 (13.5–15.0)</td><td>36.4 (33.5–39.4)</td><td>0.572</td><td>78.4 (73.3–83.4)</td><td>155.0 (145.6–164.3)</td><td>0.865</td></tr><tr><td>myrcene</td><td>19.5 (18.5–20.4)</td><td>40.0 (36.7–43.2)</td><td>2.561</td><td>31.8 (30.4–33.1)</td><td>59.1 (55.2–62.9)</td><td>1.287</td></tr><tr><td><i>β</i>-pinene</td><td>19.6 (18.8–20.3)</td><td>61.9 (57.8–65.9)</td><td>0.265</td><td>206.9(95.3–105.8)</td><td>458.4 (440.1–476.6)</td><td>3.404</td></tr><tr><td>thymol</td><td>23.4 (22.5–24.4)</td><td>45.4 (43.3–47.6)</td><td>0.683</td><td>100.57 (88.3–111.8)</td><td>168.7 (155.8–181.6)</td><td>1.642</td></tr></table> |
710447d306fe663ba229a312e8feb5fb1bc3125149cf6b9b954711af59c5baef.png | complex | <table><tr><td>Genotype</td><td>Cases, n=125 (%)</td><td>Controls, n=200 (%)</td><td>Crude OR (95% CI)</td><td>Adjusteda OR (95% CI)</td></tr><tr><td colspan="5"><i>MDM2</i> SNP309</td></tr><tr><td> TT</td><td>30 (24.0)</td><td>62 (31.0)</td><td>1.00 (reference)</td><td>1.00 (reference)</td></tr><tr><td> TG</td><td>61 (48.8)</td><td>98 (49.0)</td><td>1.29 (0.75–2.21)</td><td>1.09 (0.60–1.99)</td></tr><tr><td> GG</td><td>34 (27.2)</td><td>40 (20.0)</td><td>1.76 (0.93–3.30)</td><td>1.64 (0.81–3.28)</td></tr><tr><td></td><td></td><td></td><td>P-trend=0.08</td><td>P-trend=0.45</td></tr><tr><td>TG+GG</td><td>95 (76.0)</td><td>138 (69.0)</td><td>1.42 (0.86–2.37)</td><td>1.24 (0.70–2.18)</td></tr><tr><td colspan="5"><i>TP53</i> codon 72</td></tr><tr><td> Arg/Arg</td><td>52 (41.6)</td><td>75 (37.5)</td><td>1.00 (reference)</td><td>1.00 (reference)</td></tr><tr><td> Arg/Pro</td><td>55 (44.0)</td><td>102 (51.0)</td><td>0.78 (0.48–1.26)</td><td>0.66 (0.38–1.15)</td></tr><tr><td> Pro/Pro</td><td>18 (14.4)</td><td>23 (11.5)</td><td>1.13 (0.55–2.30)</td><td>1.17 (0.54–2.55)</td></tr><tr><td></td><td></td><td></td><td>P-trend=0.08</td><td>P-trend=0.79</td></tr><tr><td>Arg/Pro + Pro/Pro</td><td>73 (58.4)</td><td>125 (62.5)</td><td>0.84 (0.53–1.33)</td><td>0.76 (0.46–1.27)</td></tr><tr><td colspan="5"><i>ESR1 Pvu</i>II</td></tr><tr><td> TT</td><td>38 (30.4)</td><td>60 (30.0)</td><td>1.00 (reference)</td><td>1.00 (reference)</td></tr><tr><td> TC</td><td>60 (48.0)</td><td>102 (51.0)</td><td>0.93 (0.55–1.56)</td><td>0.94 (0.55–1.56)</td></tr><tr><td> CC</td><td>27 (21.5)</td><td>38 (19.0)</td><td>1.12 (0.59–2.13)</td><td>0.89 (0.43–1.86)</td></tr><tr><td></td><td></td><td></td><td>P-trend=0.78</td><td>P-trend=0.76</td></tr><tr><td> TC+CC</td><td>87 (69.6)</td><td>140 (70.0)</td><td>0.98 (0.60–1.60)</td><td>0.93 (0.53–1.60)</td></tr><tr><td colspan="5"><i>ESR1 Xba</i>I</td></tr><tr><td> AA</td><td>77 (61.6)</td><td>127 (63.5)</td><td>1.00 (reference)</td><td>1.00 (reference)</td></tr><tr><td> AG</td><td>42 (33.6)</td><td>64 (32.0)</td><td>1.08 (0.67–1.75)</td><td>0.88 (0.51–1.53)</td></tr><tr><td> GG</td><td>6 (4.8)</td><td>9 (4.5)</td><td>1.10 (0.38–3.21)</td><td>0.60 (0.16–2.24)</td></tr><tr><td></td><td></td><td></td><td>P-trend=0.74</td><td>P-trend=0.43</td></tr><tr><td> AG+GG</td><td>48 (38.4)</td><td>73 (36.5)</td><td>1.09 (0.68–1.72)</td><td>0.84 (0.50–1.43)</td></tr><tr><td colspan="5"><i>p2</i>1 codon 31</td></tr><tr><td> Ser/Ser</td><td>21 (16.8)</td><td>38 (19.0)</td><td>1.00 (reference)</td><td>1.00 (reference)</td></tr><tr><td> Ser/Arg</td><td>73 (58.4)</td><td>109 (54.5)</td><td>1.21 (0.66–2.23)</td><td>1.13 (0.57–2.22)</td></tr><tr><td> Arg/Arg</td><td>31 (24.8)</td><td>53 (26.5)</td><td>1.06 (0.53–2.12)</td><td>1.01 (0.47–2.19)</td></tr><tr><td></td><td></td><td></td><td>P-trend=0.95</td><td>P-trend=0.98</td></tr><tr><td> Ser/Arg + Arg/Arg</td><td>104 (83.2)</td><td>162 (81.0)</td><td>1.16 (0.65–2.09)</td><td>1.09 (0.57–2.09)</td></tr></table> |
06cb522567a8038be003f143f4b508fcc7fe9db3890e0e156716b3c1cfeb96b6.png | complex | <table><tr><td>Valence class/Emotion</td><td colspan="3">Europeans</td><td colspan="3">Iranians</td></tr><tr><td></td><td>β</td><td><i>T</i></td><td>Partial <i>r</i></td><td>β</td><td><i>T</i></td><td>Partial <i>r</i></td></tr><tr><td>Negative pictures</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Happiness</td><td>0.13</td><td>2.61*</td><td>0.28</td><td>0.09</td><td>2.23*</td><td>0.23</td></tr><tr><td>Sadness</td><td>0.40</td><td>5.89***</td><td>0.56</td><td>0.42</td><td>7.98***</td><td>0.65</td></tr><tr><td>Fear</td><td>0.49</td><td>8.43***</td><td>0.69</td><td>0.63</td><td>10.94***</td><td>0.76</td></tr><tr><td>Surprise</td><td>0.09</td><td>1.35</td><td>0.15</td><td>0.04</td><td>0.63</td><td>0.07</td></tr><tr><td>Anger</td><td>0.03</td><td>0.67</td><td>0.08</td><td>0.08</td><td>1.74</td><td>0.18</td></tr><tr><td>Disgust</td><td>0.31</td><td>5.70***</td><td>0.54</td><td>0.08</td><td>1.73</td><td>0.18</td></tr><tr><td>Positive pictures</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Happiness</td><td>0.85</td><td>14.87***</td><td>0.86</td><td>0.36</td><td>4.91***</td><td>0.51</td></tr><tr><td>Sadness</td><td>0.12</td><td>2.18*</td><td>0.24</td><td>0.01</td><td>0.14</td><td>0.02</td></tr><tr><td>Fear</td><td>0.39</td><td>6.15***</td><td>0.57</td><td>0.34</td><td>3.43**</td><td>0.38</td></tr><tr><td>Surprise</td><td>0.05</td><td>0.78</td><td>0.09</td><td>0.40</td><td>5.36***</td><td>0.54</td></tr><tr><td>Anger</td><td>0.09</td><td>1.49</td><td>0.16</td><td>0.08</td><td>0.78</td><td>0.09</td></tr><tr><td>Disgust</td><td>0.13</td><td>2.40*</td><td>0.26</td><td>0.22</td><td>2.98**</td><td>0.34</td></tr></table> |
78e1b2c07318b5a96a5b3db338e3f072178730132ff92d34df9bf07f816a0f09.png | simple | <table><tr><td>AFL</td><td>AML</td><td>Stack</td><td>Description</td></tr><tr><td>signal S</td><td>-</td><td>(--)</td><td>Definition of a signal S.</td></tr><tr><td>: $S .. ;</td><td>DEF</td><td>(arg --)</td><td>Definition of a handler for signal S. The signal argument is pushed on the top of the data stack.</td></tr><tr><td>raise</td><td>RAISE</td><td>(arg sig# pid --)</td><td>Send a signal <i>S</i> with an argument to the process <i>pid</i>.</td></tr><tr><td>timer</td><td>TIMER</td><td>(sig# tmo --)</td><td>Install a timer (<i>tmo</i> > 0) raising signal <i>sig</i> if the time-out has passed. If <i>tmo</i> = 0, then the timer is removed.</td></tr></table> |
8f0d519e13ce27dfbf8df6570a99ea9c8c1a5d703e3b285fef1d5cf0ef17c82c.png | complex | <table><tr><td> </td><td colspan="2">n</td><td>% who correctly identified the firstline anti-malarial therapy</td><td>Unadjusted odds ratio (95% confidence interval; P value)</td></tr><tr><td>Malaria training</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Attended malaria workshop</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> </td><td>Yes</td><td>46</td><td>65%</td><td>0.94 (0.42 - 2.07; 0.873)</td></tr><tr><td> </td><td>No</td><td>66</td><td>67%</td><td>Ref</td></tr><tr><td colspan="5">Attended malaria workshop after 2006</td></tr><tr><td> </td><td>Yes</td><td>34</td><td>62%</td><td>0.32 (0.06 - 1.71; 0.184)</td></tr><tr><td> </td><td>No</td><td>12</td><td>83%</td><td>Ref</td></tr><tr><td>Received drug information from MOH</td><td> </td><td> </td><td colspan="2"> </td></tr><tr><td> </td><td>Yes</td><td>94</td><td>69%</td><td>0.96 (0.85 - 1.08; 0.483)</td></tr><tr><td> </td><td>No</td><td>19</td><td>53%</td><td>Ref</td></tr><tr><td colspan="5">Dispensing Practices</td></tr><tr><td colspan="5">Recommended AL for uncomplicated malaria in children under 5</td></tr><tr><td> </td><td>Yes</td><td>43</td><td>74%</td><td>2.41 (1.01 - 5.76; 0.048)*</td></tr><tr><td> </td><td>No</td><td>53</td><td>55%</td><td>Ref</td></tr><tr><td colspan="4">Recommend AL for uncomplicated malaria in adults</td><td> </td></tr><tr><td> </td><td>Yes</td><td>55</td><td>76%</td><td>3.55 (1.49 - 8.47; 0.004)*</td></tr><tr><td> </td><td>No</td><td>42</td><td>48%</td><td>Ref</td></tr><tr><td colspan="5">Table 4b: Relationship between shop worker recommendation of AL to children under 5 and their response to clinical scenarios</td></tr><tr><td> </td><td> </td><td>n</td><td>% who would recommend AL to children under 5</td><td>Unadjusted odds ratio and (95% confidence interval; P value)</td></tr><tr><td colspan="5">Paediatric Case Management**</td></tr><tr><td colspan="5">Refer pediatric patients rather than treat</td></tr><tr><td> </td><td>Yes</td><td>43</td><td>49%</td><td>2.45 (1.04 - 5.79; 0.041)*</td></tr><tr><td> </td><td>No</td><td>65</td><td>31%</td><td>Ref</td></tr><tr><td colspan="5">Refuse Fansidar to a mother requesting it</td></tr><tr><td> </td><td>Yes</td><td>94</td><td>67%</td><td>3.59 (1.08 - 11.90; 0.036)*</td></tr><tr><td> </td><td>No</td><td>19</td><td>58%</td><td>Ref</td></tr></table> |
eeca671ae6424d4415409a394f1818262193e465951ae91784f830eccd06b445.png | complex | <table><tr><td rowspan="2">Link</td><td rowspan="2">Antecedent</td><td rowspan="2">Consequent</td><td rowspan="2">Measure(s) of consequent</td><td colspan="2">results</td></tr><tr><td>Link found?</td><td>Consequent (‘effect’) stronger in DLC?</td></tr><tr><td rowspan="3">A</td><td rowspan="4">DLC training (DLC sites only)</td><td rowspan="3">Staff characteristics</td><td>DAS, ADQ, SNCW</td><td>Yes</td><td>No for DAS, ADQ and parts of SNCW. Yes for SNCW Development and Patient Knowledge components.</td></tr><tr><td>Sick-leave</td><td>Yes</td><td>Yes</td></tr><tr><td>Turnover</td><td>No</td><td>No</td></tr><tr><td>B</td><td>PDSA cycles</td><td>Reported/not reported</td><td>Yes</td><td>Yes</td></tr><tr><td>C</td><td>Staff characteristics</td><td rowspan="2">Immediate impact of work routines</td><td rowspan="2">DCM WIB scores</td><td>Partly: for SNCW but not DAS, ADQ.</td><td>No</td></tr><tr><td>D</td><td>PDSA</td><td>Yes, but ‘High-WIB’ homes only</td><td>Yes, but ‘High-WIB’ homes only</td></tr><tr><td rowspan="4">E</td><td rowspan="4">Immediate impact of work routines</td><td rowspan="4">Quality of life</td><td>QUALID</td><td>Yes</td><td>No</td></tr><tr><td>End-of-life care discussion</td><td>No</td><td>No</td></tr><tr><td>End-of-life care plans</td><td>No</td><td>No</td></tr><tr><td>TEP decision forms</td><td>No</td><td>No</td></tr><tr><td rowspan="2">F</td><td rowspan="2">Quality of Life</td><td rowspan="2">External impacts</td><td>Ambulance call-outs</td><td>No</td><td>No</td></tr><tr><td>Emergency admissions</td><td>No</td><td>No</td></tr></table> |
b48eefb983f74c663e3aef0ce501c67cc96d04304029cf1912178e0f5a8c729a.png | simple | <table><tr><td>Characteristics</td><td> </td><td>HAP (n = 94)</td><td> </td><td> </td><td>VAP (n = 117)</td><td> </td></tr><tr><td> </td><td>Adequate treatment n = 43 (%)</td><td>Inadequate treatment n = 51 (%)</td><td>p</td><td>Adequate treatment n = 37 (%)</td><td>Inadequate treatment n = 80 (%)</td><td>p</td></tr><tr><td>Age (years)</td><td>60.67 ± 16.04</td><td>65.14 ± 13.75</td><td>0.167</td><td>63.59 ± 16.65</td><td>63.85 ± 17.07</td><td>0.907</td></tr><tr><td>Sex (male)</td><td>32(74.4)</td><td>37 (72.5)</td><td>1.000</td><td>24 (64.9)</td><td>45 (56.3)</td><td>0.497</td></tr><tr><td>Surgical unit</td><td>9 (20.9)</td><td>8 (15.7)</td><td>0.697</td><td>21 (56.8)</td><td>25 (31.3)</td><td>0.015</td></tr><tr><td>Underlying diseases</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Diabetes mellitus</td><td>5 (11.6)</td><td>8 (15.7)</td><td>0.789</td><td>5 (13.5)</td><td>11 (13.8)</td><td>1.000</td></tr><tr><td> COPD</td><td>13 ( 30.2)</td><td>10 (19.6)</td><td>0.341</td><td>11 (29.7)</td><td>17 (21.3)</td><td>0.443</td></tr><tr><td> Chronic renal failure</td><td>5 (11.6)</td><td>4 (7.8)</td><td>0.727</td><td>0 (0)</td><td>3 (3.8)</td><td>0.551</td></tr><tr><td> Congestive heart failure</td><td>4 (9.3)</td><td>9 (17.6)</td><td>0.386</td><td>6 (16.2)</td><td>13 (16.3)</td><td>1.000</td></tr><tr><td> Cerebrovascular disease</td><td>1 (2.3)</td><td>9 (17.6)</td><td>0.019</td><td>3 (8.1)</td><td>15 (18.8)</td><td>0.227</td></tr><tr><td> Malignancy</td><td>6 (14.0)</td><td>9 (17.6)</td><td>0.838</td><td>6 (16.2)</td><td>11 (13.8)</td><td>0.944</td></tr><tr><td>Central venous catheterization</td><td>16 (37.2)</td><td>22 (43.1)</td><td>0.710</td><td>30 (81.1)</td><td>58 (72.5)</td><td>0.442</td></tr><tr><td>Urinary catheterization</td><td>33 (76.7)</td><td>37 (72.5)</td><td>0.820</td><td>37 (100)</td><td>78 (97.5)</td><td>1.000</td></tr><tr><td>Late-onset pneumonia</td><td>34 (79.1)</td><td>46 (90.2)</td><td>0.223</td><td>34 (91.9)</td><td>72 (90)</td><td>1.000</td></tr><tr><td>Acquisition of other site infection</td><td>12 (27.9)</td><td>11 (21.6)</td><td>0.637</td><td>11 (29.7)</td><td>42 (52.5)</td><td>0.036</td></tr><tr><td>Previous antibiotic usage</td><td>20 (46.5)</td><td>23 (45.1)</td><td>1.000</td><td>11 (29.7)</td><td>36 (45.0)</td><td>0.173</td></tr><tr><td>MDR bacteria</td><td>29 (67.4)</td><td>38 (74.5)</td><td>0.599</td><td>32 (86.5)</td><td>60 (75)</td><td>0.243</td></tr><tr><td>Polymicrobial etiology</td><td>1 (2.3)</td><td>8 (15.7)</td><td>0.036</td><td>2 (5.4)</td><td>6 (7.5)</td><td>1.000</td></tr><tr><td>Length of stay before HAP</td><td>7.6 ± 4.3</td><td>9.18 ± 5.8</td><td>0.194</td><td>13.89 ± 11.56</td><td>14.88 ± 10.34</td><td>0.313</td></tr><tr><td>APACHE II score</td><td>12.7 ± 5.83</td><td>14.92 ± 5.83</td><td>0.031</td><td>16.08 ± 6.94</td><td>16.69 ± 6.72</td><td>0.654</td></tr><tr><td>Exitus</td><td>16 (37.2)</td><td>24 (47.1)</td><td>0.452</td><td>27 (73)</td><td>53 (66.3)</td><td>0.608</td></tr></table> |
9136c937ab592bed6fe174cf50c79e378c88febff661046adf19d716aa1845c8.png | simple | <table><tr><td>Characteristic</td><td>cv-lysozyme-3</td><td>cv-lysozyme-1*</td><td>cv-lysozyme-2**</td></tr><tr><td><underline>Lysozyme activity</underline></td><td></td><td></td><td></td></tr><tr><td> Optimal pH</td><td>7.5-8.5</td><td>5.5-6.5</td><td>5.5-6.5</td></tr><tr><td> Optimal ionic strength (I)</td><td>0.005-0.01</td><td>0.18-0.20</td><td>0.005-0.01</td></tr><tr><td><underline>Antibacterial activity (MIC)</underline></td><td></td><td></td><td></td></tr><tr><td> <i>E. coli</i></td><td>12.5 μg/mL</td><td>1.56 μg/mL</td><td>50 μg/mL</td></tr><tr><td> <i>V. vulnificus</i></td><td>ND***</td><td>12.5 μg/mL</td><td>100 μg/mL</td></tr><tr><td><underline>Molecular properties</underline></td><td></td><td></td><td></td></tr><tr><td> MW (Dalton)<sup>b</sup></td><td>17782.3</td><td>17861.0</td><td>12984.6</td></tr><tr><td> Theoretical pI</td><td>6.84 (7.12)</td><td>8.95</td><td>6.33</td></tr><tr><td><underline>Amino acid sequence</underline></td><td></td><td></td><td></td></tr><tr><td> Total amino acid number</td><td>168</td><td>164</td><td>117</td></tr><tr><td> Arginine residue number</td><td>5</td><td>19</td><td>5</td></tr><tr><td><underline>Protease cutting sites</underline></td><td></td><td></td><td></td></tr><tr><td> Trypsin</td><td>9</td><td>18</td><td>9</td></tr><tr><td> Thermolysin</td><td>32</td><td>28</td><td>20</td></tr><tr><td> Pepsin (pH > 2.0)</td><td>19</td><td>12</td><td>5</td></tr><tr><td><underline>Major sites of gene expression</underline></td><td>Digestive glands</td><td>Labial palps, mantle</td><td>Digestive glands</td></tr><tr><td><underline>Tissues with low mRNA level</underline></td><td>Mantle, labial palps, gill, style sac-midgut, hemocytes</td><td>Gill, style sac-midgut, digestive gland, gonad</td><td>Style sac-midgut</td></tr></table> |
735c4e9ba50dac2e3ad69463102f60ae0768721c90814dacd0e325cef86bf49b.png | complex | <table><tr><td></td><td colspan="3">Utilization of postnatal care</td><td></td></tr><tr><td></td><td></td><td colspan="2">Confidence interval</td><td></td></tr><tr><td>Characteristics</td><td>Odds ratio</td><td>Lower</td><td>Upper</td><td><i>p</i></td></tr><tr><td>Occupation</td><td></td><td></td><td></td><td></td></tr><tr><td> Agriculture</td><td>1</td><td></td><td></td><td></td></tr><tr><td> Service</td><td>4.82</td><td>1.18</td><td>19.62</td><td>0.028</td></tr><tr><td> Business</td><td>3.47</td><td>0.75</td><td>16.12</td><td>0.112</td></tr><tr><td> Wage laborer</td><td>2.88</td><td>0.44</td><td>18.86</td><td>0.270</td></tr><tr><td> Housewife</td><td>2.55</td><td>0.85</td><td>7.62</td><td>0.094</td></tr><tr><td>Wealth quintile</td><td></td><td></td><td></td><td></td></tr><tr><td> Lowest</td><td>1</td><td></td><td></td><td></td></tr><tr><td> Second</td><td>3.21</td><td>0.82</td><td>12.52</td><td>0.093</td></tr><tr><td> Middle</td><td>3.24</td><td>0.75</td><td>13.94</td><td>0.115</td></tr><tr><td> Fourth</td><td>7.03</td><td>1.87</td><td>26.45</td><td>0.004</td></tr><tr><td> Highest</td><td>7.12</td><td>1.84</td><td>27.95</td><td>0.005</td></tr><tr><td>Ethnicity</td><td></td><td></td><td></td><td></td></tr><tr><td> Disadvantaged Janajati and Dalit</td><td>1</td><td></td><td></td><td></td></tr><tr><td> Newar</td><td>0.44</td><td>0.18</td><td>1.08</td><td>0.073</td></tr><tr><td> Brahmin/Chhetri</td><td>0.34</td><td>0.14</td><td>0.84</td><td>0.019</td></tr></table> |
8c968fbd1242c061c46c83acc102d35fceabe8143ddc31c65eed6211430d50db.png | complex | <table><tr><td></td><td colspan="3">Placebo</td><td colspan="3">TOL ER</td></tr><tr><td></td><td>< 65 years (<i>n</i> = 1171)</td><td>65–74 years (<i>n</i> = 477)</td><td>≥ 75 years (<i>n</i> = 288)</td><td>< 65 years (<i>n</i> = 1360)</td><td>65–74 years (<i>n</i> = 582)</td><td>≥ 75 years (<i>n</i> = 285)</td></tr><tr><td colspan="7">Discontinuations, <i>n</i> (%)</td></tr><tr><td>Total*</td><td>126 (11)</td><td>49 (10)</td><td>43 (15)</td><td>115 (9)</td><td>45 (8)</td><td>35 (12)</td></tr><tr><td>Owing to an AE*</td><td>37 (3)</td><td>22 (5)</td><td>16 (6)</td><td>33 (2)</td><td>14 (2)</td><td>14 (5)</td></tr><tr><td>Men, <i>n</i> (%)</td><td>265 (23)</td><td>168 (35)</td><td>118 (41)</td><td>259 (19)</td><td>180 (31)</td><td>93 (33)</td></tr><tr><td>Mean (SD) age, years</td><td>50.8 (9.9)</td><td>69.0 (2.8)</td><td>79.1 (4.0)</td><td>50.7 (10.1)</td><td>69.1 (2.8)</td><td>78.9 (3.4)</td></tr><tr><td>Range</td><td>19–64</td><td>65–74</td><td>75–93</td><td>18–64</td><td>65–74</td><td>75–90</td></tr><tr><td colspan="7">Race, <i>n</i> (%)</td></tr><tr><td>White</td><td>1034 (88)</td><td>452 (95)</td><td>278 (97)</td><td>1224 (90)</td><td>555 (95)</td><td>278 (98)</td></tr><tr><td>Black</td><td>73 (6)</td><td>15 (3)</td><td>6 (2)</td><td>71 (5)</td><td>13 (2)</td><td>4 (1)</td></tr><tr><td>Asian</td><td>17 (2)</td><td>4 (1)</td><td>1 (< 1)</td><td>18 (1)</td><td>4 (1)</td><td>2 (1)</td></tr><tr><td>Other</td><td>47 (4)</td><td>6 (1)</td><td>3 (1)</td><td>47 (3)†</td><td>10 (2)</td><td>1 (< 1)</td></tr><tr><td>Mean (SD) body mass index, kg/m<sup>2</sup></td><td>29.1 (6.9)</td><td>29.0 (5.9)</td><td>26.6 (4.5)</td><td>29.1 (9.0)</td><td>28.9 (5.7)</td><td>27.7 (12.4)</td></tr><tr><td>Range</td><td>15.1–63.9</td><td>16.8–49.9</td><td>15.7–47.2</td><td>16.5–211.5</td><td>17.1–60.3</td><td>15.8–198.8</td></tr></table> |
715b9c2c2641cb5f363cf80646ab029f190c39f0eebd98d11b0edbab081afb2a.png | complex | <table><tr><td></td><td></td><td colspan="2"><i>6 MeV</i></td><td colspan="2"><i>9 MeV</i></td><td colspan="2"><i>12 MeV</i></td><td colspan="2"><i>16 MeV</i></td><td colspan="2"><i>20 MeV</i></td></tr><tr><td><i>Cone</i></td><td><i>Depth</i></td><td><i>Measured</i></td><td><i>eMC</i></td><td><i>Measured</i></td><td><i>eMC</i></td><td><i>Measured</i></td><td><i>eMC</i></td><td><i>Measured</i></td><td><i>eMC</i></td><td><i>Measured</i></td><td><i>eMC</i></td></tr><tr><td>6.0</td><td>R50</td><td>25.6</td><td>26.0</td><td>31.9</td><td>33.4</td><td>39.6</td><td>41.1</td><td>47.9</td><td>47.3</td><td>54.6</td><td>51.5</td></tr><tr><td>10.0</td><td>R50</td><td>25.9</td><td>27.1</td><td>32.3</td><td>32.7</td><td>41.0</td><td>41.6</td><td>50.8</td><td>49.9</td><td>60.6</td><td>57.1</td></tr><tr><td>15.0</td><td>R50</td><td>26.2</td><td>26.7</td><td>31.6</td><td>33.5</td><td>40.7</td><td>41.6</td><td>50.4</td><td>50.6</td><td>61.4</td><td>59.1</td></tr><tr><td>20.0</td><td>R50</td><td>26.3</td><td>27.3</td><td>32.2</td><td>34.1</td><td>40.0</td><td>42.5</td><td>49.7</td><td>50.8</td><td>61.7</td><td>57.3</td></tr><tr><td>25.0</td><td>R50</td><td>26.5</td><td>27.8</td><td>33.7</td><td>34.6</td><td>41.3</td><td>42.8</td><td>50.3</td><td>52.4</td><td>62.2</td><td>57.3</td></tr><tr><td>6.0</td><td>R90</td><td>25.4</td><td>25.3</td><td>30.6</td><td>30.7</td><td>36.7</td><td>38.3</td><td>41.3</td><td>42.4</td><td>42.0</td><td>41.9</td></tr><tr><td>10.0</td><td>R90</td><td>25.9</td><td>25.8</td><td>30.7</td><td>31.0</td><td>37.9</td><td>38.5</td><td>44.0</td><td>45.3</td><td>46.6</td><td>45.9</td></tr><tr><td>15.0</td><td>R90</td><td>26.4</td><td>25.3</td><td>30.6</td><td>31.3</td><td>38.1</td><td>38.4</td><td>44.1</td><td>44.9</td><td>46.9</td><td>46.1</td></tr><tr><td>20.0</td><td>R90</td><td>26.1</td><td>25.4</td><td>30.8</td><td>31.9</td><td>37.0</td><td>39.1</td><td>43.3</td><td>44.7</td><td>46.8</td><td>46.7</td></tr><tr><td>25.0</td><td>R90</td><td>26.1</td><td>25.7</td><td>32.2</td><td>31.8</td><td>38.0</td><td>39.0</td><td>43.3</td><td>46.0</td><td>47.1</td><td>46.3</td></tr><tr><td>6.0</td><td>dmax</td><td>21.7</td><td>21.4</td><td>23.7</td><td>23.8</td><td>24.8</td><td>25.7</td><td>18.7</td><td>19.1</td><td>12.0</td><td>12.9</td></tr><tr><td>10.0</td><td>dmax</td><td>22.1</td><td>21.6</td><td>24.0</td><td>24.0</td><td>25.7</td><td>26.3</td><td>20.6</td><td>21.3</td><td>12.3</td><td>13.3</td></tr><tr><td>15.0</td><td>dmax</td><td>22.5</td><td>21.3</td><td>23.8</td><td>24.2</td><td>26.0</td><td>26.6</td><td>20.5</td><td>22.1</td><td>12.1</td><td>14.0</td></tr><tr><td>20.0</td><td>dmax</td><td>22.2</td><td>21.6</td><td>24.0</td><td>24.6</td><td>25.1</td><td>26.6</td><td>20.0</td><td>22.3</td><td>11.9</td><td>14.3</td></tr><tr><td>25.0</td><td>dmax</td><td>22.0</td><td>21.7</td><td>24.5</td><td>24.3</td><td>25.7</td><td>27.1</td><td>20.1</td><td>22.3</td><td>11.8</td><td>13.7</td></tr></table> |
a8f16c10b17c79c0ec52e9b078006439b8ee193a43ce4e9d8f9a6db4136a6b27.png | complex | <table><tr><td> </td><td colspan="2">RIP A (ICMB 841-P3 × 863B-P2)</td><td colspan="2">RIP B (H 77/833-2 × PRLT 2/89-33)</td><td colspan="2">RIP C (81B-P6 × ICMP 451-P8)</td><td colspan="2">RIP D (PT 732B-P2 × P1449-2-P1)</td><td colspan="2">Consensus map</td></tr><tr><td>Linkage groups</td><td>No. of markers</td><td>Map length (cM)</td><td>No. of markers</td><td>Map length (cM)</td><td>No. of markers</td><td>Map length (cM)</td><td>No. of markers</td><td>Map length (cM)</td><td>No. of markers</td><td>Map length (cM)</td></tr><tr><td>LG1 or LG1a</td><td>18</td><td>130</td><td>17</td><td>123</td><td>13</td><td>76</td><td>6</td><td>29</td><td>29</td><td>147</td></tr><tr><td>LG1b</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td>2</td><td>0.3</td><td> </td><td> </td></tr><tr><td>LG2</td><td>18</td><td>104</td><td>14</td><td>139</td><td>10</td><td>108</td><td>4</td><td>6</td><td>30</td><td>193</td></tr><tr><td>LG3</td><td>8</td><td>44</td><td>9</td><td>102</td><td>7</td><td>54</td><td>8</td><td>34</td><td>17</td><td>94</td></tr><tr><td>LG4</td><td>12</td><td>49</td><td>6</td><td>68</td><td>6</td><td>21</td><td>9</td><td>69</td><td>17</td><td>87</td></tr><tr><td>LG5</td><td>13</td><td>86</td><td>8</td><td>84</td><td>10</td><td>117</td><td>9</td><td>48</td><td>22</td><td>134</td></tr><tr><td>LG6 or LG6a</td><td>20</td><td>98</td><td>14</td><td>86</td><td>7</td><td>10</td><td>4</td><td>9</td><td>32</td><td>113</td></tr><tr><td>LG6b</td><td> </td><td> </td><td> </td><td> </td><td>4</td><td>8</td><td>2</td><td>3</td><td> </td><td> </td></tr><tr><td>LG6c</td><td> </td><td> </td><td> </td><td> </td><td>2</td><td>3</td><td>2</td><td>2</td><td> </td><td> </td></tr><tr><td>LG7</td><td>15</td><td>104</td><td>10</td><td>88</td><td>5</td><td>31</td><td>11</td><td>74</td><td>27</td><td>130</td></tr><tr><td>LGA (unlinked)</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>2</td><td>2</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>104</td><td>615</td><td>78</td><td>690</td><td>64</td><td>428</td><td>59</td><td>276</td><td>174</td><td>898</td></tr></table> |
b8e3e66aefe2bdead05aaba70c36a96321b0a18a3131ae0f97b158b5f5e05a12.png | simple | <table><tr><td>Isolate name</td><td>rpoB<sup>a</sup></td><td>Spoligotype classification</td></tr><tr><td>R160</td><td>Ser531Leu</td><td>LCC</td></tr><tr><td>R376</td><td>Ser531Leu</td><td>Haarlem</td></tr><tr><td>R458</td><td>Ser531Leu</td><td>Unknown/unique</td></tr><tr><td>R486</td><td>Leu533Pro</td><td>Beijing</td></tr><tr><td>R631</td><td>His526Tyr</td><td>Unknown/unique</td></tr><tr><td>R637</td><td>Ser531Leu</td><td>Beijing</td></tr><tr><td>R641</td><td>Leu533Pro</td><td>Beijing</td></tr><tr><td>R721</td><td>Ser531Leu</td><td>Beijing</td></tr><tr><td>R912</td><td>His526Tyr</td><td>EAI</td></tr><tr><td>R965</td><td>Leu533Pro</td><td>Beijing</td></tr><tr><td>R966</td><td>His526Tyr</td><td>Beijing</td></tr><tr><td>R1035</td><td>Ser531Leu</td><td>LAM</td></tr><tr><td>R1415</td><td>His526Tyr</td><td>Beijing</td></tr></table> |
65e973fe40fc911e5d75427cbe235d2568b79c130060905d8d627dd12ec234b1.png | complex | <table><tr><td rowspan="2">Gene</td><td>Forward primer (3′-5′)</td><td>Product length (bp)</td><td rowspan="2">NCBI Genbank</td><td rowspan="2">Slope</td><td rowspan="2">R<sup>2#</sup></td><td rowspan="2">Efficiency*</td></tr><tr><td>Reverse primer (5′-3′)</td><td> </td></tr><tr><td colspan="7"><i>Reference genes</i></td></tr><tr><td rowspan="2">ATP5G1</td><td>CAGTCACCTTGAGCCGGGCGA</td><td rowspan="2">94</td><td rowspan="2">NM_001025218</td><td rowspan="2">−3.42</td><td rowspan="2">0.999</td><td rowspan="2">1.96</td></tr><tr><td>TAGCGCCCCGGTGGTTTGC</td></tr><tr><td rowspan="2">ACTB</td><td>GACATCCGCAAGGACCTCTA</td><td rowspan="2">205</td><td rowspan="2">XM_003124280</td><td rowspan="2">−3.60</td><td rowspan="2">0.998</td><td rowspan="2">1.89</td></tr><tr><td>ACATCTGCTGGAAGGTGGAC</td></tr><tr><td rowspan="2">RPS9</td><td>GTCGCAAGACTTATGTGACC</td><td rowspan="2">325</td><td rowspan="2">XM_003356050</td><td rowspan="2">−3.64</td><td rowspan="2">0.999</td><td rowspan="2">1.88</td></tr><tr><td>AGCTTAAAGACCTGGGTCTG</td></tr><tr><td colspan="7"><i>Target genes</i></td></tr><tr><td rowspan="2">COX4/1</td><td>GTGGAACTGTACCGCCTGAA</td><td rowspan="2">257</td><td rowspan="2">XM_003355730</td><td rowspan="2">−3.44</td><td rowspan="2">1.000</td><td rowspan="2">1.95</td></tr><tr><td>TTGTCGTAGTCCCACTTGGC</td></tr><tr><td rowspan="2">COX6A1</td><td>CTCAGCTCGCATGTGGAAGA</td><td rowspan="2">139</td><td rowspan="2">NM_001190221</td><td rowspan="2">−3.34</td><td rowspan="2">0.996</td><td rowspan="2">1.99</td></tr><tr><td>GATGCGAAGATGGGGGTAGG</td></tr><tr><td rowspan="2">CACT/SLC25A20</td><td>GCAAAGCCCATTAGCCCTCT</td><td rowspan="2">235</td><td rowspan="2">XM_003483178</td><td rowspan="2">−3.21</td><td rowspan="2">0.988</td><td rowspan="2">2.05</td></tr><tr><td>GAGCACATCCTCTGGGTGTT</td></tr><tr><td rowspan="2">PPARGC1A</td><td>TAAAGATGCCGCCTCTGACT</td><td rowspan="2">168</td><td rowspan="2">NM_213963</td><td rowspan="2">−3.94</td><td rowspan="2">0.993</td><td rowspan="2">1.79</td></tr><tr><td>TGACCGAAGTGCTTGTTCAG</td></tr><tr><td rowspan="2">PPARGC1B</td><td>AAGTGCGGCTTCGTCACCTA</td><td rowspan="2">216</td><td rowspan="2">XM_003124093</td><td rowspan="2">−3.28</td><td rowspan="2">0.998</td><td rowspan="2">2.02</td></tr><tr><td>GCTGTCGAAATCCATGGCTT</td></tr><tr><td rowspan="2">SLC22A5</td><td>TGCATTTGGCTACATGCTGC</td><td rowspan="2">174</td><td rowspan="2">XM_003123912</td><td rowspan="2">−3.76</td><td rowspan="2">0.995</td><td rowspan="2">1.85</td></tr><tr><td>ATGATCACCTCAGCTTCCTG</td></tr><tr><td rowspan="2">SDHA</td><td>CTACGCCCCCGTCGCAAAGG</td><td rowspan="2">380</td><td rowspan="2">DQ402993</td><td rowspan="2">−3.24</td><td rowspan="2">1.000</td><td rowspan="2">2.03</td></tr><tr><td>AGTTTGCCCCCAGGCGGTTG</td></tr><tr><td rowspan="2">MYH2</td><td>GGCCCTTTGATGCCAAGACA</td><td rowspan="2">188</td><td rowspan="2">NM_214136</td><td rowspan="2">−3.45</td><td rowspan="2">1.000</td><td rowspan="2">1.95</td></tr><tr><td>GGCCATGTCCTCGATCTTGT</td></tr><tr><td rowspan="2">MYH4</td><td>GTGCCCTGCTGCCATCAATA</td><td rowspan="2">363</td><td rowspan="2">NM_001123141</td><td rowspan="2">−3.53</td><td rowspan="2">1.000</td><td rowspan="2">1.92</td></tr><tr><td>TGCGTAACGCTCTTTGAGGT</td></tr><tr><td rowspan="2">MYH7</td><td>TGCCAGCTTGAGCCTCTTTC</td><td rowspan="2">380</td><td rowspan="2">NM_213855</td><td rowspan="2">−3.33</td><td rowspan="2">0.999</td><td rowspan="2">2.00</td></tr><tr><td>GTAGCGCTCCTTGAGGTTGT</td></tr><tr><td rowspan="2">FATP1</td><td>GGTTCCAGCCTGTTGAATGT</td><td rowspan="2">275</td><td rowspan="2">NM_001083931</td><td rowspan="2">−3.44</td><td rowspan="2">0.990</td><td rowspan="2">1.95</td></tr><tr><td>AACAAAACCTTGGTGCTTGG</td></tr><tr><td rowspan="2">UCP2</td><td>AGTGTGAGACCTGACGAAGC</td><td rowspan="2">435</td><td rowspan="2">NM_214289</td><td rowspan="2">−3.64</td><td rowspan="2">0.996</td><td rowspan="2">1.88</td></tr><tr><td>GCTTGACGGAGTCGTAGAGG</td></tr><tr><td rowspan="2">UCP3</td><td>GCCACTTTGTCTCTGCCTTC</td><td rowspan="2">219</td><td rowspan="2">NM_214049</td><td rowspan="2">−3.49</td><td rowspan="2">0.998</td><td rowspan="2">1.93</td></tr><tr><td>CAAACATCACCACGTTCCAG</td></tr></table> |
cc078399ea8850505ef65eafd3891e399f5a5f262bfabc63d6bd7d132aae9780.png | complex | <table><tr><td>OTU</td><td>No. of clones</td><td>Phylogenetic class</td><td>Closest cultivated species (% similarity)</td></tr><tr><td colspan="4">Bioreactor for CH<sub>4</sub> production</td></tr><tr><td><i>Archaea</i></td><td></td><td></td><td></td></tr><tr><td> MET-BR-A01</td><td>49</td><td><i>Methanobacteria</i></td><td><i>Methanothermobacter thermautotrophicus (99)</i></td></tr><tr><td> Total</td><td>49</td><td></td><td></td></tr><tr><td><i>Bacteria</i></td><td></td><td></td><td></td></tr><tr><td> MET-BR-B01</td><td>79</td><td><i>Clostridia</i></td><td><i>Tepidanaerobacter syntrophicus (93)</i></td></tr><tr><td> MET-BR-B02</td><td>5</td><td><i>Clostridia</i></td><td><i>Acetivibrio cellulolyticus (91)</i></td></tr><tr><td> MET-BR-B03</td><td>4</td><td><i>Clostridia</i></td><td><i>Gelria glutamica (98)</i></td></tr><tr><td> MET-BR-B04</td><td>1</td><td><i>Clostridia</i></td><td><i>Tepidanaerobacter syntrophicus (92)</i></td></tr><tr><td> MET-BR-B05</td><td>1</td><td><i>Clostridia</i></td><td><i>Desulfosporosinus acidiphilus (95)</i></td></tr><tr><td> Total</td><td>90</td><td></td><td></td></tr><tr><td colspan="4">Bioreactor for H<sub>2</sub> production</td></tr><tr><td><i>Bacteria</i></td><td></td><td></td><td></td></tr><tr><td> HYD-BR-B01</td><td>47</td><td><i>Clostridia</i></td><td><i>Thermotalea metallivorans (99)</i></td></tr><tr><td> HYD-BR-B02</td><td>10</td><td><i>Clostridia</i></td><td><i>Tepidanaerobacter syntrophicus (83)</i></td></tr><tr><td> HYD-BR-B03</td><td>9</td><td><i>Flavobacteria</i></td><td><i>Schleiferia thermophila (88)</i></td></tr><tr><td> HYD-BR-B04</td><td>5</td><td><i>Clostridia</i></td><td><i>Desulfotomaculum putei (99)</i></td></tr><tr><td> HYD-BR-B05</td><td>5</td><td><i>Clostridia</i></td><td><i>Desulfotomaculum putei (89)</i></td></tr><tr><td> HYD-BR-B06</td><td>4</td><td><i>Clostridia</i></td><td><i>Thermosyntropha lipolytica (94)</i></td></tr><tr><td> HYD-BR-B07</td><td>4</td><td><i>Clostridia</i></td><td><i>Thermotalea metallivorans (99)</i></td></tr><tr><td> HYD-BR-B08</td><td>3</td><td><i>Clostridia</i></td><td><i>Oxobacter pfennigii (92)</i></td></tr><tr><td> HYD-BR-B09</td><td>3</td><td><i>Clostridia</i></td><td><i>Clostridium thermosuccinogenes (93)</i></td></tr><tr><td> HYD-BR-B10</td><td>1</td><td><i>Clostridia</i></td><td><i>Anaerobranca horikoshii (98)</i></td></tr><tr><td> Total</td><td>91</td><td></td><td></td></tr></table> |
24d7823532ef34ee245768024dafb0337b1264f2aef69b35d752cffb75e9eb92.png | simple | <table><tr><td></td><td>Average (in days)</td><td>Within 1 week (in %)</td><td>Within 1 month (in %)</td><td>Within 3 months (in %)</td></tr><tr><td>All scientific fields</td><td>39</td><td>15</td><td>61</td><td>92</td></tr><tr><td>General</td><td>40</td><td>14</td><td>58</td><td>92</td></tr><tr><td>Natural sciences</td><td>34</td><td>17</td><td>66</td><td>94</td></tr><tr><td>Engineering</td><td>32</td><td>18</td><td>71</td><td>95</td></tr><tr><td>Mathematics and Computer sciences</td><td>33</td><td>18</td><td>69</td><td>95</td></tr><tr><td>Medicine</td><td>38</td><td>15</td><td>60</td><td>93</td></tr><tr><td>Public health</td><td>29</td><td>18</td><td>71</td><td>99</td></tr><tr><td>Psychology</td><td>50</td><td>12</td><td>46</td><td>90</td></tr><tr><td>Economics and Business</td><td>64</td><td>3</td><td>39</td><td>79</td></tr><tr><td>Social sciences</td><td>50</td><td>9</td><td>49</td><td>87</td></tr><tr><td>Humanities</td><td>47</td><td>10</td><td>52</td><td>90</td></tr></table> |
407bce523f792fa4dd730104257daf7818102117bb68c6bff75d637e4c18b45f.png | complex | <table><tr><td></td><td colspan="2">MAP-tau expression</td><td></td></tr><tr><td>Variable</td><td>Low (%) (AQUA score < 462)</td><td>High (%) (AQUA score > 462)</td><td><i>P* </i></td></tr><tr><td>Menopausal status</td><td></td><td></td><td></td></tr><tr><td> Premenopausal</td><td>108 (22.8)</td><td>31 (6.5)</td><td>0.734</td></tr><tr><td> Postmenopausal</td><td>265 (55.9)</td><td>70 (14.8)</td><td></td></tr><tr><td>Tumor size</td><td></td><td></td><td></td></tr><tr><td> < 2 cm</td><td>128 (29.1)</td><td>31 (7.1)</td><td>0.535</td></tr><tr><td> 2-5 cm</td><td>155 (35.2)</td><td>50 (11.4)</td><td></td></tr><tr><td> > 5 cm</td><td>59 (13.4)</td><td>17 (3.9)</td><td></td></tr><tr><td>Nuclear grade</td><td></td><td></td><td></td></tr><tr><td> Small/uniform nuclei</td><td>60 (13.4)</td><td>15 (3.4)</td><td>0.225</td></tr><tr><td> Intermediate nuclei</td><td>182 (40.6)</td><td>61 (13.6)</td><td></td></tr><tr><td> Large nuclei</td><td>107 (23.9)</td><td>23 (5.1)</td><td></td></tr><tr><td>Nodal status</td><td></td><td></td><td></td></tr><tr><td> Node positive</td><td>199 (41.8)</td><td>47 (9.9)</td><td>0.201</td></tr><tr><td> Node negative</td><td>175 (36.8)</td><td>55 (11.6)</td><td></td></tr><tr><td>ER</td><td></td><td></td><td></td></tr><tr><td> Negative</td><td>227 (48.6)</td><td>38 (8.1)</td><td>< 0.0001</td></tr><tr><td> Positive</td><td>140 (29.9)</td><td>62 (13.3)</td><td></td></tr><tr><td>PR</td><td></td><td></td><td></td></tr><tr><td> Negative</td><td>240 (52.4)</td><td>31 (6.8)</td><td>< 0.0001</td></tr><tr><td> Positive</td><td>120 (26.2)</td><td>67 (14.6)</td><td></td></tr><tr><td>HER2</td><td></td><td></td><td></td></tr><tr><td> Negative</td><td>283 (61.3)</td><td>88 (19.1)</td><td>0.010</td></tr><tr><td> Positive</td><td>80 (17.3)</td><td>11 (2.4)</td><td></td></tr></table> |
ccb14d5a0be626201e2d182de2864135bed3fc8a518074ff78e02c7741d56290.png | complex | <table><tr><td>Type or gene involved</td><td>Number</td><td>Mean, kb</td><td>Range, kb</td></tr><tr><td colspan="4">Copy number losses : large</td></tr><tr><td> Interstitial deletion</td><td>18</td><td>5,070</td><td>1,048–16,837</td></tr><tr><td> Terminal deletion</td><td>14</td><td>5,273</td><td>1,218–13,593</td></tr><tr><td> Unbalanced translocation</td><td>15</td><td>7,053</td><td>880–17,107</td></tr><tr><td> Subtotal</td><td>47</td><td colspan="2"></td></tr><tr><td colspan="4">Copy number losses: small</td></tr><tr><td> <i>DOCK8</i></td><td>24</td><td>299</td><td>97–431</td></tr><tr><td> <i>KANK1</i></td><td>3</td><td>369</td><td>184–670</td></tr><tr><td> <i>DOCK8</i> and <i>KANK1</i></td><td>3</td><td>419</td><td>75–676</td></tr><tr><td> <i>EHMT1</i></td><td>16</td><td>417</td><td>22–790</td></tr><tr><td> <i>ASTN2</i></td><td>4</td><td>150</td><td>78–271</td></tr><tr><td> <i>FREM1</i></td><td>2</td><td>369</td><td>166–573</td></tr><tr><td> <i>STXBP1</i></td><td>1</td><td>592</td><td>NA</td></tr><tr><td> <i>COL5A1</i></td><td>1</td><td>370</td><td>NA</td></tr><tr><td> <i>GLDC</i></td><td>1</td><td>50</td><td>25–75</td></tr><tr><td> <i>TOPORS</i></td><td>1</td><td>337</td><td>NA</td></tr><tr><td> <i>CDK5RAP2</i></td><td>1</td><td>74</td><td>NA</td></tr><tr><td>Subtotal</td><td>57</td><td colspan="2"></td></tr><tr><td colspan="4">Large copy number gains</td></tr><tr><td> Trisomy 9p/proximal 9q</td><td>15</td><td>45,996</td><td>13,826–95,453</td></tr><tr><td> 9q duplications</td><td>6</td><td>12,172</td><td>6,277–18,399</td></tr><tr><td> Unbalanced translocation</td><td>4</td><td>25,717</td><td>6,794–68,089</td></tr><tr><td> Tetrasomy 9q and proximal 9q due to isochromosome</td><td>3</td><td>66,477</td><td>49,843–81,113</td></tr><tr><td> Trisomy 9</td><td>2</td><td>140,833</td><td>NA</td></tr><tr><td> Triplication</td><td>1</td><td>15,972</td><td>NA</td></tr><tr><td> Subtotal</td><td>31</td><td colspan="2"></td></tr><tr><td colspan="4">Complex chromosomal rearrangements (CCRs)</td></tr><tr><td> Inverted duplication with terminal deletion of 9p</td><td>3</td><td colspan="2">Deletion: 6,377; Duplication: 32,271</td></tr><tr><td> Inverted duplication with terminal deletion of 9q</td><td>1</td><td colspan="2">Deletion: 161; Duplication: 3,127</td></tr><tr><td> Multiple deletion and duplication</td><td>2</td><td colspan="2">Losses: 1091; Gains: 12,517</td></tr><tr><td> Chromothripsis</td><td>1</td><td colspan="2">Loss: 134; Gains: 21,094</td></tr><tr><td> Subtotal</td><td>7</td><td colspan="2"></td></tr><tr><td> Total</td><td>142</td><td colspan="2"></td></tr></table> |
96ef8d874b7a18e0f8f7dfea76b37ada2697a903cbdfb539991c5447621173fb.png | complex | <table><tr><td colspan="2">Age group of children (months)</td><td colspan="2">Rotavirus status of Children</td><td></td><td></td></tr><tr><td></td><td></td><td>Positive</td><td>Negative</td><td>Total</td><td>P-value</td></tr><tr><td>0-6</td><td>count</td><td>2</td><td>8</td><td>10</td><td></td></tr><tr><td></td><td>% of total</td><td>1.3%</td><td>5.0%</td><td>6.3%</td><td></td></tr><tr><td>7-12</td><td>count</td><td>12</td><td>40</td><td>52</td><td></td></tr><tr><td></td><td>% of total</td><td>7.5%</td><td>25.0%</td><td>32.5%</td><td>0.047</td></tr><tr><td>13-24</td><td>count</td><td>6</td><td>54</td><td>60</td><td></td></tr><tr><td></td><td>% of total</td><td>3.8%</td><td>33.8%</td><td>37.5%</td><td></td></tr><tr><td>25-60</td><td>count</td><td>2</td><td>36</td><td>38</td><td></td></tr><tr><td></td><td>% of total</td><td>1.3%</td><td>22.5%</td><td>23.8%</td><td></td></tr><tr><td>Total</td><td>count</td><td>22</td><td>138</td><td>160</td><td></td></tr><tr><td></td><td>% of total</td><td>13.8%</td><td>86.2%</td><td>100.0%</td><td></td></tr></table> |
3b6dbc0d8bf64f00c1a079eaba11c4cf06952805b789ca64ebdb5e61e5ffdeb7.png | complex | <table><tr><td>Dataset</td><td></td><td>#Subjects</td><td>#Case</td><td>Platform</td><td>#SNPs</td></tr><tr><td>Croatia</td><td><i>(Before QC)</i></td><td>306</td><td>103</td><td>Illumina 550 K</td><td>561,466</td></tr><tr><td></td><td><i>(After QC)</i></td><td>305</td><td>103</td><td></td><td>489,200</td></tr><tr><td>NINDS</td><td><i>(Before QC)</i></td><td>542</td><td>0</td><td>Illumina 550 K</td><td>561,466</td></tr><tr><td></td><td><i>(After QC)</i></td><td>534</td><td>0</td><td></td><td>489,096</td></tr><tr><td>HGDP</td><td><i>(Before QC)</i></td><td>1,043</td><td>0</td><td>Illumina 650Y</td><td>660,918</td></tr><tr><td></td><td><i>(After QC)</i></td><td>1,043</td><td>0</td><td></td><td>584,835</td></tr><tr><td></td><td></td><td colspan="2"><i>Merged datasets</i></td><td></td><td></td></tr><tr><td>Croatia+NINDS</td><td><i>(After QC)</i></td><td>839</td><td>103</td><td>-</td><td>475,964</td></tr><tr><td>Croatia+HGDP</td><td><i>(After QC)</i></td><td>1,348</td><td>103</td><td>-</td><td>478,287</td></tr></table> |
d8257b36c26cdfcdfbf2e24c0d8f910257d8758e58a59ab6bd8ed33377e69397.png | simple | <table><tr><td>Species</td><td>Female</td><td>Male</td></tr><tr><td><i>Dichaetophora acutissima</i></td><td>20</td><td>25</td></tr><tr><td><i>Drosophila annulipes</i></td><td>31</td><td>27</td></tr><tr><td><i>Drosophila bizonata</i></td><td>31</td><td>31</td></tr><tr><td><i>Drosophila busckii</i></td><td>35</td><td>41</td></tr><tr><td><i>Drosophila curviceps</i></td><td>20</td><td>26</td></tr><tr><td><i>Drosophila hydei</i></td><td>11</td><td>20</td></tr><tr><td><i>Drosophila immigrans</i></td><td>41</td><td>41</td></tr><tr><td><i>Drosophila lutescens</i></td><td>14</td><td>42</td></tr><tr><td><i>Drosophila rufa</i></td><td>41</td><td>41</td></tr><tr><td><i>Drosophila sternopleuralis</i></td><td>42</td><td>42</td></tr><tr><td><i>Drosophila suzukii</i></td><td>22</td><td>19</td></tr><tr><td><i>Hirtodrosophila sexvittata</i></td><td>41</td><td>41</td></tr><tr><td><i>Liodrosophila aerea</i></td><td>41</td><td>41</td></tr><tr><td><i>Microdrosophila sp.</i></td><td>15</td><td>10</td></tr><tr><td><i>Scaptodrosophila coracina</i></td><td>5</td><td>34</td></tr><tr><td><i>Scaptomyza graminum</i></td><td>36</td><td>32</td></tr></table> |
7afd6aac715c42448417c27835b5916ec1d0c1381ab0353dacfa16eac7e1d4ff.png | complex | <table><tr><td></td><td colspan="2"><i>Arabidopsis</i></td><td colspan="2">Rice</td></tr><tr><td>Origin of nat-siRNAs</td><td>Total</td><td>Unique</td><td>Total</td><td>Unique</td></tr><tr><td>Entire NATs</td><td>33,826</td><td>17,059</td><td>162,397</td><td>56,209</td></tr><tr><td> Introns in entire NATs</td><td>14,500</td><td>6,988</td><td>88,605</td><td>29,654</td></tr><tr><td>OR of NATs</td><td>10,429</td><td>6,532</td><td>27,852</td><td>10,761</td></tr><tr><td>Introns in OR of NATs</td><td>4,367</td><td>2,350</td><td>14,207</td><td>5,494</td></tr></table> |
9d38cca8061d6243bde68d74cb3d9885cbd84ec6e7ca92692af08a2785d6f8b4.png | simple | <table><tr><td>Sample</td><td>Potential (mV)</td><td>Dissolution Current Density at −400 mV (A cm<sup>−2</sup>)</td></tr><tr><td>No Exposure</td><td>−486.5</td><td>1.3 × 10<sup>−4</sup></td></tr><tr><td>Arica</td><td>−574.7</td><td>4.0 × 10<sup>−4</sup></td></tr><tr><td>Quintero</td><td>−611.1</td><td>12 × 10<sup>−4</sup></td></tr><tr><td>Laja</td><td>−515.0</td><td>1.6 × 10<sup>−4</sup></td></tr><tr><td>Antarctic</td><td>−548.7</td><td>4.6 × 10<sup>−4</sup></td></tr></table> |
c6ff94937c8395b95b5267de471aa107e5dfbce476b3cffd00da47a0d0dac1ce.png | simple | <table><tr><td></td><td></td><td></td><td></td><td></td><td>It is likely that people who</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>have consumed bushmeat in</td></tr><tr><td>Variable</td><td>Response</td><td>Estimatea</td><td>SE</td><td>RVIb</td><td>the year prior to survey...</td></tr><tr><td>ARUc</td><td>yes</td><td>−0.652</td><td>0.218</td><td>1.00</td><td>are not ARUs</td></tr><tr><td>Marital status</td><td>single</td><td>0.619</td><td>0.216</td><td>0.99</td><td>are from single parent households</td></tr><tr><td>Benefit from MUPd</td><td>yes</td><td>0.424</td><td>0.172</td><td>0.95</td><td>have benefitted from MUP</td></tr><tr><td>Well‐beinge</td><td>somewhat bad</td><td>0.030</td><td>0.223</td><td>0.95</td><td>rate their lives average or somewhat bad</td></tr><tr><td></td><td>worst</td><td>−0.644</td><td>0.319</td><td></td><td></td></tr><tr><td>Education</td><td>4 years or more</td><td>−0.309</td><td>0.174</td><td>0.45</td><td>have 3 or fewer years of formal education</td></tr></table> |
0c2f52c568b147e3d125f48909fef0966f61a7ebf127564fde4ffe30b36ea5ac.png | simple | <table><tr><td>Gene</td><td>GC% <i>M. davidii</i></td><td>GC% <i>P. alecto</i></td><td>Gene length <i>M. davidii</i></td><td>Gene length <i>P. alecto</i></td></tr><tr><td><i>IKZF1</i></td><td>49.6</td><td>53.2 / 51.5</td><td>1908</td><td>228/816</td></tr><tr><td><i>GPSM1</i></td><td>49.1</td><td>65.4</td><td>705</td><td>2118</td></tr><tr><td><i>SPRR1</i></td><td>44.0</td><td>47.1</td><td>339</td><td>342</td></tr></table> |
e58fa7f6e0307889a412ae9e84d581309b93e22f92d6aeb79e9141f69a613a1f.png | complex | <table><tr><td> </td><td> </td><td colspan="2">All subjects (N = 15)</td><td> </td></tr><tr><td> </td><td> </td><td>Completed (N = 10)</td><td>Withdrawn (N = 5)</td><td> </td></tr><tr><td> </td><td>Mean (SD)</td><td> </td><td> </td><td>P</td></tr><tr><td>Age yrs</td><td>67.9 (9.4)</td><td>67.6 (10.9)</td><td>68.4 (6.3)</td><td>0.88</td></tr><tr><td>Body mass index kg/m<sup>2</sup></td><td>23.1 (4.6)</td><td>23.7(4.9)</td><td>22.1(4.2)</td><td>0.52</td></tr><tr><td> </td><td>N (%)</td><td> </td><td> </td><td> </td></tr><tr><td colspan="5">Sex</td></tr><tr><td> M</td><td>9 (60)</td><td>4 (40)</td><td>5 (100)</td><td> </td></tr><tr><td> F</td><td>6 (40)</td><td>6 (60)</td><td>0 (0)</td><td>0.04</td></tr><tr><td colspan="5">PS</td></tr><tr><td> 1</td><td>2 (13)</td><td>2 (20)</td><td>0 (0)</td><td> </td></tr><tr><td> 2</td><td>6 (40)</td><td>4 (40)</td><td>2 (40)</td><td> </td></tr><tr><td> 3</td><td>7 (47)</td><td>4 (40)</td><td>3 (60)</td><td>0.79</td></tr><tr><td colspan="5">Diagnosis</td></tr><tr><td> Lung cancer</td><td>4 (27)</td><td>3 (30)</td><td>1 (20)</td><td> </td></tr><tr><td> GI cancer</td><td>6 (40)</td><td>2 (20)</td><td>4 (80)</td><td> </td></tr><tr><td> Other</td><td>5 (33)</td><td>5 (50)</td><td>0 (0)</td><td>NA</td></tr><tr><td colspan="5">Cancer stage</td></tr><tr><td> III</td><td>1 (7)</td><td>1 (10)</td><td>0 (0)</td><td> </td></tr><tr><td> IV</td><td>11 (73)</td><td>6 (60)</td><td>5 (100)</td><td> </td></tr><tr><td> NA</td><td>3 (20)</td><td>3 (30)</td><td>0 (0)</td><td>NA</td></tr><tr><td colspan="5">Chemotherapy</td></tr><tr><td> Y</td><td>10 (67)</td><td>6 (60)</td><td>4 (80)</td><td> </td></tr><tr><td> N</td><td>5 (33)</td><td>4 (40)</td><td>1 (20)</td><td>0.60</td></tr><tr><td colspan="5">Recent steroid use</td></tr><tr><td> Y</td><td>6 (40)</td><td>4 (40)</td><td>2 (40)</td><td> </td></tr><tr><td> N</td><td>9 (60)</td><td>6 (60)</td><td>3 (60)</td><td>1.00</td></tr></table> |
f65cebf232ae274a7c001723cec95926c153d278535f33cd379cfa4985d43397.png | complex | <table><tr><td rowspan="2" colspan="2">Clinicopathological parameters</td><td rowspan="2"><i>n</i></td><td colspan="2">NgBR expression</td><td rowspan="2"><i>P</i></td></tr><tr><td>Low</td><td>High</td></tr><tr><td colspan="2">Age (y)</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>≤ 54</td><td>47</td><td>22</td><td>25</td><td>0.051</td></tr><tr><td></td><td>> 54</td><td>42</td><td>11</td><td>31</td><td></td></tr><tr><td colspan="2">Gender</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Male</td><td>80</td><td>29</td><td>51</td><td>0.906</td></tr><tr><td></td><td>Female</td><td>9</td><td>4</td><td>5</td><td></td></tr><tr><td colspan="2">Hepatitis history</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>No</td><td>27</td><td>8</td><td>19</td><td>0.474</td></tr><tr><td></td><td>Yes</td><td>62</td><td>25</td><td>37</td><td></td></tr><tr><td colspan="2">Cirrhosis</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>No</td><td>27</td><td>8</td><td>19</td><td>0.474</td></tr><tr><td></td><td>Yes</td><td>62</td><td>25</td><td>37</td><td></td></tr><tr><td colspan="2">Tumor size</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>≤ 5 cm</td><td>38</td><td>13</td><td>25</td><td>0.306</td></tr><tr><td></td><td>> 5 cm</td><td>51</td><td>20</td><td>31</td><td></td></tr><tr><td colspan="2">Tumor number</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Single</td><td>46</td><td>15</td><td>31</td><td>0.389</td></tr><tr><td></td><td>Multiple</td><td>43</td><td>18</td><td>25</td><td></td></tr><tr><td colspan="2">Vascular invation</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>No</td><td>78</td><td>30</td><td>48</td><td>0.700</td></tr><tr><td></td><td>Yes</td><td>11</td><td>3</td><td>8</td><td></td></tr><tr><td colspan="2">TNM stage</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>I + II</td><td>46</td><td>19</td><td>27</td><td>0.511</td></tr><tr><td></td><td>III + IV</td><td>43</td><td>14</td><td>29</td><td></td></tr></table> |
e25aacf3bda98cacea411243f473c944b7c231c54759e345574840dbffd21a66.png | complex | <table><tr><td></td><td colspan="3">Parameter</td></tr><tr><td>GROUP</td><td>Norepinephrine</td><td>Dopamine</td><td>Serotonin</td></tr><tr><td>Control</td><td>0.376 ± 0.07</td><td>1.45 ± 0.12</td><td>0.80 ± 0.115</td></tr><tr><td>Leaded gasoline</td><td>0.47 ± 0.086 a*</td><td>1.71 ± 0.14 a*</td><td>0.60 ± 0.043 a**</td></tr><tr><td>Unleaded gasoline</td><td>0.41 ± 0.036</td><td>1.35 ± 0.24 b**</td><td>0.385 ± 0.057 a*** b**</td></tr></table> |
6c6c7cb22b78adeb384a3d258920c2d7cf5be3d8745656a38f625a9ceed19014.png | simple | <table><tr><td>MIGS ID</td><td>Characteristic</td><td>Details</td></tr><tr><td>MIGS-28</td><td>Libraries used</td><td>2kb (pUC19) and 40kb (pcc1FOS) Sanger and 454 standard libraries</td></tr><tr><td>MIGS-29</td><td>Sequencing platform</td><td>ABI-3730, 454 GS FLX Titanium</td></tr><tr><td>MIGS-31.2</td><td>Sequencing coverage</td><td>1.1× Sanger 40kb insert, 31.3× pyrosequencing</td></tr><tr><td>MIGS-31</td><td>Finishing Quality</td><td>Finished</td></tr><tr><td>MIGS-30</td><td>Assembler</td><td>gsAssembler (Newbler) version 2.5.3</td></tr><tr><td>MIGS-32</td><td>Gene calling method</td><td>IMG-ER pipeline [27](CRISPR: CRT [28] and PILERCR [29];tRNAs: tRNAScan-SE-1.23 [30]; rRNA: RNAmmer [31];other genes: Prodigal [32])</td></tr><tr><td></td><td>GenBank ID</td><td>CP003985, CP003986</td></tr><tr><td></td><td>GenBank date of release</td><td>14.01.2013</td></tr><tr><td></td><td>GOLD ID</td><td>Gi18068</td></tr><tr><td></td><td>NCBI project ID</td><td>91121</td></tr><tr><td></td><td>IMG Taxon ID</td><td>2512875001</td></tr><tr><td>MIGS-13</td><td>Source material identifier</td><td>DSM 10523T</td></tr><tr><td></td><td>Project relevance</td><td>Sulfur cycle</td></tr></table> |
2b8211cb2061ac5f9536a54165c10133d89ce53a637cf3bc630e3a78d6692ad4.png | simple | <table><tr><td>Criteria</td><td>Percentage</td></tr><tr><td>WHO</td><td>61.43%</td></tr><tr><td>Not sure</td><td>17.14%</td></tr><tr><td>ADA</td><td>12.38%</td></tr><tr><td>IADPS</td><td>9.05%</td></tr></table> |
10722a89f5df707a39e8ff980fed13741e27fdd09ec7192a4593b9c8b2fb8f11.png | complex | <table><tr><td rowspan="2"></td><td colspan="5">Coefficient of drug interaction (CDI)</td></tr><tr><td>Etoposide</td><td>Epirubicin</td><td>Doxorubicin</td><td>Vincristine</td><td>Colchicine</td></tr><tr><td>Ad5GS3</td><td>0.27</td><td>0.31</td><td>0.33</td><td>0.89</td><td>0.78</td></tr><tr><td>Ad5WS1</td><td>0.67</td><td>0.46</td><td>0.88</td><td>0.79</td><td>0.81</td></tr></table> |
4d83408a2d327c3d5a07f5bad3d359a4918cd56585e0dff35ab181c472454cb7.png | complex | <table><tr><td>Exophily</td><td>No. caught</td><td>Exiting % (95% CI)</td><td>Median IQR exiting</td><td>OR</td><td>95% CI</td><td><i>P</i>-value</td><td><i>Z</i></td></tr><tr><td colspan="8">Control net</td></tr><tr><td> West African hut</td><td>587</td><td>35 (31–39)</td><td>2 (0.5–3)</td><td>1</td><td></td><td></td><td></td></tr><tr><td> Ifakara hut</td><td>2067</td><td>64 (62–66)</td><td>23 (14–33.5)</td><td>4.18</td><td>3.18–5.51</td><td>< 0.0001</td><td>10.18</td></tr><tr><td colspan="8">Olyset® Net</td></tr><tr><td> West African hut</td><td>553</td><td>60 (56–64)</td><td>4 (2–11)</td><td>1</td><td></td><td></td><td></td></tr><tr><td> Ifakara hut</td><td>1658</td><td>88 (86–89)</td><td>27.5 (17.5–34.5)</td><td>4.77</td><td>3.56–6.37</td><td>< 0.0001</td><td>10.53</td></tr><tr><td> Metofluthrin 0.00625%</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> West African hut</td><td>122</td><td>49 (40–56)</td><td>0 (0–2)</td><td>1</td><td></td><td></td><td></td></tr><tr><td> Ifakara hut</td><td>1489</td><td>82 (80–84)</td><td>20 (13–28)</td><td>5.41</td><td>3.54–8.28</td><td>< 0.0001</td><td>7.79</td></tr><tr><td> Metofluthrin 0.0097%</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> West African hut</td><td>130</td><td>40 (31–48)</td><td>0 (0–1)</td><td>1</td><td></td><td></td><td></td></tr><tr><td> Ifakara hut</td><td>1054</td><td>85 (83–87)</td><td>18 (10–24)</td><td>8.88</td><td>5.74–13.73</td><td>< 0.0001</td><td>9.82</td></tr></table> |
10ddc7ec107ac96bd78edac195b580cd288ba32bad503e18e523480ce01f7219.png | complex | <table><tr><td></td><td></td><td>WT</td><td>AS5<sup>ox</sup>-1</td><td>AS5<sup>ox</sup>-2</td></tr><tr><td colspan="2">*Days to Flowering from Planting</td><td>50.60 ± 1.43</td><td>53.80 ± 0.79</td><td>53.80 ± 0.79</td></tr><tr><td colspan="2">*Total Chlorophyll (g/m<sup>2</sup>) at Maturity</td><td>0.75 ± 0.05</td><td>0.69 ± 0.04</td><td>0.66 ± 0.04</td></tr><tr><td colspan="2">*Plant Height (cm)</td><td>99.97 ± 1.65</td><td>81.46 ± 2.36</td><td>86.66 ± 1.90</td></tr><tr><td colspan="2">*Shoot Fresh Weight (g)</td><td>101.69 ± 3.02</td><td>82.39 ± 3.29</td><td>83.21 ± 3.04</td></tr><tr><td>Internode 3</td><td>Length (cm)</td><td>5.71 ± 0.19</td><td>5.37 ± 0.24</td><td>5.12 ± 0.29</td></tr><tr><td></td><td>*Circumference (cm)</td><td>4.44 ± 0.05</td><td>4.06 ± 0.06</td><td>4.16 ± 0.09</td></tr><tr><td>Internode 9</td><td>*Length (cm)</td><td>15.98 ± 0.49</td><td>12.61 ± 0.61</td><td>13.27 ± 0.78</td></tr><tr><td></td><td>*Circumference (cm)</td><td>3.98 ± 0.10</td><td>3.16 ± 0.12</td><td>3.52 ± 0.11</td></tr><tr><td>Leaf 3</td><td>Length (cm)</td><td>30.77 ± 0.77</td><td>32.17 ± 1.22</td><td>30.11 ± 0.95</td></tr><tr><td></td><td>Width (cm)</td><td>19.85 ± 0.47</td><td>21.04 ± 0.95</td><td>19.82 ± 0.69</td></tr><tr><td></td><td>Fresh Weight (mg/cm<sup>2</sup>)</td><td>20.53 ± 0.79</td><td>17.16 ± 0.43</td><td>20.23 ± 0.73</td></tr><tr><td></td><td>*Dry Weight (mg/cm<sup>2</sup>)</td><td>1.68 ± 0.07</td><td>1.80 ± 0.04</td><td>1.95 ± 0.06</td></tr><tr><td>Leaf 9</td><td>*Length (cm)</td><td>33.82 ± 1.25</td><td>27.10 ± 1.92</td><td>25.02 ± 1.42</td></tr><tr><td></td><td>*Width (cm)</td><td>16.34 ± 0.66</td><td>11.93 ± 1.27</td><td>11.01 ± 0.90</td></tr><tr><td></td><td>Fresh Weight (mg/cm<sup>2</sup>)</td><td>14.34 ± 0.54</td><td>11.97 ± 0.17</td><td>13.99 ± 0.37</td></tr><tr><td></td><td>Dry Weight (mg/cm<sup>2</sup>)</td><td>2.02 ± 0.07</td><td>1.86 ± 0.09</td><td>2.13 ± 0.08</td></tr></table> |
d080e8458cde6eb9acab2dbfb6726e007dbb1e4dcd2a45a0cbdc7bf2806928d0.png | simple | <table><tr><td>Wired</td><td>Wireless</td></tr><tr><td>High bandwidth</td><td>Low-medium bandwidth</td></tr><tr><td>High performance</td><td>Higher latency</td></tr><tr><td>Robust</td><td>Interference</td></tr><tr><td>Reliable</td><td>Unreliable by nature</td></tr><tr><td>Installation expensive</td><td>Installation cheap</td></tr><tr><td>“Unlimited” resources</td><td>Low power, memory</td></tr><tr><td>Static network</td><td>Mobile network</td></tr><tr><td>Less security problems</td><td>More security problems</td></tr></table> |
7627df30d784cf6a77ce32da2996aa5a3650489916451bec7e868a65891dd0b0.png | complex | <table><tr><td rowspan="2">Characteristics</td><td>Total</td><td></td><td colspan="2">Physical activity</td></tr><tr><td>N</td><td>n<sup>d</sup> (%)</td><td>COR(95%CI)</td><td>AOR(95%CI)</td></tr><tr><td>Total</td><td>2063</td><td>2007 (97.3%)</td><td></td><td></td></tr><tr><td colspan="5">Age groups</td></tr><tr><td> 18–29</td><td>735</td><td>714 (97.1%)</td><td>1.0</td><td></td></tr><tr><td> 30–39</td><td>532</td><td>514 (96.6)</td><td>0.83 (0.44–1.59)</td><td>−</td></tr><tr><td> 40–49</td><td>387</td><td>378 (97.7)</td><td>1.23 (0.56–2.72)</td><td>−</td></tr><tr><td> 50–59</td><td>289</td><td>284 (98.3)</td><td>1.67 (0.62–0.62)</td><td>−</td></tr><tr><td> 60+</td><td>120</td><td>117 (97.5)</td><td>1.14 (0.33–3.90)</td><td>−</td></tr><tr><td colspan="5">Education level</td></tr><tr><td> No education</td><td>396</td><td>381 (96.2)</td><td>1.0</td><td></td></tr><tr><td> Primary</td><td>1391</td><td>1359 (97.7)</td><td>1.67 (0.89–3.11)</td><td>−</td></tr><tr><td> Secondary and above</td><td>276</td><td>267 (97.7)</td><td>1.16 (0.50–2.71)</td><td>−</td></tr><tr><td colspan="5">Occupation</td></tr><tr><td> Professionals</td><td>80</td><td>74 (92.5)</td><td>1.0</td><td>1.0</td></tr><tr><td> Farming</td><td>1543</td><td>1518 (98.4)</td><td>4.92 (1.95–12.36)</td><td>9.75 (3.68–5.82)***</td></tr><tr><td> Business</td><td>132</td><td>125 (94.7)</td><td>1.44 (0.46–4.47)</td><td>1.80 (0.56–5.74)</td></tr><tr><td> Skilled work</td><td>123</td><td>114 (92.7)</td><td>1.02 (0.35–3.00)</td><td>1.43 (0.47–4.33)</td></tr><tr><td> Unskilled work</td><td>164</td><td>155 (94.5)</td><td>1.39 (0.47–4.06)</td><td>2.02 (0.67–6.11)</td></tr><tr><td colspan="5">Residence</td></tr><tr><td> Urban</td><td>627</td><td>619 (98.7)</td><td>1.0</td><td>1.0</td></tr><tr><td> Rural</td><td>1434</td><td>1386 (96.7)</td><td>0.37 (0.17–0.79)</td><td>0.19 (0.08–0.42)***</td></tr><tr><td colspan="5">Marital status</td></tr><tr><td> Single/never married</td><td>547</td><td>532 (97.3)</td><td>1.0</td><td></td></tr><tr><td> Married</td><td>1515</td><td>1474 (97.3)</td><td>1.01 (0.55–1.84)</td><td>−</td></tr></table> |
431025477d31f6c9a3fe61b84830ab1a104e300e6c6d706583f13a4b5847c714.png | complex | <table><tr><td></td><td colspan="2">ALT (U/L)</td><td colspan="2">AST (U/L)</td><td colspan="2">Alkaline Phosphatase (U/L)</td><td colspan="2">Total Billirubin (mg/dL)</td></tr><tr><td></td><td>HP</td><td>SP</td><td>HP</td><td>SP</td><td>HP</td><td>SP</td><td>HP</td><td>SP</td></tr><tr><td>Baseline</td><td>27.07 ± 13.97</td><td>28.84 ± 15.00</td><td>25.2 ± 11.44</td><td>23.33 ± 13.00</td><td>66.2 ± 37.00</td><td>71.88 ± 41.00</td><td>0.75 ± 0.26</td><td>0.77 ± 0.40</td></tr><tr><td>Month 3</td><td>25.4 ± 7.51</td><td>28.53 ± 15.00</td><td>24.23 ± 7.30</td><td>24.39 ± 16.00</td><td>69.64 ± 39.00</td><td>72.85 ± 18.58</td><td>0.75 ± 0.20</td><td>0.82 ± 0.20</td></tr><tr><td>Month 6</td><td>24.87 ± 11.22</td><td>27.23 ± 16.00</td><td>24.26 ± 14.00</td><td>23.44 ± 5.17</td><td>69.89 ± 19.13</td><td>72.21 ± 17.78</td><td>0.80 ± 0.25</td><td>0.83 ± 0.30</td></tr><tr><td>Month 12</td><td>24.1 ± 12.00</td><td>26.91 ± 14.23</td><td>23.00 ± 13.00</td><td>23.76 ± 14.00</td><td>71.48 ± 40.00</td><td>69.18 ± 18.65</td><td>0.76 ± 0.36</td><td>0.84 ± 0.40</td></tr></table> |
76e52396f436a46fec2f1895e5b61e018c4a9c44b4d903392f6ddd7c2bea52af.png | complex | <table><tr><td>Dose, Subgroup (n at final visit)</td><td>Physical ComponentSummary</td><td>Mental ComponentSummary</td><td>Mental HealthDomain</td></tr><tr><td colspan="4">Elderly</td></tr><tr><td colspan="4">1 mg, with psychiatric disorders (n = 37)<sup>a</sup></td></tr><tr><td>Baseline</td><td>40.9 (15.9)</td><td>43.6 (9.9)</td><td>39.5 (12.2)</td></tr><tr><td>Final visit (LOCF)</td><td>42.4 (12.2)</td><td>50.8 (10.9)</td><td>47.3 (11.2)</td></tr><tr><td>Change from baseline</td><td>1.5 (10.4)</td><td>6.8 (11.2)*</td><td>7.3 (12.0)*</td></tr><tr><td colspan="4">2 mg, with psychiatric disorders (n = 42)</td></tr><tr><td>Baseline</td><td>41.1 (15.7)</td><td>44.7 (10.6)</td><td>41.5 (13.2)</td></tr><tr><td>Final visit (LOCF)</td><td>43.3 (12.4)</td><td>50.5 (9.0)</td><td>47.0 (11.3)</td></tr><tr><td>Change from baseline</td><td>2.3 (10.6)</td><td>5.8 (8.4)*</td><td>5.5 (8.8)*</td></tr><tr><td colspan="4">1 mg, without psychiatric disorders (n = 42)</td></tr><tr><td>Baseline</td><td>46.8 (10.3)</td><td>54.7 (7.2)</td><td>53.7 (8.7)</td></tr><tr><td>Final visit (LOCF)</td><td>48.4 (7.4)</td><td>57.5 (6.8)</td><td>57.0 (7.2)</td></tr><tr><td>Change from baseline</td><td>1.6 (7.0)</td><td>2.9 (7.2)<sup>†</sup></td><td>3.3 (8.2)<sup>†</sup></td></tr><tr><td colspan="4">2 mg, without psychiatric disorders (n = 41)</td></tr><tr><td>Baseline</td><td>51.7 (5.0)</td><td>55.3 (7.9)</td><td>54.6 (7.7)</td></tr><tr><td>Final visit (LOCF)</td><td>51.5 (6.2)</td><td>56.1 (7.4)</td><td>55.7 (7.0)</td></tr><tr><td>Change from baseline</td><td>−0.2 (5.3)</td><td>0.8 (7.5)</td><td>1.1 (8.7)</td></tr><tr><td colspan="4">Nonelderly</td></tr><tr><td colspan="4">2 mg, with psychiatric disorders (n = 43)</td></tr><tr><td>Baseline</td><td>47.1 (10.4)</td><td>38.3 (8.7)</td><td>37.7 (9.1)</td></tr><tr><td>Final visit (LOCF)</td><td>47.5 (9.8)</td><td>44.6 (9.7)</td><td>43.6 (10.1)</td></tr><tr><td>Change from baseline</td><td>0.4 (10.5)</td><td>6.3 (9.3)*</td><td>5.9 (9.8)*</td></tr><tr><td colspan="4">3 mg, with psychiatric disorders (n = 36)<sup>a</sup></td></tr><tr><td>Baseline</td><td>49.4 (8.8)</td><td>39.8 (8.2)</td><td>39.5 (6.9)</td></tr><tr><td>Final visit (LOCF)</td><td>49.5 (11.0)</td><td>44.2 (8.3)</td><td>44.4 (10.1)</td></tr><tr><td>Change from baseline</td><td>−0.1 (8.9)</td><td>4.3 (9.2)<sup>‡</sup></td><td>4.8 (11.3)<sup>†</sup></td></tr><tr><td colspan="4">2 mg, without psychiatric disorders (n = 41)</td></tr><tr><td>Baseline</td><td>50.6 (8.0)</td><td>49.8 (7.6)</td><td>50.1 (9.1)</td></tr><tr><td>Final visit (LOCF)</td><td>51.7 (9.7)</td><td>50.8 (9.2)</td><td>50.7 (10.5)</td></tr><tr><td>Change from baseline</td><td>1.2 (8.6)</td><td>1.0 (9.6)</td><td>0.7 (12.0)</td></tr><tr><td colspan="4">3 mg, without psychiatric disorders (n = 39)<sup>a</sup></td></tr><tr><td>Baseline</td><td>50.9 (11.4)</td><td>49.4 (7.9)</td><td>50.4 (7.8)</td></tr><tr><td>Final visit (LOCF)</td><td>52.5 (8.1)</td><td>51.2 (8.1)</td><td>51.9 (7.8)</td></tr><tr><td>Change from baseline</td><td>1.7 (10.8)</td><td>1.7 (5.9)</td><td>1.6 (7.3)</td></tr></table> |
bf8717435e25f4921fbbccc8d062ad427eea9501c31f7fedbaa3b3fcedf9c7ad.png | simple | <table><tr><td>Training section</td><td>Examples for tasks</td></tr><tr><td>Planning strategies</td><td>Shopping lists, key search of the BADS subscales, to get items out of a bottle, special wooden 3-dimensional jig saw </td></tr><tr><td>Mnemonics</td><td>Using memory hooks, writing of suitable mnemonics, and planning where to place them</td></tr><tr><td>Decision making</td><td>Computer tasks, painting</td></tr><tr><td>Set shifting</td><td>To solve various tasks according to changing rules, to calculate for 5 min, then to read for 10 min and to write for 5 min, or to switch tasks after every third answer, categorising items according to different rules</td></tr><tr><td>Calculation</td><td>Calculation tasks</td></tr><tr><td>Navigational skills</td><td>Finding the way through a maze on a screen, finding the way around obstacles on a paper or on a screen</td></tr><tr><td>Information speed processing</td><td>Connecting numbers or letters, connecting figures to an image, and finding the meaning of a fictive word</td></tr><tr><td>Summary</td><td>Extracting the relevant information from news or from a story or a short movie</td></tr><tr><td>Concentration</td><td> Finding similar or dissimilar items </td></tr></table> |
81c84f70c8501db144c63e5a51e12df4157abeb8031fc7d5bf521a751b15544c.png | simple | <table><tr><td>Gene</td><td></td><td>N</td><td>Mean ± SD</td><td>P-value (Mann-Whitney test)</td></tr><tr><td>APC</td><td>Cases</td><td>11</td><td>2.06 ± 2.6</td><td>0.3</td></tr><tr><td></td><td>Controls</td><td>10</td><td>0.95 ± 1.31</td><td></td></tr><tr><td>ATM</td><td>Cases</td><td>9</td><td>0.5 ± 0.9</td><td>0.9</td></tr><tr><td></td><td>Controls</td><td>10</td><td>1.48 ± 2.2</td><td></td></tr></table> |
da80c8d6937df834221f4acfb1bfd6df8b616078fac06ea17f5fd30c3687d900.png | complex | <table><tr><td>25OHD, ng/mL</td><td colspan="2">25OHD ≤ 12</td><td colspan="2">13 < 25OHD ≤ 19</td><td colspan="2">20 < 25OHD ≤ 30</td><td colspan="2">25OHD > 30</td><td></td></tr><tr><td></td><td colspan="2"><i>n</i> = 2</td><td colspan="2"><i>n</i> = 9</td><td colspan="2"><i>n</i> = 15</td><td colspan="2"><i>n</i> = 24</td><td><i>p</i></td></tr><tr><td>Boys</td><td>0</td><td>0%</td><td>3</td><td>33%</td><td>7</td><td>47%</td><td>18</td><td>75%</td><td rowspan="2">0.04</td></tr><tr><td>Girls</td><td>2</td><td>100%</td><td>6</td><td>67%</td><td>8</td><td>53%</td><td>6</td><td>25%</td></tr><tr><td>Isolated GH deficiency</td><td>1</td><td>50%</td><td>6</td><td>67%</td><td>4</td><td>27%</td><td>11</td><td>46%</td><td rowspan="2">0.2</td></tr><tr><td>Multiple HP deficiency</td><td>1</td><td>50%</td><td>3</td><td>33%</td><td>11</td><td>73%</td><td>13</td><td>54%</td></tr><tr><td>Sunny season</td><td>0</td><td>0%</td><td>0</td><td>0%</td><td>4</td><td>27%</td><td>11</td><td>46%</td><td rowspan="2">0.01</td></tr><tr><td>Cold season</td><td>2</td><td>100%</td><td>6</td><td>100%</td><td>11</td><td>73%</td><td>13</td><td>54%</td></tr><tr><td></td><td colspan="2">Mean ± SD</td><td colspan="2">Mean ± SD</td><td colspan="2">Mean ± SD</td><td colspan="2">Mean ± SD</td><td></td></tr><tr><td>Age at diagnosis, years</td><td colspan="2">13.5 ± 4.5</td><td colspan="2">4.7 ± 5.1</td><td colspan="2">6.5 ± 6.7</td><td colspan="2">4.4 ± 2.8</td><td>0.1</td></tr><tr><td>Bone age, years</td><td colspan="2">12 ± 5</td><td colspan="2">3.6 ± 5.6</td><td colspan="2">3.2 ± 3.5</td><td colspan="2">2.5 ± 1.9</td><td>0.1</td></tr><tr><td>Height, SDS</td><td colspan="2">−2.7 ± −2.7</td><td colspan="2">−2.6 ± 0.6</td><td colspan="2">−3 ± 1.2</td><td colspan="2">−2.8 ± 1.5</td><td>0.9</td></tr><tr><td>BMI, SDS</td><td colspan="2">1.3 ± 0.8</td><td colspan="2">0.4 ± 1.6</td><td colspan="2">0.3 ± 2.3</td><td colspan="2">0 ± 1.6</td><td>0.6</td></tr><tr><td>Growth rate, SDS</td><td colspan="2">− 2.6 ± 0</td><td colspan="2">− 2.4 ± 0.6</td><td colspan="2">− 2.7 ± 1.2</td><td colspan="2">− 3 ± 1.2</td><td>NS</td></tr><tr><td>IGF1, SDS</td><td colspan="2">−4.7 ± 0</td><td colspan="2">−2.4 ± 1.8</td><td colspan="2">−3.9 ± 0.8</td><td colspan="2">−3.6 ± 1</td><td>NS</td></tr></table> |
a54a838394a154ff1f6bf680a185903452ab31380bea4365204abcea306ba5b6.png | simple | <table><tr><td>Variable</td><td><i>N</i></td><td> </td></tr><tr><td>Age (yrs)</td><td>51</td><td>66.7 (12.0)</td></tr><tr><td>Sex (M/F)</td><td>51</td><td>26/25</td></tr><tr><td>MMSE</td><td>51</td><td>28.7 (1.4)</td></tr><tr><td>Education</td><td>51</td><td>5 (2)</td></tr><tr><td>NRS 50 kPa </td><td>51</td><td>1.2 (1.6)</td></tr><tr><td>NRS 200 kPa </td><td>51</td><td>2.9 (2.3)</td></tr><tr><td>NRS 400 kPa</td><td>51</td><td>5.0 (2.6)</td></tr><tr><td>Facial expressions 50 kPa </td><td>51</td><td>0.4 (0.6)</td></tr><tr><td>Facial expressions 200 kPa </td><td>50</td><td>0.7 (0.9)</td></tr><tr><td>Facial expressions 400 kPa</td><td>51</td><td>1.2 (1.4)</td></tr><tr><td>Stroop Word card (s)</td><td>51</td><td>55.9 (15.9)</td></tr><tr><td>Stroop Color card (s)</td><td>51</td><td>67.3 (20.1)</td></tr><tr><td>Stroop Color/Word card (s)</td><td>51</td><td>127.5 (95.2)</td></tr><tr><td>Zoo Map score</td><td>51</td><td>11.0 (4.0)</td></tr><tr><td>Digit Span Backward</td><td>51</td><td>5.8 (2.3)</td></tr><tr><td>AVLT immediate recall</td><td>51</td><td>38.6 (11.1)</td></tr><tr><td>AVLT delayed recognition</td><td>51</td><td>27.3 (2.9)</td></tr><tr><td>RBMT immediate story recall</td><td>51</td><td>7.5 (3.4)</td></tr><tr><td>RBMT delayed story recall </td><td>51</td><td>6.3 (3.2)</td></tr></table> |
1eba8e3be118026bfdca23e414f245d5a90c40e8f90d0bbf1af10836c4cd7c19.png | complex | <table><tr><td>Characteristic</td><td>Value</td></tr><tr><td>Blood flow (ml/min)<sup>a</sup></td><td>421 ± 42</td></tr><tr><td>Time of utilization (h)</td><td>30.6 ± 21.0</td></tr><tr><td>Access pressure (mmHg)<sup>a</sup></td><td>− 145 ± 14</td></tr><tr><td>Filter pressure (mmHg)<sup>a</sup></td><td>301 ± 19</td></tr><tr><td>Return pressure (mmHg)<sup>a</sup></td><td>154 ± 21</td></tr><tr><td>Heparin bolus at insertion (IU)</td><td>3100 ± 1330</td></tr><tr><td>Heparin (IU/kg/24 h)</td><td>230 ± 78</td></tr><tr><td>Activated partial thromboplastin time ratio</td><td>1.8 ± 0.6</td></tr><tr><td colspan="2">Serious adverse event<sup>b</sup></td></tr><tr><td> Nonfatal cardiac arrest</td><td>1 (5)</td></tr><tr><td colspan="2">Study-related adverse event</td></tr><tr><td> Mild hemoptysis resolved with stopping anticoagulation<sup>c</sup></td><td>2 (10)</td></tr><tr><td> Membrane clotting</td><td>10 (50)</td></tr><tr><td>Time it occurred (h)</td><td>20.0 ± 9.7</td></tr></table> |
39c83d841fb7bfd067468ca10467a0cc29e7198e34f225c49b57669206070cfa.png | complex | <table><tr><td></td><td><i>N</i></td><td>Dog Owners(<i>n</i> = 43)</td><td>Non dog owners(<i>n</i> = 43)</td></tr><tr><td colspan="4">Match Characteristics</td></tr><tr><td> Gender (<i>N</i> female, %)</td><td>43</td><td>27 (63%)</td><td>27 (63%)</td></tr><tr><td> Age at start of study (years)</td><td>43</td><td>69.9 (± 4.1)</td><td>70.2 (± 4.1)</td></tr><tr><td> Ethnicity (<i>N</i> White British)</td><td>43</td><td>43 (100%)</td><td>43 (100%)</td></tr><tr><td> Cat ownership (<i>N</i> yes)</td><td>43</td><td>4 (9%)</td><td>4 (9%)</td></tr><tr><td>Townsend Index</td><td>43</td><td></td><td></td></tr><tr><td> 1 (least deprived)</td><td></td><td>11 (26%)</td><td>11 (26%)</td></tr><tr><td> 2</td><td></td><td>15 (35%)</td><td>15 (35%)</td></tr><tr><td> 3</td><td></td><td>12 (28%)</td><td>12 (28%)</td></tr><tr><td> 4</td><td></td><td>4 (9%)</td><td>4 (9%)</td></tr><tr><td> 5 (most deprived)</td><td></td><td>1 (2%)</td><td>1 (2%)</td></tr><tr><td colspan="4">Other Characteristics</td></tr><tr><td> Distance between homes (km)</td><td>42</td><td colspan="2">12.8 [22.8]</td></tr><tr><td> BMI (kg.m<sup>−2</sup>)</td><td>43</td><td>25.4 (± 4.3)</td><td>25.8 (± 3.7)</td></tr><tr><td> Participants reporting a chronic health condition at start of study</td><td>38/41</td><td>14 (37%)</td><td>15 (37%)</td></tr><tr><td> Self-reported continuous walking distance (km)</td><td>38/37</td><td>6.1 ± (2.2)</td><td>6.5 ± (2.6)</td></tr></table> |
3170b79440346a0705624ecc74b203247da82840a066b415aa809d7b5b39cd3b.png | simple | <table><tr><td>FAK location</td><td>Parameter</td><td>Correlation co-efficient</td><td>p-value</td></tr><tr><td>Vessels</td><td>Patient age</td><td>0.096</td><td>0.246</td></tr><tr><td> </td><td>Tumour size</td><td>0.089</td><td>0.28</td></tr><tr><td>Tumour cells</td><td>Patient age</td><td>-0.138</td><td>0.094</td></tr><tr><td> </td><td>Tumour size</td><td>0.119</td><td>0.148</td></tr></table> |
9ba2149647106a1eff8b3da3427ad7637fa31d300b2883bc8b0b7ba18b153cd7.png | complex | <table><tr><td>Parameters</td><td>DMFT index</td><td><i>H</i></td><td>Found <i>p</i></td><td><i>p</i></td><td>Sig./N. sig.</td></tr><tr><td rowspan="3">Zn concentration, mmol/l (before stimulation)</td><td><1</td><td rowspan="3">2.54</td><td rowspan="3">0.28</td><td rowspan="3">>0.05</td><td rowspan="3">N. sig.</td></tr><tr><td>1–6</td></tr><tr><td>>6</td></tr><tr><td rowspan="3">Zn concentration, mmol/l (after stimulation)</td><td><1</td><td rowspan="3">3.56</td><td rowspan="3">0.16</td><td rowspan="3">>0.05</td><td rowspan="3">N. sig.</td></tr><tr><td>1–6</td></tr><tr><td>>6</td></tr><tr><td rowspan="3">Zn quantity, <i>μ</i>mol/l (before stimulation)</td><td><1</td><td rowspan="3">5.66</td><td rowspan="3">0.05</td><td rowspan="3">>0.05</td><td rowspan="3">N. sig.</td></tr><tr><td>1–6</td></tr><tr><td>>6</td></tr><tr><td>Zn quantity, <i>μ</i>mol/l (after stimulation)</td><td><1</td><td>7.99</td><td>0.01</td><td><0.05</td><td>Sig.</td></tr></table> |
60bf0fbcab5d35144db59c08c161ee2f75a678ca8ab50fa43d31f9db35271dc8.png | simple | <table><tr><td>Parameter</td><td>FS (<i>n</i> = 848)</td><td>FGLS (<i>n</i> = 1556)</td><td>Total (<i>n</i> = 2404)</td></tr><tr><td>Gestational age at birth</td><td></td><td></td><td></td></tr><tr><td>< 28 weeks</td><td>2 (0.2)</td><td>1 (0.1)</td><td>3 (0.1)</td></tr><tr><td>28–32 weeks</td><td>3 (0.4)</td><td>6 (0.4)</td><td>9 (0.4)</td></tr><tr><td>32–37 weeks</td><td>56 (6.6) </td><td>62 (4.0) </td><td>118 (4.9)</td></tr><tr><td>37–43 weeks</td><td>787 (92.8) </td><td>1487 (95.6)</td><td>2274 (94.6)</td></tr><tr><td>Birth weight</td><td></td><td></td><td></td></tr><tr><td>< 1000 g</td><td>1 (0.1)</td><td>2 (0.1)</td><td>3 (0.1)</td></tr><tr><td>1000–1499 g</td><td>5 (0.6)</td><td>1 (0.1)</td><td>6 (0.2)</td></tr><tr><td>1500–1999 g</td><td>9 (1.1)</td><td>15 (1.0) </td><td>24 (1.0) </td></tr><tr><td>2000–2499 g</td><td>79 (9.3) </td><td>76 (4.9) </td><td>155 (6.4)</td></tr><tr><td>≥ 2500 g</td><td>754 (88.9) </td><td>1462 (94.0)</td><td>2216 (92.2)</td></tr></table> |
306b33246fa9587d6f12dd881e0bedfe7a1c997f0960530eeefab8226fdf3382.png | simple | <table><tr><td>Experimental groups</td><td>n</td><td>DT days, Mean±SE</td><td>GD days, mean</td><td>Inhibition ratio (%)</td><td>CR number</td></tr><tr><td>Control</td><td>8</td><td>4.6±0.5</td><td></td><td>0</td><td>0</td></tr><tr><td>CDDP</td><td>8</td><td>10.6±1.21</td><td>5.5</td><td>33</td><td>0</td></tr><tr><td>EP</td><td>8</td><td>6.6±0.5</td><td>2.0</td><td>32</td><td>0</td></tr><tr><td>ECT</td><td>10</td><td>20.1±1.2</td><td>15.5</td><td>61</td><td>0</td></tr><tr><td>IR (3 Gy)</td><td>9</td><td>15.7±1.4</td><td>11.1</td><td>63</td><td>0</td></tr><tr><td>CDDP + IR (3 Gy)</td><td>9</td><td>15.9±2.4</td><td>11.3</td><td>61</td><td>0</td></tr><tr><td>EP + IR (3 Gy)</td><td>8</td><td>13.4±2.1</td><td>8.8</td><td>51</td><td>0</td></tr><tr><td>ECT + IR (3 Gy)</td><td>10</td><td>30.3±2.6</td><td>25.7</td><td>76</td><td>0</td></tr><tr><td>IR (5 Gy)</td><td>8</td><td>25.2±1.1</td><td>20.6</td><td>70</td><td>0</td></tr><tr><td>CDDP + IR (5 Gy)</td><td>8</td><td>25.6±1.2</td><td>21.0</td><td>75</td><td>0</td></tr><tr><td>EP + IR (5 Gy)</td><td>8</td><td>22.4±1.4</td><td>17.8</td><td>59</td><td>0</td></tr><tr><td>ECT + IR (5 Gy)</td><td>8</td><td>43.2±1.5</td><td>38.6</td><td>87</td><td>2</td></tr></table> |
11d671bf1b59949d2b1b71e70c5d7951e5a07b513541a5e13897a7f298b2cc60.png | simple | <table><tr><td>Risk</td><td>Kupelian</td><td>D'Amico</td><td>Pound</td></tr><tr><td>Low</td><td>85%</td><td>83%</td><td>94-82%</td></tr><tr><td>Intermediate</td><td>65%</td><td>50%</td><td>72%</td></tr><tr><td>High</td><td>32%</td><td>28%</td><td>54%</td></tr></table> |
8d44b927d7ec7b8db4f9a71be8ac7a6a54ad7f3d65761a5a150ad2b598cd7a82.png | complex | <table><tr><td></td><td colspan="7">Days of pseudopregnancy</td></tr><tr><td>Cell Types</td><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td><td>6</td><td>7</td></tr><tr><td>Luminal epithelium</td><td>+</td><td>+</td><td>+</td><td>+/-</td><td>+/-</td><td>+/-</td><td>+/-</td></tr><tr><td>Glandular epithelium</td><td>+/-</td><td>+</td><td>+</td><td>+/-</td><td>+/-</td><td>+/-</td><td>+/-</td></tr><tr><td>Stromal cells</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td></tr></table> |
21570fbf3703a9d6b4d370d906efd6327920ccd7194f78c8e6168990c7d4e65d.png | complex | <table><tr><td>Database name</td><td>Organization</td><td>Remarks</td><td>Relevance to investigation interests</td></tr><tr><td>National Health and Nutrition Examination Survey (NHANES)</td><td>CDC</td><td>Section on “Hearing/audiometry (AUQ) for 1 year and over, 1999-2012 with component or lab tests conducted on original sample description. In 2013-2014, there was no component/lab test conducted.</td><td>Yes</td></tr><tr><td>National Health Interview Survey Occupational Health Supplement (NHIS-OHS)</td><td>CDC</td><td>Does not contain any audiometric topics.</td><td>No</td></tr><tr><td rowspan="2">Behavioral Risk Factor Surveillance System (BRFSS)</td><td>National Center for Chronic</td><td rowspan="2">Option to respond ‘hearing problem’ as the major impairment that limits activities 1998-2002, 2013; Veteran’s Status included, 2003-2008, 2010-2012</td><td rowspan="2">Yes</td></tr><tr><td>Disease Prevention and Health Promotion (NCCDPHP)</td></tr><tr><td>National Health Survey</td><td>CDC</td><td>Questions by family and individuals on hearing can derive some information about associations with the military, data available from 1997 onward. QOL is a supplemental (optional) component of the survey, available 2010-2012</td><td>Yes</td></tr><tr><td>Health and Retirement Study (HRS)</td><td>University of Michigan</td><td>Data from 1992-2014 on hearing status, employment, and QOL measures</td><td>Yes</td></tr></table> |
8a531e2f1bcb4748bb5a3b10c2b3979f4d5a61d7780bc95527acf7241e407a6f.png | complex | <table><tr><td></td><td>Period</td><td colspan="2">Incidence Rate (per 100,000)</td><td colspan="2">Mortality Rate (per 100,000)</td><td colspan="2">Relative Survival Ratio (%)</td></tr><tr><td></td><td></td><td><i>Total</i></td><td><i>Rate (95% CI)</i></td><td><i>Total</i></td><td><i>Rate (95% CI)</i></td><td><i>N*</i></td><td><i>Ratio (95% CI)</i></td></tr><tr><td><i>All</i></td><td>1968–1972</td><td>94</td><td>6.7 (5.3–8.4)</td><td>23</td><td>1.6 (0.9–2.4)</td><td>-</td><td>-</td></tr><tr><td></td><td>1973–1977</td><td>143</td><td>8.6 (7.1–10.2)</td><td>35</td><td>2.0 (1.4–2.9)</td><td>31.7</td><td>48.1 (34.6–62.5)</td></tr><tr><td></td><td>1978–1982</td><td>239</td><td>11.3 (9.8–12.9)</td><td>69</td><td>3.4 (2.6–4.3)</td><td>57.4</td><td>53.0 (43.4–62.8)</td></tr><tr><td></td><td>1983–1987</td><td>356</td><td>13.8 (12.4–15.4)</td><td>106</td><td>4.1 (3.3–5.0)</td><td>94.8</td><td>49.7 (41.7–57.8)</td></tr><tr><td></td><td>1988–1992</td><td>527</td><td>16.3 (14.9–17.7)</td><td>187</td><td>5.7 (4.9–6.6)</td><td>155.7</td><td>55.8 (49.1–62.6)</td></tr><tr><td></td><td>1993–1997</td><td>903</td><td>23.2 (21.7–24.8)</td><td>303</td><td>7.7 (6.9–8.7)</td><td>214.9</td><td>53.5 (48.1–59.0)</td></tr><tr><td></td><td>1998–2002</td><td>1351</td><td>29.2 (27.6–30.8)</td><td>434</td><td>9.3 (8.5–10.3)</td><td>394.5</td><td>60.9 (56.6–65.1)</td></tr><tr><td><i>Chinese</i></td><td>1968–1972</td><td>74</td><td>6.4 (4.9–8.2)</td><td>18</td><td>1.5 (0.8–2.5)</td><td>-</td><td>-</td></tr><tr><td></td><td>1973–1977</td><td>104</td><td>7.7 (6.2–9.4)</td><td>30</td><td>2.2 (1.4–3.2)</td><td>22.8</td><td>36.5 (23.3–51.5)</td></tr><tr><td></td><td>1978–1982</td><td>179</td><td>10.5 (9.0–12.2)</td><td>52</td><td>3.1 (2.3–4.1)</td><td>37.6</td><td>46.6 (35.9–57.8)</td></tr><tr><td></td><td>1983–1987</td><td>257</td><td>12.7 (11.2–14.4)</td><td>75</td><td>3.6 (2.8–4.6)</td><td>65.1</td><td>46.8 (37.6–56.5)</td></tr><tr><td></td><td>1988–1992</td><td>411</td><td>16.3 (14.7–17.9)</td><td>148</td><td>5.6 (4.7–6.6)</td><td>111.8</td><td>58.8 (50.9–66.6)</td></tr><tr><td></td><td>1993–1997</td><td>718</td><td>24.1 (22.3–25.9)</td><td>239</td><td>7.8 (6.8–8.8)</td><td>167.4</td><td>53.0 (46.8–59.2)</td></tr><tr><td></td><td>1998–2002</td><td>1091</td><td>30.9 (29.1–32.8)</td><td>342</td><td>9.6 (8.6–10.7)</td><td>306.4</td><td>61.7 (56.8–66.5)</td></tr><tr><td><i>Malays</i></td><td>1968–1972</td><td>9</td><td>7.2 (3.1–14.2)</td><td>2</td><td>1.2 (0.1–4.5)</td><td></td><td></td></tr><tr><td></td><td>1973–1977</td><td>19</td><td>11.4 (6.5–18.6)</td><td>2</td><td>0.9 (0.1–3.7)</td><td>3.7</td><td>78.1 (28.7–125.1)</td></tr><tr><td></td><td>1978–1982</td><td>25</td><td>11.6 (7.3–17.5)</td><td>7</td><td>2.9 (1–6.4)</td><td>8.4</td><td>69.1 (40.3–97.2)</td></tr><tr><td></td><td>1983–1987</td><td>45</td><td>15.5 (11.2–21.0)</td><td>13</td><td>4.5 (2.4–7.9)</td><td>14.7</td><td>51 (30.3–73)</td></tr><tr><td></td><td>1988–1992</td><td>54</td><td>14.9 (11.1–19.6)</td><td>22</td><td>6.4 (3.9–9.7)</td><td>19.6</td><td>26.3 (14.2–42)</td></tr><tr><td></td><td>1993–1997</td><td>90</td><td>21.3 (17.1–26.2)</td><td>41</td><td>10.4 (7.4–14.1)</td><td>16.0</td><td>35.9 (21.5–52.4)</td></tr><tr><td></td><td>1998–2002</td><td>137</td><td>26.8 (22.4–31.8)</td><td>51</td><td>10.0 (7.4–13.3)</td><td>30.5</td><td>64.1 (50–77.4)</td></tr><tr><td><i>Indians</i></td><td>1968–1972</td><td>7</td><td>4.9 (1.6–11.3)</td><td>2</td><td>1.7 (0.1–7.9)</td><td></td><td></td></tr><tr><td></td><td>1973–1977</td><td>16</td><td>11.6 (5.7–21.1)</td><td>3</td><td>2.0 (0.4–5.8)</td><td>1.0</td><td>31.7 (4.7–75.8)</td></tr><tr><td></td><td>1978–1982</td><td>26</td><td>15.3 (9.6–23.3)</td><td>5</td><td>3.1 (0.9–7.5)</td><td>6.1</td><td>67.5 (35.9–95.0)</td></tr><tr><td></td><td>1983–1987</td><td>41</td><td>16.6 (11.7–22.8)</td><td>13</td><td>6.2 (3.0–11.1)</td><td>14.2</td><td>63.5 (43.1–83.1)</td></tr><tr><td></td><td>1988–1992</td><td>42</td><td>13.4 (9.5–18.5)</td><td>11</td><td>4.8 (2.3–9.0)</td><td>20.6</td><td>59.1 (39.7–78.2)</td></tr><tr><td></td><td>1993–1997</td><td>65</td><td>16.3 (12.4–20.9)</td><td>13</td><td>3.3 (1.7–5.8)</td><td>23.2</td><td>86.6 (67.0–102.8)</td></tr><tr><td></td><td>1998–2002</td><td>84</td><td>18.6 (14.6–23.3)</td><td>29</td><td>6.0 (3.9–8.7)</td><td>35.3</td><td>44.5 (32.4–57.0)</td></tr></table> |
164d0878a882db6911fcc702e7f7eae1ddbddb1e17852d63592ce4c552272983.png | simple | <table><tr><td>Genes</td><td>Forward primer (5′–3′)</td><td>Reverse primer (5′–3′)</td></tr><tr><td>m-PAX2</td><td>AAGCCCGGAGTGATTGGTG</td><td>CAGGCGAACATAGTCGGGTT</td></tr><tr><td>m-WT1</td><td>CAGTTCCCCAACCATTCCTT</td><td>AAGCTGGGAGGTCATTTGGT</td></tr><tr><td>m-Brachyury (Bry)</td><td>ACCCAGACTCGCCCAATTTT</td><td>GGAAAGCAGTGGCTGGTGAT</td></tr><tr><td>m-CD24</td><td>GTTGCACCGTTTCCCGGTAA</td><td>CCCCTCTGGTGGTAGCGTTA</td></tr><tr><td>m-Osr1</td><td>ATTCACCCTAAGCCAGAGATCA</td><td>AGGCCAGGTTAGCGAAATCAA</td></tr><tr><td>m-Six2</td><td>CTCACCACCACGCAAGTCAG</td><td>CTCGGAACTGCCTAGCACC</td></tr><tr><td>m-Sall1</td><td>CTCAACATTTCCAATCCGACCC</td><td>GGCATCCTTGCTCTTAGTGGG</td></tr><tr><td>m-E-cad</td><td>CTCCAGTCATAGGGAGCTGTC</td><td>TCTTCTGAGACCTGGGTACAC</td></tr><tr><td>m-AQP1</td><td>AGGCTTCAATTACCCACTGGA</td><td>GTGAGCACCGCTGATGTGA</td></tr><tr><td>m-PDGFR</td><td>CCACACCCTTGGGGAATAGT</td><td>TTTGAAGGGCAAGGAATGTG</td></tr><tr><td>m-GAPDH</td><td>ACTTCAACAGCAACTCCCACTC</td><td>TAGGCCCCTCCTGTTATTATGG</td></tr><tr><td>r-IL-10</td><td>TAACTGCACCCACTTCCCAGT</td><td>TGGCAACCCAAGTAACCCTTA</td></tr><tr><td>r-bFGF</td><td>CGACCCACACGTCAAACTAC</td><td>CCAGGCGTTCAAAGAAGAAA</td></tr><tr><td>r-TGF-β1</td><td>GCCCTGGATACCAACTACTGCT</td><td>GTTGGTTGTAGAGGGCAAGGAC</td></tr><tr><td>r-EGF</td><td>CGTCTCAGTGGTCATGGATTT</td><td>TCAGAAGAACACGGGAATTGT</td></tr><tr><td>r-HGF</td><td>CTCTCGTTCCTTGGGATTATTG</td><td>GATCCCCCACAGATGTGTTTAT</td></tr><tr><td>r-PDGF</td><td>ATCGAGCCAAGACACCTCAAAC</td><td>ATGGGGGCAGTACAGCAAATAC</td></tr><tr><td>r-GAPDH</td><td>AGTGCCAGCCTCGTCTCATAG</td><td>CGTTGAACTTGCCGTGGGTAG</td></tr></table> |
c1106d2328412b83e37b5925f8b1fce443cb1a76ea3c0b28b07a658e76e29da1.png | complex | <table><tr><td></td><td></td><td>N (%) participants</td><td>N (%) valid days</td></tr><tr><td>Full sample</td><td></td><td>23,188 (100%)</td><td>158,784 (100%)</td></tr><tr><td>Sex</td><td>Male</td><td>8819 (38%)</td><td>62,745 (40%)</td></tr><tr><td></td><td>Female</td><td>14,369 (62%)<sup>†</sup></td><td>96,039 (60%)</td></tr><tr><td>Age</td><td>5-6 years</td><td>1800 (8%)</td><td>7855 (5%)</td></tr><tr><td></td><td>7-8 years</td><td>711 (3%)</td><td>4963 (3%)</td></tr><tr><td></td><td>9-10 years</td><td>5769 (25%)</td><td>30,702 (19%)</td></tr><tr><td></td><td>11-12 years</td><td>9616 (41%)</td><td>61,352 (39%)</td></tr><tr><td></td><td>13-14 years</td><td>4206 (18%)</td><td>46,530 (29%)</td></tr><tr><td></td><td>15-16 years</td><td>1086 (5%)</td><td>7382 (5%)</td></tr><tr><td rowspan="9">Country [No. studies]</td><td>Australia [N = 2]</td><td>2459 (11%)</td><td>18,679 (12%)</td></tr><tr><td>Brazil [N = 1]</td><td>453 (2%)</td><td>1577 (1%)</td></tr><tr><td>Denmark [N = 2]</td><td>2031 (9%)</td><td>11,030 (7%)</td></tr><tr><td>England [N = 4]</td><td>10,284 (44%)</td><td>83,420 (53%)</td></tr><tr><td>Estonia [N = 1]</td><td>656 (3%)</td><td>2537 (2%)</td></tr><tr><td>Madeira [N = 1]</td><td>1214 (5%)</td><td>4899 (3%)</td></tr><tr><td>Norway [N = 1]</td><td>384 (2%)</td><td>1459 (1%)</td></tr><tr><td>Switzerland [N = 1]</td><td>404 (2%)</td><td>2569 (2%)</td></tr><tr><td>United States [N = 2]</td><td>5303 (23%)</td><td>32,614 (21%)</td></tr><tr><td rowspan="3">Weight status</td><td>Normal/underweight</td><td>17,573 (76%)</td><td>121,350 (76%)</td></tr><tr><td>Overweight</td><td>4116 (18%)</td><td>27,967 (18%)</td></tr><tr><td>Obese</td><td>1499 (6%)</td><td>9467 (6%)</td></tr><tr><td rowspan="2">Mother’s education</td><td>Up to high school</td><td>7422 (48%)</td><td>54,547 (48%)</td></tr><tr><td>College/vocational</td><td>2656 (17%)</td><td>19,352 (17%)</td></tr><tr><td></td><td>University level</td><td>5251 (34%)</td><td>38,723 (34%)</td></tr></table> |
99c465583576b13636199ed7d67c3eb02d103c8b6ab4fbdcb5750353f024094d.png | complex | <table><tr><td>Locus no.</td><td>Putative identification</td><td>Avg fold difference</td></tr><tr><td colspan="3">Mobile and extrachromosomal element functions: Transposon functions</td></tr><tr><td>PG0019</td><td>ISPg4 transposase</td><td>1.57</td></tr><tr><td>PG0050</td><td>ISPg4, transposase</td><td>1.81</td></tr><tr><td>PG0177</td><td>ISPg4, transposase</td><td>1.87</td></tr><tr><td>PG0194</td><td>ISPg3, transposase</td><td>2.18</td></tr><tr><td>PG0225</td><td>ISPg4, transposase</td><td>1.80</td></tr><tr><td>PG0261</td><td>ISPg3, transposase</td><td>2.20</td></tr><tr><td>PG0459</td><td>ISPg5, transposase</td><td>1.60</td></tr><tr><td>PG0487</td><td>ISPg4, transposase</td><td>1.98</td></tr><tr><td>PG0798</td><td>ISPg3, transposase</td><td>2.11</td></tr><tr><td>PG0819</td><td>Integrase</td><td>1.80</td></tr><tr><td>PG0838</td><td>Integrase</td><td>3.36</td></tr><tr><td>PG0841</td><td>Mobilizable transposon, excision protein, putative</td><td>3.78</td></tr><tr><td>PG0842</td><td>Mobilizable transposon, hypothetical protein, putative</td><td>2.84</td></tr><tr><td>PG0872</td><td>Mobilizable transposon, xis protein</td><td>3.87</td></tr><tr><td>PG0873</td><td>Mobilizable transposon, tnpC protein</td><td>9.34</td></tr><tr><td>PG0874</td><td>Mobilizable transposon, int protein</td><td>2.42</td></tr><tr><td>PG0875</td><td>Mobilizable transposon, tnpA protein</td><td>1.68</td></tr><tr><td>PG0970</td><td>ISPg4, transposase</td><td>1.79</td></tr><tr><td>PG1032</td><td>ISPg3, transposase</td><td>2.23</td></tr><tr><td>PG1061</td><td>ISPg6, transposase</td><td>2.03</td></tr><tr><td>PG1261</td><td>ISPg4, transposase</td><td>2.06</td></tr><tr><td>PG1262</td><td>ISPg3, transposase</td><td>2.11</td></tr><tr><td>PG1435</td><td>Integrase</td><td>2.77</td></tr><tr><td>PG1454</td><td>Integrase</td><td>1.88</td></tr><tr><td>PG1658</td><td>ISPg4, transposase</td><td>1.83</td></tr><tr><td>PG1673</td><td>ISPg4, transposase</td><td>1.77</td></tr><tr><td>PG2194</td><td>ISPg4, transposase</td><td>1.85</td></tr><tr><td>PG0461</td><td>ISPg7, transposase</td><td>−2.77</td></tr><tr><td>PG0277</td><td>ISPg2, transposase</td><td>−1.58</td></tr><tr><td>PG0865</td><td>ISPg2, transposase</td><td>−1.53</td></tr><tr><td>PG1746</td><td>ISPg2, transposase</td><td>−1.63</td></tr><tr><td>PG2176</td><td>ISPg2, transposase</td><td>−1.58</td></tr><tr><td>PG1350</td><td>ISPg2, transposase</td><td>−1.53</td></tr></table> |
afdb807f28daa793af6d9a075872bb54e6e11c770c8ad94bf6d2d1671a69afc0.png | simple | <table><tr><td>TCGA acronym</td><td>Cancer type</td><td>Paired samples</td><td>Unpaired tumor samples</td><td>Reference</td></tr><tr><td>BRCA</td><td>Breast invasive carcinoma</td><td>107</td><td>929</td><td>(3)</td></tr><tr><td>COAD</td><td>Colon adenocarcinoma</td><td>26</td><td>236</td><td>(1)</td></tr><tr><td>HNSC</td><td>Head/neck squamous cell carcinoma</td><td>38</td><td>384</td><td>(27)</td></tr><tr><td>KICH</td><td>Kidney chromophobe</td><td>21</td><td>41</td><td>https://tcga-data.nci.nih.gov/</td></tr><tr><td>KIRC</td><td>Kidney renal clear cell carcinoma</td><td>71</td><td>434</td><td>(4)</td></tr><tr><td>LUAD</td><td>Lung adenocarcinoma</td><td>57</td><td>431</td><td>(28)</td></tr><tr><td>LUSC</td><td>Lung squamous cell carcinoma</td><td>50</td><td>433</td><td>(2)</td></tr><tr><td>PRAD</td><td>Prostate adenocarcinoma</td><td>48</td><td>247</td><td>https://tcga-data.nci.nih.gov/</td></tr><tr><td>THCA</td><td>Thyroid carcinoma</td><td>58</td><td>439</td><td>https://tcga-data.nci.nih.gov/</td></tr></table> |
04b02d4cbcef3fc14af5957e66b15490c8c956801ff539891ba8683080aaede7.png | simple | <table><tr><td>Description</td><td>Number of features</td></tr><tr><td>Mean, range, interquartile range (<i>x</i>, <i>y</i>, <i>z</i>)</td><td>9</td></tr><tr><td>Moments: standard deviation, skew, kurtosis (<i>x</i>, <i>y</i>, <i>z</i>)</td><td>9</td></tr><tr><td>Histogram: bin counts of −2 to 1 <i>z</i>-scores (<i>x</i>, <i>y</i>, <i>z</i>)</td><td>12</td></tr><tr><td>Derivative of moments: mean, standard deviation, skew, kurtosis (<i>x</i>, <i>y</i>, <i>z</i>)</td><td>12</td></tr><tr><td>Mean of the squared norm</td><td>1</td></tr><tr><td>Sum of axial standard deviations</td><td>1</td></tr><tr><td>Pearson correlation coefficient, <i>r</i> (<i>xy</i>), <i>r</i> (<i>xz</i>), <i>r</i> (<i>yz</i>)</td><td>3</td></tr><tr><td>Mean cross products (raw and normalized), <i>xy</i>, <i>xz</i>, <i>yz</i></td><td>6</td></tr><tr><td>Absolute mean of cross products (raw and normalized)</td><td>6</td></tr><tr><td>Power spectra: mean, standard deviation, skew, kurtosis (<i>x</i>, <i>y</i>, <i>z</i>)</td><td>12</td></tr><tr><td>Mean power in 0.5 Hz bins between 0 and 10 Hz (<i>x</i>, <i>y</i>, <i>z</i>)</td><td>60</td></tr></table> |
dd0aabcfbfabaf3ec42363239e0d6e02dcb71d033d44b9c2b3268750e407e174.png | complex | <table><tr><td rowspan="2">Gene Ontology (GO) Name</td><td rowspan="2">Number of Genes Involve</td><td rowspan="2">Fold Change</td><td colspan="2">Genes</td></tr><tr><td>Highly Expressed in Susceptible Group</td><td>Highly Expressed in Resistant Group</td></tr><tr><td>Negative regulation of transcription from RNA polymerase II promoter</td><td>21</td><td>2.0</td><td><i>ELK4</i>, <i>GATAD2A</i>, <i>KANK2</i>, <i>MNT</i>, <i>ARHGAP35</i>, <i>SMAD3</i>, <i>TAL1</i>, <i>CBX6</i>, <i>GFI1</i>, <i>HDAC4</i>, <i>NFATC2</i>, <i>RXRA</i>, <i>RUNX3</i>, <i>ZNF8</i></td><td><i>N4BP2L2</i>, <i>ANKRD2</i>, <i>BMP4</i>, <i>DUSP26</i>, <i>FOXH1</i>, <i>HSF4</i>, <i>IRF7</i></td></tr><tr><td>Ion transport</td><td>17</td><td>2.0</td><td><i>ATP7A</i>, <i>KCNA1</i>, <i>SLC39A10</i>, <i>TTYH3</i>, <i>TPCN1</i></td><td><i>ATP5E</i>, <i>ATP5I</i>, <i>FXYD1</i>, <i>CACNA2D4</i>, <i>CHRNA2</i>, <i>KCNK7</i>, <i>KCNJ15</i>, <i>SLC10A1</i>, <i>SLC22A17</i>, <i>SLC26A8</i></td></tr><tr><td>Protein phosphorylation</td><td>15</td><td>2.2</td><td><i>PDPK1</i>, <i>ATM</i>, <i>BCR</i>, <i>JAK3</i>, <i>SBK1</i>, <i>ACVR1B</i>, <i>EIF2AK3</i>, <i>HUNK</i>, <i>LMTK2</i>, <i>PRKCI</i>, <i>PDK4</i>, <i>RUNX3</i></td><td><i>DMPK</i>, <i>NTRK1</i>, <i>TEX14</i></td></tr><tr><td>Immunity</td><td>13</td><td>1.9</td><td><i>DDX3X</i>, <i>ETS1</i>, <i>JAK3</i>, <i>C3</i>, <i>ERAP1</i>, <i>LST1</i></td><td><i>CLEC4E</i>, <i>ISG15</i>, <i>S100A12</i>, <i>ZBP1</i>, <i>APOBEC3A</i>, <i>IRF7</i>, <i>PGLYRP1</i></td></tr><tr><td>Innate immunity</td><td>9</td><td>2.5</td><td><i>DDX3X</i>, <i>JAK3</i>, <i>C3</i></td><td><i>ISG15</i>, <i>S100A12</i>, <i>ZBP1</i>, <i>APOBEC3A</i>, <i>IRF7</i>, <i>PGLYRP1</i></td></tr><tr><td>Innate immune response</td><td>9</td><td>1.4</td><td><i>DDX3X</i>, <i>JAK3</i>, <i>APOBEC3A</i>, <i>F12</i></td><td><i>CLEC4E</i>, <i>S100A12</i>, <i>ZBP1</i>, <i>IRF7</i>, <i>PGLYRP1</i></td></tr><tr><td>RNA polymerase II regulatory region seq-specific DNA binding</td><td>9</td><td>2.9</td><td><i>GATAD2A</i>, <i>MNT</i>, <i>PRDM15</i>, <i>SMAD3</i>, <i>TAL1</i>, <i>RXRA</i>, <i>RUNX3</i>, <i>ZNF8</i></td><td>-</td></tr><tr><td>GTPase activation</td><td>9</td><td>3.4</td><td><i>AGAP1</i>, <i>ADAP1</i>, <i>BCR</i>, <i>ARHGAP23</i>, <i>ARHGAP35</i>, <i>TBC1D2B</i>, <i>TBC1D9</i>, <i>SIPA1L3</i></td><td><i>TBCD7</i></td></tr><tr><td>Peptidyl-serine phosphorylation</td><td>8</td><td>4.4</td><td><i>PDPK1</i>, <i>ATM</i>, <i>BCL2</i>, <i>RICTOR</i>, <i>EIF2AK3</i>, <i>LMTK2</i>, <i>PRKCI</i></td><td><i>DMPK</i></td></tr><tr><td>Rab GTPase binding</td><td>6</td><td>3.0</td><td><i>ERC1</i>, <i>RAB11FIP4</i>, <i>RAB29</i>, <i>TBC1D2B</i>, <i>TBC1D9</i></td><td><i>TBC1D7</i></td></tr></table> |
27c8108eb21c3cb57f22c11f3fd0e66ade6b842f9838298f10fb74efaa095713.png | simple | <table><tr><td>Clinicopathological characteristic</td><td>Number (%)</td></tr><tr><td>Age, years</td><td></td></tr><tr><td> Median</td><td>70</td></tr><tr><td> Range</td><td>47–84</td></tr><tr><td>Sex</td><td></td></tr><tr><td> Male</td><td>30 (85.7)</td></tr><tr><td> Female</td><td>5 (14.3)</td></tr><tr><td>Smoking status</td><td></td></tr><tr><td> Smoker</td><td>31 (88.6)</td></tr><tr><td> Never-smoker</td><td>4 (11.4)</td></tr><tr><td>Histological subtype</td><td></td></tr><tr><td> Pure SCLC</td><td>2 (5.7)</td></tr><tr><td> Combined SCLC</td><td>11 (31.4)</td></tr><tr><td> Pure LCNEC</td><td>8 (22.9)</td></tr><tr><td> Combined LCNEC</td><td>14 (40.0)</td></tr><tr><td>Accompanied component in combined SCLC</td><td>Number (% in all combined SCLC)</td></tr><tr><td> LCNEC</td><td>9 (81.8)</td></tr><tr><td> Adenocarcinoma</td><td>4 (36.4)</td></tr><tr><td> Squamous cell carcinoma</td><td>1 (9.1)</td></tr><tr><td> Large cell carcinoma</td><td>2 (18.2)</td></tr><tr><td>Accompanied component in combined LCNEC</td><td>Number (% in all combined LCNEC)</td></tr><tr><td> Adenocarcinoma</td><td>10 (71.4)</td></tr><tr><td> Squamous cell carcinoma</td><td>6 (42.9)</td></tr><tr><td> Large cell carcinoma</td><td>0 (0)</td></tr></table> |
d3956e87417bfa8fd113c1c6544c0c14c6d27cbf6339f1c6f7eaa50d15cf0f42.png | complex | <table><tr><td rowspan="3"></td><td rowspan="3">RNA-Seq datasets comparison</td><td colspan="4">number of DEGs</td></tr><tr><td colspan="2">48 hai</td><td colspan="2">96 hai</td></tr><tr><td>up</td><td>down</td><td>up</td><td>down</td></tr><tr><td rowspan="4">2Hb8</td><td>R NIL <i>Fusarium</i> inoculated – R NIL mock inoculated (R_F/M)</td><td>11</td><td>21</td><td>415</td><td>192</td></tr><tr><td>M69 <i>Fusarium</i> inoculated – M69 mock inoculated (M69_F/M)</td><td>45</td><td>167</td><td>1283</td><td>354</td></tr><tr><td>R NIL <i>Fusarium</i> inoculated – M69 <i>Fusarium</i> inoculated (R/M69_F)</td><td>350</td><td>80</td><td>321</td><td>426</td></tr><tr><td>R NIL mock inoculated – M69 mock inoculated (R/M69_M)</td><td>355</td><td>70</td><td>401</td><td>282</td></tr><tr><td rowspan="4">6Hb7</td><td>R NIL <i>Fusarium</i> inoculated – R NIL mock inoculated (R_F/M)</td><td>100</td><td>14</td><td>304</td><td>15</td></tr><tr><td>Lacey <i>Fusarium</i> inoculated – Lacey mock inoculated (Lacey_F/M)</td><td>12</td><td>53</td><td>693</td><td>227</td></tr><tr><td>R NIL <i>Fusarium</i> inoculated – Lacey <i>Fusarium</i> inoculated (R/Lacey_F)</td><td>66</td><td>36</td><td>5</td><td>10</td></tr><tr><td>R NIL mock inoculated – Lacey mock inoculated (R/Lacey_M)</td><td>12</td><td>89</td><td>4</td><td>19</td></tr></table> |
33705279fd0268b4c34c29459f6940c3265a6ab07393ff789b394804ea49e761.png | simple | <table><tr><td>Study name</td><td>Treatment arms</td><td>Time horizon (weeks)</td><td>Relapses</td><td>AE-related disc's</td><td>Non-AE-related disc's</td><td>Completers</td><td>Total Nr of patients</td><td>Nr of patients experiencing >7% weight gain (total Nr of patients)</td><td>Nr of patients experiencing EPS (total Nr of patients)</td></tr><tr><td>Kane (42)</td><td>Haloperidol depota</td><td>52</td><td>17</td><td>1</td><td>18</td><td>44</td><td>80</td><td>NA</td><td>NA</td></tr><tr><td></td><td>Placebob</td><td>52</td><td>15</td><td>0</td><td>2</td><td>8</td><td>25</td><td>NA</td><td>NA</td></tr><tr><td>Kane (41)</td><td>Olanzapine pamoatec</td><td>24</td><td>68</td><td>21</td><td>91</td><td>419</td><td>599</td><td>100 (599)</td><td>52 (599)</td></tr><tr><td></td><td>Olanzapine oral</td><td>24</td><td>23</td><td>8</td><td>33</td><td>258</td><td>322</td><td>68 (322)</td><td>28 (322)</td></tr><tr><td></td><td>Placebob</td><td>24</td><td>42</td><td>6</td><td>20</td><td>76</td><td>144</td><td>12 (144)</td><td>12 (144)</td></tr><tr><td>Hough 2010 (38)</td><td>Paliperidone palmitate</td><td>31</td><td>36</td><td>3</td><td>28</td><td>139</td><td>206</td><td>12 (206)</td><td>21 (206)</td></tr><tr><td></td><td>Placebo</td><td>42</td><td>97</td><td>2</td><td>27</td><td>78</td><td>204</td><td>6 (204)</td><td>12 (204)</td></tr><tr><td>Kane (40)</td><td>Aripiprazole once-monthly</td><td>52</td><td>27</td><td>9</td><td>31</td><td>202</td><td>269</td><td>17 (269)</td><td>45 (269)</td></tr><tr><td></td><td>Placebo</td><td>52</td><td>53</td><td>5</td><td>15</td><td>61</td><td>134</td><td>7 (134)</td><td>14 (134)</td></tr><tr><td>Fleischhacker (37)</td><td>Paliperidone palmitate</td><td>53</td><td>95</td><td>29</td><td>100</td><td>155</td><td>379</td><td>50 (346)</td><td>67 (379)</td></tr><tr><td></td><td>Risperidone LAI</td><td>53</td><td>56</td><td>25</td><td>105</td><td>184</td><td>370</td><td>52 (338)</td><td>76 (370)</td></tr><tr><td>Fleischhacker (39)</td><td>Aripiprazole once-monthly</td><td>38</td><td>22</td><td>8</td><td>39</td><td>196</td><td>265</td><td>42 (265)</td><td>52 (265)</td></tr><tr><td></td><td>Aripiprazole oral</td><td>38</td><td>21</td><td>7</td><td>60</td><td>178</td><td>266</td><td>43 (266)</td><td>46 (266)</td></tr><tr><td></td><td>Placebob</td><td>38</td><td>29</td><td>7</td><td>34</td><td>61</td><td>131</td><td>8 (131)</td><td>18 (131)</td></tr></table> |
00310c728dc432062bd97bfa5537fc9562ef8dee3af72104a22cfee0f20374eb.png | simple | <table><tr><td>Compound</td><td>RRI <sup>a</sup></td><td><i>S. boveanum </i></td><td><i>C. myrica</i></td><td><i>H. flagelliformis </i></td></tr><tr><td>Heptadecane</td><td>1698</td><td>-</td><td>-</td><td>4.1 ± 0.63</td></tr><tr><td>Tetradecanoic acid methyl ester</td><td>1718</td><td>8.1 ± 0.7</td><td>20.3 ± 3.5</td><td>8.2 ± 0.9</td></tr><tr><td>9-(<i>Z</i>)-Hexadecenoic acid methyl ester</td><td>1900</td><td>4.0 ± 1.2</td><td>54.6 ± 36.3</td><td>-</td></tr><tr><td>Hexadecanoic acid methyl ester</td><td>1922</td><td>58.2 ± 4.5</td><td>165.7 ± 23.7</td><td>95.9 ± 11.5</td></tr><tr><td>9,12-(<i>Z,Z</i>)-octadecadienoic acid methyl ester</td><td>2094</td><td>-</td><td>5.8 ± 1.8</td><td>-</td></tr><tr><td>9-(<i>Z</i>)-octadecenoic acid methyl ester</td><td>2101</td><td>8.4 ± 2.4</td><td>30.1 ± 10.6</td><td>8.1 ± 1.2</td></tr><tr><td>9-(<i>E</i>)-octadecenoic acid methyl ester</td><td>2107</td><td>-</td><td>16.1 ± 2.0</td><td>7.9 ± 1.03</td></tr><tr><td>Octadecanoic acid methyl ester</td><td>2120</td><td>3.6 ± 0.7</td><td>11.9 ± 1.5</td><td>4.6 ± 0.3</td></tr></table> |
cc1063edacd6ede8e7e5e3f556128a9da70bd93c2dcf19b470a2483087ace527.png | simple | <table><tr><td>Traits</td><td>TL</td><td>BL</td><td>BH</td><td>HL</td><td>BW</td></tr><tr><td>TL</td><td>1</td><td></td><td></td><td></td><td></td></tr><tr><td>BL</td><td>0.993</td><td>1</td><td></td><td></td><td></td></tr><tr><td>BH</td><td>0.849</td><td>0.841</td><td>1</td><td></td><td></td></tr><tr><td>HL</td><td>0.782</td><td>0.782</td><td>0.723</td><td>1</td><td></td></tr><tr><td>BW</td><td>0.934</td><td>0.934</td><td>0.931</td><td>0.780</td><td>1</td></tr></table> |
1a03c25c391845f3d25d1b1a314a2e3240569f13d2760d2de327cee598f84951.png | simple | <table><tr><td>Farm location</td><td>Goat breed</td><td>Feed type</td></tr><tr><td>Farm 1 (F1), Hulu Langat, Selangor</td><td>Saanen cross (SC)</td><td>Napier grass silageBarley sproutsDatesMulberry leavesCorn grainGoat pellet</td></tr><tr><td>Farm 2 (F2), Banting, Selangor</td><td>Saanen pure (SP)</td><td>Napier grass freshDairy bran</td></tr><tr><td>Farm 3 (F3), Hulu Langat, Selangor</td><td>Saanen pure (SP)</td><td>Napier grass freshGoat pellet 1Goat pellet 2</td></tr><tr><td>Farm 4 (F4), Sungai Buloh, Selangor</td><td>Saanen–Boer cross (SBC)</td><td>Napier grass freshGrower pelletBreeder pelletRice straw</td></tr><tr><td>Farm 5 (F5), Nilai, Negeri Sembilan</td><td>Jamnapari Koplo (JK)</td><td>Napier grass silageWide leavesSoy-bran mixture</td></tr><tr><td>Farm 6 (F6), Sungai Buloh, Selangor</td><td>Jamnapari Peranakan Etawa cross (JPEC)</td><td>Napier grass freshSoy wasteGoat pellet</td></tr><tr><td>Farm 7 (F7), Shah Alam, Selangor</td><td>Jamnapari–Toggenburg cross (JTC)</td><td>Napier grass freshMix grassesDairy bran</td></tr><tr><td>Farm 8 (F8), Jeram, Selangor</td><td>Jamnapari cross (JC)</td><td>Sarang Buaya grass (<i>Ischaemum timorense</i> Kunth)Mix bran</td></tr></table> |
dc93eee411db1e04d7d0f88678e57884295c8b19ed61ab12a41879cb45f24419.png | simple | <table><tr><td>Treament</td><td>G0/G1</td><td>S</td><td>G2/M</td><td>Sub G0</td></tr><tr><td>24 Hr Control</td><td>61.6 ± 0.4</td><td>11.6 ± 0.6</td><td>22.5 ± 0.6</td><td>1.5 ± 0.1</td></tr><tr><td>24 Hr Luteolin</td><td>49.3 ± 1.4c</td><td>12.7 ± 1.3</td><td>31.2 ± 0.9b</td><td>3.4 ± 0.2</td></tr><tr><td>24 Hr Control Removed for 24 Hr</td><td>65.9 ± 0.8</td><td>8.5 ± 0.3</td><td>22.1 ± 0.4</td><td>1.4 ± 0.03</td></tr><tr><td>24 Hr Luteolin Removed for 24 Hr</td><td>39.3 ± 0.7c</td><td>10.6 ± 0.3</td><td>29.0 ± 0.9a</td><td>8.8 ± 1.2c</td></tr><tr><td>24 Hr Control Removed for 48 Hr</td><td>83.7 ± 0.7</td><td>3.5 ± 0.4</td><td>8.8 ± 0.7</td><td>2.7 ± 0.4</td></tr><tr><td>24 Hr Luteolin Removed for 48 Hr</td><td>47.5 ± 0.5c</td><td>8.5 ± 0.5a</td><td>24.3 ± 0.4c</td><td>9.4 ± 1.1b</td></tr><tr><td>24 Hr Control Removed for 72 Hr</td><td>86 ± 1.4</td><td>2.8 ± 0.5</td><td>8.0 ± 0.7</td><td>1.6 ± 0.03</td></tr><tr><td>24 Hr Luteolin Removed for 72 Hr</td><td>54.4 ± 1.0c</td><td>7.6 ± 0.9a</td><td>24.7 ± 0.8c</td><td>6.4 ± 0.2</td></tr></table> |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.